

INHN
Archives
Rado Collection
July 29, 2021

János P. Radó's Collection **Collated by Mateo Kreiker and Olaf Fjetland**

Table of contents

János Radó: Biographic Sketch	March 17, 2016
János Radó: My 64-year (1954-2018) life product (Supplement to My Biographic Sketch)	July 26, 2018
János Radó: Contributions to psychotropic drug development with special reference to carbamazepine	September 8, 2016
János Radó: The use of modern antidiuretic agents in the treatment of permanent lithium-induced nephrogenic diabetes insipidus	January 25, 2018
Barry Blackwell's comment	May 10, 2018
János Radó's reply to Blackwell's comment	January 8, 2020
Gordon Johnson's comment	July 5, 2018
János Radó's reply to Johnson's comment	July 11, 2019
János Radó's additional information: Calcitonin in lithium-induced nephrogenic diabetes insipidus	September 13, 2018
Hector Warnes' comment	January 17, 2019
János Radó's reply to Warnes' comment	August 15, 2019
János Radó: Renal Toxicity of Lithium in Historical Perspective with Special Reference to Nephrogenic Diabetes Insipidus and its Treatment	May 2, 2019
Janusz Rybakowski's commentary	June 20, 2019
János Radó's reply to Rybakowski's commentary	June 27, 2019
Janusz Rybakowski's response to Radó's reply	November 14, 2019
János Radó: Desmopressin may counteract polyuria in lithium-induced nephrogenic diabetes insipidus: Review of the literature	June 27, 2019
Robert H. Belmaker's comments	November 21, 2019
János Radó's reply to Belmaker's comments	January 9, 2020
János Radó: Mechanism of Lithium Induced Polyuria in Historical Perspective	July 4, 2019
Samuel Gershon's comment	November 14, 2019
János Radó's reply to Gershon's comment	January 23, 2020

Edward Shorter: The Q-T interval and the Mellaril story: a cautionary tale	July 18, 2013
János Radó's comment	September 24, 2015
Milestones and the lifetime achievements of a scientist and clinician – Happy Birthday Professor János Radó! By Ágnes Haris	December 10, 2020
János Radó: 90th Year Birthday	January 21, 2021
Janos Radó's comment on the 2017 research article of Lin, Zhang, Feng, et al., "Aliskiren increases aquaporin-2 expression and attenuates lithium-induced nephrogenic diabetes insipidus"	March 4, 2021
János Radó: My teacher, Pál Gömöri (1905-1973)	May 13, 2021
János Radó: Iron Pen Award	June 24, 2021
Photos of János Radó	
Nadia Kuprina, Giorgina Piccoli, János Radó, Stanley Sheldon and Jacques Bernheim. Vignette 1 (August 2, 2018) Vignette 2 (December 20, 2018)	July 19, 2018
János Radó and Thomas Ban	September 3, 2015

Biographic sketch by János P. Radó

Family History

My full name is János Péter Radó. I was born in Budapest, Hungary, May 25, 1930. My parents were living in the same flat, where I have spent my entire life since age 10. They were printers and owners of a printing office, which was located on the ground floor of a building (Hajós street 25, Budapest), on the first floor of which is our present home. The press was confiscated twice: for the first time in 1944, when Hungary was invaded by the Nazi army and the second time, in 1949 by the Soviet-backed Communist regime. This last time, the presses were destroyed. After the 1956 revolution, my parents left Hungary for Canada. They lived in Toronto for more than 25 years until they died there.

Degrees

I attended (1948-1954) and graduated from the Medical School of Budapest and became a specialist in Internal Medicine (1958), Endocrinology (1980) and Nephrology (1984). I successfully passed the examination of a course for Nuclear Medicine in 1966. (At that time, Nuclear Medicine was not yet a Specialty, not even a Subspecialty, in Hungary).

Employment

My clinical work began in 1954, in the Second Medical Department of the János Hospital, Budapest. I worked in this hospital for the next 26 and half years. From 1958 to 1980, I worked in the Isotopic Department and Metabolic Unit. This included four years in the Outpatient Clinic for Diabetic Patients (1958-1962) and a two-year absence on leave in The Netherlands (1976-1978). My clinical work was continued after the János Hospital years (1954-1980) in the Department of Hypertension and Nephrology in the Uzsoki Hospital (1980-1997). Here, as the leader of the department, I founded the Dialysis Unit of the Uzsoki Hospital and a Nephrological Laboratory for clinical and investigational purposes. After retiring from hospital clinical work in 1997, I became and am still a consultant in internal medicine, nephrology and endocrinology in a private medical institute, Virányos Outpatient Clinic.

Invention of Furosemide (Diuretic) Renography

A "by-product" of our Hungarian nuclear renal clearance studies with Hippuran 131 and 125 was the invention of the so-called "frusemide renography" which was first published in December 1967 in The Lancet and after then the extended studies, in 1968 in Nuclear Medicine.

Visiting Employment History

I was invited by Professor Evert Dorhout Mees as a visiting scientist to the Clinic of Hypertension and Nephrology of the Medical University of Utrecht, The Netherlands. The purpose of this invitation was to introduce in Utrecht those renal clearance studies for measuring glomerular filtration rate, as well as renal plasma flow, which was used by us in Budapest. I was paid by the Nierstichting Netherland. The Hypertension and Nephrology Clinic was working on nuclear methodologies in a very good cooperation with the Nuclear Department of Utrecht. The leader of this department, at that time, was

Prof. Ephraim and his staff assistant was Dr. Oei HJ, a physician of Indonesian Chinese background, trained in Vienna. During our 2-year stay in The Netherlands, we became good friends with Dr. Oei and his family; we (my wife accompanied me to Holland) met several times in our homes. Although the scope of our nuclear studies in Utrecht was strictly confined on the renal isotopic clearances, I also discussed several times with Dr. Oei my favorite topic of furosemide (diuretic) renography. I gave reprints to Dr. Oei dedicated to him concerning furosemide (diuretic) renography, appearing in the aforementioned *Lancet* and Nuclear Medicine papers. I was glad to learn several years later, when I had already left The Netherlands to Hungary that my friend Dr. Oei, working in collaboration with Prof. EJ Dorhout Mees and Geyskes GG discovered the "captopril renography." "Captopril renography" was another example of a drug-induced distortion of the normal renogram used for the diagnosis for renovascular hypertension as was "diuretic renography" used in obstructive ureteral disorders, as well as other nephrological conditions.

Editorial Activity

I was Chief Editor of the *Hungarian Journal of Hypertension and Nephrology* from 1999 to 2012.

PhD, habilitation, Private Docent, Doctor of Science

For my scientific and clinical research work, I was awarded a PhD, in 1980, habilitation, in 1995 in the Semmelweis University, Budapest, the title of "private docent," in 1998, in the Semmelweis University Budapest, and Doctor of Science, in 1999, in the Hungarian Scientific Academy.

Titles of my dissertations

PhD: Clinicopharmacological Studies of Renal Pharmacons, Antidiuretics and Diuretics. Endocrine and Renal Pharmacology (1980). ***Habilitation***: Renal Tubular Acidosis and its Complication of Nephrogenic Diabetes Insipidus (1995). ***Doctor of Science***: Interaction of Medicines and Diseases in the Regulation of Serum Potassium. Hyperkalemias (1999).

Awards

In Hungary, for my scientific and clinical research work I was awarded the Semmelweis Prize (1972), Markusovszky Prize (Hungarian Medical Weekly, 1989), Batthány Strattman László Prize (Governmental Award, 1996), Korányi Sándor Prize (Award of The Hungarian Nephrological Society, 2004), Life Achievement Award (award of the Medical University of Debrecen, 2005), Paul Gömöri Prize (award of The Hungarian Hypertension Foundation, 2005), Life Achievement Award of the Hungarian Foundation of Nephrology (2007), Török Eszter Prize (award of The Hungarian Hypertension Society, 2012). I was selected for the Album of Portraits of the Pioneers, European Nephrological Archives, published by the EDTA-ERA at the Congress of the EDTA-ERA, on 24th May 2012, Paris, France. On March 15, 2021, I received the of “Iron Pen” of the Association of Hungarian Journalists (Magyar Ujságírók Országos Szovetsege – MUOSZ) in recognition of lifetime contributions. The Association awards its members with this recognition after their 90th birthday.

Memberships

European Renal Association (ERA-EDTA), European Society of Hypertension (past), New York Scientific Academy (past), Hungarian Nephrological Society, Hungarian Hypertension Society, Hungarian Society of Internal Medicine, Hungarian Society of Radiology, Hungarian Society of Diabetes. President of the Committee for History of The Hungarian Nephrological Society.

Scientometria. Number of publications (405), Book and book chapters, Hirsch factor (30), citedness, (1929) impact factor

Number of publications: 355 printed articles on Hungarian, English and German from 1954 to 2013. Since then:2; altogether 357 (Compiled on the basis of the Library of the Hungarian Scientific Academie). Can be found in the INHN webpage, "Profiles").

Book

Haris Ágnes, Radó János: *A víz- és elektrolitháztartás zavarai: Differenciáldiagnosztika és terápia*. Budapest: Medicina Könyvkiadó, 2008. 395 pages

Book chapters (17) in 3 Manuals

Thirteen book chapters In: Kakuk György (szerk.) Klinikai nephrologia: a vese belgyógyászati betegségeinek kézikönyve. 1201 p. Budapest: Medicina Könyvkiadó, 2004. One book chapter In: Rosivall L, Kiss I (eds.) Nephrologia. Elmélet és klinikum, dialysis, transplantatio. Budapest: Medintel Kiadó, 2003. p. 373. Three book chapters In: Kornya László (szerk.) Betegség enciklopédia I-II. 2564 p. Budapest: Springer Tudományos Kiadó, 2002. p. 691

Impact factor: exact sum of cumulative impact factor: 75,849 (collected in the years after 1974); estimated sum of the total cumulative impact factor: (estimated from the years from 1954 to 1974 based on the 1998 impact factor values): 182,385

Titles of my 10 most important articles

Radó JP, Banos C, Tako J
Frusemide renography.
Lancet 2: pp. 1419-1420. (1967)

Radó JP, Banos C, Tako J
Radioisotope renography during furosemide (lasix) diuresis.
Nuklearmedizin-Nuclear Medicine 7: pp. 212-221. (1968)

Herman E, Radó J
Fatal hyperkalemic paralysis associated with spironalactone. Observation on a patient with severe renal disease and refractory edema.
Archives of Neurology (Chicago) 15: pp. 74-77. (1966)

Radó JP
Water intoxication during carbamazepine treatment
British Medical Journal (BMJ) 3: p. 479. (1973)

Radó JP
Falsely high fluorescence in cortisol determinations due to the carbamazepine.
Hormone and Metabolic Research 5: p. 63. (1973)

Radó JP, Borbely L
Enhancement of polyuria by glibenclamide in diabetes insipidus.
Lancet 2: p. 216. (1971)

Radó JP

Combination of carbamazepine and chlorpropamide in the treatment of "hypo-responder" pituitary diabetes insipidus.

Journal of Clinical Endocrinology and Metabolism 38: pp. 1-7. (1974)

Radó JP , Szende L , Marosi J

Influence of glyburide on the antidiuretic response induced by 1-deamino-8-D-arginine vasopressin (DDAVP) in patients with pituitary diabetes insipidus.

Metabolism-Clinical and Experimental 23: pp. 1057-1063. (1974)

Radó JP, Tako J , Geder L , Jeney E

Herpes Zoster House Epidemic in Steroid-Treated Patients. A Clinical and Viral Study.

Archives of Internal Medicine (Chicago) 116: pp. 329-335. (1965)

Radó JP

Response to vasopressin analogues in diabetes insipidus

New England Journal of Medicine 295: p. 393. (1976)

March 17, 2016

János Radó: My 64-year (1954-2018) life product

Supplement to My Biographic Sketch

(Number in brackets below: publication list numbers

Underlined: indicates connection with neuropsychopharmacology)

Most important achievement:

Invention of "Furosemide renography" (41, 58, 73, 299, 300, 343, 356)

1. Renal pharmacology

Hyperkalemic paralysis associated with spironolactone therapy (34, 60, 240)

Increase of sodium reabsorption in the distal tubule in response to furosemide (67)

Furosemide induced antidiuresis in diabetes insipidus (47)

Chlorpropamide antidiuresis in diabetes insipidus (69, 84, 93, 94)

Paradoxical increase of the renal concentrating operation in response to furosemide during infusion of hypertonic salt in man; description of the technic of two-minute clearance periods (74)

The effect of diazoxide and chlorpropamide on renal functions in man (114)

Dose-effect relationships in SIADH induced by clofibrate and carbamazepine (135)

Opposite effects of antikaluretic and antiprostaglandine compounds in Bartter syndrome (168)

Pharmacological investigation of dDAVP in diabetes insipidus: description of three different peak effects, relationships between the dose and duration of action, interindividual differences, and change in the metabolism of dDAVP in response to the prolonged treatment itself as well as coadministration of medicines having enzyminducer capabilities. (138, 139, 147, 148, 150, 155, 163, 166, 167)

Decrease in the venous blood pressure and venomotor tone in response to a mercurial diuretic in cardiac insufficiency (5,13)

Effect of aldosterone and spironolactone on the renal tubules in Cushing syndrome associated with polyuria (29)

Site of effect of furosemide in man (43, 45, 47, 48, 57, 65, 67, 72, 74, 81, 83, 85, 96)

Mechanism of thiazide antidiuresis (31)

Mechanism of the chlorothiazide antidiuresis in diabetes insipidus and psychogenic polydipsia (36)

Patterns of potassium wasting in response to stepwise combinations of diuretics (286, 291)

Diuretic and antidiuretic effects of furosemide before and after Pitresssin (89)

Furosemide and thiazide potentiation because of differing site of effects (72)

Use of furosemide for the evaluation of the concentrating mechanism (61, 64)

Extreme antidiuresis in response to the combination of chlorpropamide with angiotensine (70, 77, 90)

Effects of Ethacrynic acid on the specific renal functions (85, 86)

Drug-induced antidiuresis in partial nephrogenic diabetes insipidus (249, INHN list, 2.)

Comparison of the diuretic effect of Azosemide and Furosemide (191,192)

Renal effects of angiotensine in man (296, 304)

TTKG (transtubular potassium gradient) (293, 294)

2. Nephrology

Hipertonology Combined administration of Furosemide wash-out pyelography and furosemide radioisotope renography for the diagnosis of renovascular hypertension (101)

Furosemide-bicarbonate therapy in hyperkalemia and coma associated with renal tubular acidosis in refractory edema (104, 106)

Acute effects of high dose furosemide in chronic renal insufficiency (115)

Change of the antikaluretic response in response to potassium sparing diuretics (91, 142, 144, 146, 149)

Hyperkalemia unresponsive to massive doses of aldosterone in chronic interstitial nephritis (153, 154)

Free water excretion in hypoaldosteronemic renal insufficiency (196)

“Exaggerated natriuresis” during intravenous infusion of hypertonic sodium chloride in hypertonics and healthy people (178)

“Outpatient hyperkalaemia” syndrome in hypertonic and renal patients (174)

Extreme juxtaglomerular hyperplasia in renovascular hypertension associated with “renal aldosteronism” (25)

Salt loading “in renal aldosteronism” before and after nephrectomy (71)

Effect of alpha-methyldopa, guanethidine and bethanidine on isotope-renography (68)

Different effects of frusemide administered during hypertonic saline infusion in healthy subjects and hypertensive patients (83)

Cephmandol induced acute renal insufficiency (232, 233)

Anticonvulsive osteomalacia in sclerosis tuberosa associated with renal tubular acidosis (258)

3. Endocrinology-clinical chemistry

Falsely high fluorescence in cortisol determinations due to the carbamazepine (116)

Use of a simple fluorometric 11-hydroxycorticosteroids assay in the assessment of spironolactone-metabolite level in plasma and urine (120)

Use of a simple fluorometric 11-hydroxycorticosteroids assay for the investigation of interference induced by psychotropic drugs, triamtere, bencyclane, beta blocking agents (121, 122, 141, 152, 164)

Effect of dDAVP on plasma cortisol level (145)

Increase of plasma potassium level in response to the upright posture: “upright hyperkalemia” (160, 161)

Glucose induced paradoxical hyperkalemia (183, 185, 186, 187, 206, 209-214, 219, 220, 225, 227-231)

Dose-effect relationship of the ACTH-like effect of the peptide extracted from the tumorous tissue of a patient suffering from ectopic Cushing syndrome (175)

Cushing's Syndrome Associated With Chromophobe Adenoma Of The Hypophysis (30)

Effect of adrenocortical hormones on thromboplastin generation in hemophilia B (38)

Successful extraction of complicated cataract during steroid treatment in a patient suffering from haemophilia B. (24, 26)

Adrenocortical insufficiency in spite of high corticosteroid excretion in a patient with thyrotoxicosis (63)

dDAVP Concentrating Test (166)

Diuretic effect of glibenclamide (95, 102)

Water intoxication induced by carbamazepine (117, INHN 1)

Combination of chlorpropamide and carbamazepine in the treatment of "hyporesponder" diabetes insipidus (127)

Interaction (antagonism) between dDAVP and glibenclamide (129)

Herpes zoster "house epidemic" developing in patients treated with corticosteroids; A clinical and Viral Study (28, 32, 363)

Use of modern antidiuretic agents in the treatment of permanent lithium induced nephrogenic diabetes insipidus (Administration of excessive doses of desmopressin resulted in clinically relevant antidiuresis, enhanced by indomethacine and abolished by calcitonin) (INHN 2.)

Clinical use of "additive antidiuresis" with the various combinations of vasopressine, lysin-vasopressine, desmopressine, carbamazepine, clofibrate and chlorpropamide (98, 103, 111, 112, 118, 119, 123, 127, 135)

Antidiuresis induced by vasopressine, lysin-vasopressine, desmopressine, carbamazepine, clofibrate and chlorpropamide can be abolished by the administration of glibenclamide (124, 125, 126, 128, 129, 132, 136)

Decrease of the antidiuresis during long-term treatment with carbamazepine due to enzyme induction (143, 147, 157)

Simultaneous occurrence of diabetes insipidus and ascites due to liver cirrhosis (246)

Hann-syndrome (234)

Simultaneous occurrence of hyperkalemia due to aldosterone suppression and hyperfunctioning parathyroid adenoma (197)

Hypophosphatemic metabolic osteomalacia (261, 278, 284, 285, 295)

Clinical and laboratory effects of cloprednol (169)

Effect of dDAVP on the plasma renin activity in man (171)

Effect of dDAVP and indomethacine in Bartter-syndrome (167)

Effect of the humane and standard ACTH on the urinary excretion of cortisol (180)

Calcitonin abolishes the effect of desmopressine (INH 2)

4. Diabetology

Paradoxical increase of peripheral glucose utilization in a patient with insulinoma treated with prednisolone (35)

Paradoxical effects of prednisone on glucose metabolism in cirrhosis of the liver (44)

Effect of chlopropamide in diabetes insipidus associated with diabetes mellitus (93, 94)

Congenital familiar nephrogenic diabetes insipidus associated with diabetes mellitus (352)

Glucose induced paradoxical hyperkalemia (183, 185, 186, 187, 206, 209-214, 219, 220, 225, 227-231)

5. Hematology

Polycythemia vera turning into myelofibrosis in an individual with Pelger-Huet anomaly of the leukocytes; lack of decreased tolerance of the PH leukocytes toward radiotherapy. (16)

Mononucleosis infectiosa (One hundred and twenty eight cases from three department of hematology between 1930 and 1952) (1)

6. Cardiology

Interventricular perforation of the septum in myocardial infarction (the first two case in Hungary) (12)

Congenital septal defect associated with myocardial infarction in old age (8)

Radó, János (Nephro-endokrin pharmak)**1954**

1. Devenyi P, Radó J
Mononucleosis infectiosa
Orvosi Hetilap 95: pp. 464-469. (1954)

1955

2. Fodor I, Kincsesy A, Radó J
[Diagnosis and pathology of perforated interventricular septum; intravital observation of two cases.]
Orvosi Hetilap 96: pp. 1293-1300. (1955)
3. Radó J
[A case of Waterhouse-Friedrichsen syndrome of pneumococcal origin in old age.]
Orvosi Hetilap 96: pp. 1284-1287. (1955)

1956

4. Fodor I, Blumenfeld G, Radó J
[ACTH therapy and its theoretical bases in novurit-refractor cardiac edema.]
Orvosi Hetilap 97: pp. 349-353. (1956)
5. Gonda E, Radó J
[Venomotor tonus in circulatory diseases.]
Orvosi Hetilap 97: pp. 205-210. (1956)
6. Hammer S, Radó J
[Pelger-Huet anomaly of leukocytes.]
Orvosi Hetilap 97: pp. 298-301. (1956)

1957

7. Radó J, Blumenfeld G, Barath F, Szirom I
[ACTH therapy in cardiac edema refractory to novurit. II. Role of tubular factors in hypochloruria and mercury resistance.]
Orvosi Hetilap 98: pp. 408-413. (1957)
8. Radó J, Abraham K, Eszeki J
[Combination of congenital interventricular septal defect and of a cardiac infarct in old age.]
Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete 12: pp. 1120-1123. (1957)
9. Radó J, Abraham K, Eszeki J
[Simultaneous occurrence of congenital septal defect and cardiac infarct in old age.]
Orvosi Hetilap 98: pp. 1079-1081. (1957)
10. Radó J, Frank M, Fenyés I
[Kidney function in diabetic coma.]
Orvosi Hetilap 98: pp. 650-653. (1957)

1958

11. Radó J, Blumenfeld G

ACTH treatment for novurit-resistant cardiac edema; the role of tubular factors in hypochloruria and mercury-resistance.

ACTA Medica Scandinavica 160: pp. 15-23. (1958)

12. Radó J, Kincsesy A, Fodor I
[Clinical and pathological problems of the intraventricular septum perforation in the light of the literature and our own cases.]
Zeitschrift für die Gesamte Innere MEDizin und ihre Grenzgebiete 13: pp. 227-235. (1958)
13. Radó JP, Gonda E, Kovacs E
The role of venous constriction in circulatory disorders.
British Heart Journal 20: pp. 389-396. (1958)

1959

14. Radó J, Blumenfeld G, Hammer S
[Prednisone therapy of novurite-induced refractory cardiac edema. III. Significance of tubular mechanisms in the reversal of mercurial sensitivity.]
Magyar Belorvosi Archivum 12: pp. 183-188. (1959)
15. Radó JP, Blumenfeld G, Hammer S
The effect of prednisone and 6-methylprednisolone on mercurial diuresis in patients with refractory cardiac edema.
American Journal of the Medical Sciences 238: pp. 542-551. (1959)
16. Radó JP, Hammer S
Polycythemia vera turning into myelofibrosis in an individual with Pelger-Huet anomaly of the leukocytes. Blood 14: pp. 1143-1150. (1959)

1961

17. Radó J, Hamvas J, Bikich G
[Role of various factors in the pathogenesis of skin hemorrhage (steroid ecchymosis) due to new glucocorticoids.]
Magyar Belorvosi Archivum 14: pp. 107-118. (1961)

1962

18. Radó J, Hammer S, Szilágyi L
[Effect of new synthetic glucocorticoids (dexamethasone and medrol) on mercurial diuresis in liver cirrhosis. IV. Experimental studies on the renal and extrarenal effect of steroids with special reference to the concentrating capacity of the kidney.]
Magyar Belorvosi Archivum 15: pp. 16-29. (1962)

1964

19. Radó J, Tako J, Geder L, Jeney E
[Group Occurrence of Herpes Zoster in Patients Treated with Corticosteroids.]
Orvosi Hetilap 105: pp. 1266-1270. (1964)
20. Radó J, Hammer S, Szilágyi L
Ujabb chlorothiazidszármazékok gyűjtőtubuláris hatása és annak jelentősége decompensált májcirrhosisban: a chlorothiazid és Aldacton eltérő hatása a distális nephronra
Magyar Belorvosi Archivum 17: p. 298. (1964)
21. Radó J, Blumenfeld Gy

- Pleuropneumoniával szövődött generalizált herpes zoster
Magyar Belorvosi Archivum 17: pp. 160-163. (1964)
22. Radó J, Takó J, Liszka Gy, Bodrogi Gy, Mihoczy L, Sárközy Gy, Világi Gy
Tüdőtumort utánzó arteria pulmonális aneurysma Lutembacher syndromában és
felnőttkori pitvari septumdefektusban
Magyar Belorvosi Archivum 6: p. 317. (1964)
23. Takó J, Radó J
[Generalized Herpes Zoster Complicated by Meningitis in a Patient Treated with
Corticosteroids.]
Orvosi Hetilap 105: pp. 1271-1273. (1964)

1965

24. de Grosz I, Borbely L, Szabados D, Radó JP
Successful extraction of complicated cataract in a patient suffering from
haemophilia
B. ACTA Ophthalmologica (1923-1994) 43: pp. 574-578. (1965)
25. Gomba Sz, Endes P, Radó J
Verhalten des juxtaglomerularen Apparates bei renovascularer Hypertonie
Zentralblatt für Allgemeine Pathologie und Pathologische Anatomie 111: p. 531.
(1965)
26. Grosz I, Borbély L, Szabados D, Radó J
Sikeres hályogkivonás B-típusu haemophiliában szenvedő betegen
Szemészet 102: pp. 76-80. (1965)
27. Radó J, Takó J, Miklos G
[Chromophobe Pituitary Adenoma Associated with Cushing's Syndrome.]
Orvosi Hetilap 106: pp. 223-226. (1965)
28. Radó JP, Takó J, Geder L, Jeney
E Herpes Zoster House Epidemic in Steroid-Treated Patients. A Clinical and Viral
Study.
Archives of Internal Medicine 116: pp. 329-335. (1965)
29. Radó JP, Takó J, Hammer C, Szilagyi L
[On the effect of aldosterone and aldactone A on various segments of kidney
tubules in Cushing's syndrome with polyuria]
Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete 20: pp. 521-
527. (1965)
30. Radó JP, Takó J, Miklos G
Cushing's Syndrome Associated with Chromophobe Adenoma of the Hypophysis.
ACTA Medica Scandinavica 177: pp. 667-672. (1965)
31. Radó JP
Mechanism of "thiazide" antidiuresis
Lancet*(2) p. 1015. (1965)
32. Takó J, Radó JP
Zoster Meningoencephalitis in a Steroid-Treated Patient.
Archives of Neurology 12: pp. 610-612. (1965)
33. Takó J, Radó J
[Changes in the "functional reserve capacity" of the pituitary gland and the adrenal
cortex under the effect of antithyroid therapy]
Orvosi Hetilap 106: pp. 1646-1650. (1965)

1966

34. Herman E, Radó J
Fatal hyperkalemic paralysis associated with spironalactone. Observation on a patient with severe renal disease and refractory edema.
Archives of Neurology 15: pp. 74-77. (1966)
35. Radó JP, Tako J, Salamon F, Loczka B, Major E
Paradoxical increase of peripheral glucose utilization in a patient with insulinoma treated with prednisolone.
Endokrinologie 50: pp. 266-275. (1966)
36. Radó JP, Tako J, Szilagyí L, Hammer C
[Studies on the mechanism of chlorothiazide antidiuresis in diabetes insipidus and psychogenic polydipsia]
Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete 21: pp. 425-431. (1966)

1967

37. Banos CS, Tako J, Radó JP, Krasznai I, Goschl I
Diagnostic value of the ¹³¹I-labelled triiodothyronine red blood cell uptake test.
Nuklearmedizin-Nuclear Medicine 6: pp. 124-139. (1967)
38. Borbely L, Radó JP, Tako J, Farkas G, Szabados D
[Studies on the effect of adrenal cortex hormones on hemophilia]
Folia Haematologica 87: pp. 358-372. (1967)
39. Herman E, Radó J
[Fulminant pyelonephritis associated with Conn's syndrome]
Orvosi Hetilap 108: pp. 1518-1520. (1967)
40. Radó J, Bános CS, Takó J, Szende L
Egyoldali nephrogen diabetes insipidus antibiotikus kezelés után
Magyar Belorvosi Archivum 20: pp. 241-253. (1967)
41. Radó JP, Banos C, Tako J
Frusemide renography.
Lancet 2: pp. 1419-1420. (1967)
42. Radó JP, Herman E
Conn's syndrome complicated by fulminant pyelonephritis in an old patient.
Journal of the American Geriatrics Society 15: pp. 448-454. (1967)
43. Radó JP, Tako J, Szabo T
Site of action of furosemide.
Journal of Clinical Pharmacology and the Journal of New Drugs 7: pp. 142-149. (1967)
44. Radó JP, Somogyi B, Takó J, Bikich Gy
Paradoxical effects of prednisone on glucose metabolism in cirrhosis of the liver
Zeitschrift für Vitamin Hormon und Fermentforschung 15:(4) pp. 343-355. (1967)
45. Radó JP, Borbely L, Tako J, Banos C
Effects of furosemide uring antidiuresis and antinatriuresis induced by angiotensin.
Medicina et Pharmacologia Experimentalis - International Journal of Experimental Medicine 17: pp. 373-377. (1967)
46. Radó JP, Tako J, Szanto Z
Aldosterone and cortisone requirement and metabolism in Addison's disease complicated by thyrotoxicosis.
Endokrinologie 52: pp. 12-21. (1967)

47. Radó JP, Banos CS, Marosi J, Tako J, Szilagyi L
Frusemide antidiuresis
Lancet*(2) p. 569. (1967)
48. Radó JP, Borbely L, Banos CS, Tako J, Kovacs I
Actions of frusemide and a thiazide
Lancet*(2) p. 465. (1967)

1968

49. Radó J, Tako J, Toth T, Endes P, Szabo T, Szanto E
[The effect of bethanide on aldosterone secretion in patients with renovascular hypertension]
Orvosi Hetilap 109: pp. 628-632. (1968)
50. Radó J, Marosi J, Tako J, Devenyi I
[Aldacton causing intermittent hyperkalemic muscle paralysis]
Orvosi Hetilap 109: pp. 452-455. (1968)
51. Radó J, Banos C, Tako J
[Radioisotope renography during furosemide(Lasix)-induced diuresis]
Orvosi Hetilap 109: pp. 401-405. (1968)
52. Radó J, Marosi J, Tako J
[Incidence of hyperkalemia caused by Aldactone therapy and its significance in decompensated liver cirrhosis]
Orvosi Hetilap 109: pp. 1911-1914. (1968)
53. Radó J, Szende L
A káliumkiválasztás paradox fokozódása spironolacton kezelés alatt májcirrhosisban
Magyar Belorvosi Archivum 21: p. 305. (1968)
54. Radó J
A hypertonia gyógyszeres kezeléséről: Symposium a Magyar Akadémián 1968
01 25
Magyar Belorvosi Archivum 5: p. 119. (1968)
55. Radó J, Borbély L, Takó J, Bános Cs
Diabetes mellitus és nephrogen diabetes insipidus együttes előfordulása: A pyelonephritissel járó koncentrálási zavar mechanizmusának vizsgálata
Magyar Belorvosi Archivum 21: p. 97. (1968)
56. Radó J, Bános CS, Takó J, Szabó T, Borbély L, Szende L, Kapus I, Nagy M A
Dopegyt és egyéb antihypertensiv szerek hatása az isotop renogramra
Magyar Belorvosi Archivum 21: p. 119. (1968)
57. Radó J, Bános CS, Marosi J, Borbély L, Takó J, Kovács I, Szilágyi L
A furosemid (Lasix) diuretikus és antidiuretikus hatásának vizsgálata diabetes insipidusban
Magyar Belorvosi Archivum 21: p. 178. (1968)
58. Radó JP, Banos C, Tako J
Radioisotope renography during furosemide (lasix) diuresis.
Nuklearmedizin-Nuclear Medicine 7: pp. 212-221. (1968)
59. Radó JP, Marosi J, Tako J, Devenyi I
Hyperkalemic intermittent paralysis associated with spironolactone in a patient with cardiac cirrhosis.
American Heart Journal 76: pp. 393-398. (1968)
60. Radó JP, Marosi J, Szende L, Tako J

- Hyperkalemic changes during spironolactone therapy for cirrhosis and ascites, with special reference to hyperkalemic intermittent paralysis.
Journal of the American Geriatrics Society 16: pp. 874-886. (1968)
61. Radó JP, Borbely L, Tako J, Banos C
Use of furosemide for evaluation of the urinary concentrating mechanism in chronic pyelonephritis.
Journal of the American Geriatrics Society 16: pp. 804-813. (1968)
62. Radó JP, Borbely L
Site of action of frusemide.
Lancet 1: pp. 1434-1435. (1968)
63. Radó JP, Tako J
Adrenocortical insufficiency in spite of high corticosteroid excretion in a patient with thyrotoxicosis.
Endokrinologie 52: pp. 327-334. (1968)
64. Radó JP, Szende L
Use of hypertonic saline, clopamide and furosemide for evaluation of the concentrating defect in pitressin-treated diabetes insipidus.
Medicina Experimentalis - International Journal of Experimental Medicine 18: pp. 185-190. (1968)
65. Radó JP, Banos C, Marosi J, Borbely L, Tako J
Investigation of diuretic and antidiuretic properties of furosemide in diabetes insipidus.
Endokrinologie 53: pp. 253-260. (1968)
66. Radó JP, Szabo T, Tako J, Szanto Z
Transitory primary aldosteronism-like condition.
Endokrinologie 53: pp. 122-127. (1968)
67. Radó JP, Borbely L, Szende L, Tako J
Changes in distal sodium reabsorption during angiotensin infusion in response to furosemide.
Pharmacology 1: pp. 369-374. (1968)

1969

68. Radó J, Banos C, Tako J, Szabo T, Borbely L, Szende L, Kapus I, Nagy M
Effect of alpha-methyl-dopa (Dopegyt) and other antihypertensive drugs (guanethidine, bethanidine) on the isotope renogram.
Therapia Hungarica 17: pp. 76-82. (1969)
69. Radó J, Borbely L, Szende L, Tako J, Szam I
Chlorpropamide antidiuresis.
Lancet 2: pp. 433-434. (1969)
70. Radó J, Borbély L, Kalcseva Sz, TakóJ, Szende L
Átmeneti anuria angiotensin (Hypertensin) infusio alatt decompensált májcirrhosisos betegen
Orvosi Hetilap 110: p. 407. (1969)
71. Radó JP, Tako J, Szabo T, Endes P, Wabrosch G, Szanto Z
Salt loading in renal aldosteronism before and after nephrectomy.
Archives of Surgery 98: pp. 357-364. (1969)
72. Radó JP, Szende L, Tako J, Banos C, Borbely L
Further studies on the sites of action of clopamide and furosemide.
Journal of Clinical Pharmacology and the Journal of New Drugs 9: pp. 99-103. (1969)

73. Radó JP, Banos C, Tako J, Szende L
Renographic studies during furosemide diuresis in partial ureteral obstruction.
Radiologia Clinica et Biologica 38: pp. 132-146. (1969)
74. Radó JP, Szende L, Borbely L, Banos C, Tako J
Paradoxical increase in renal concentrating operation in response to furosemide during hypertonic saline infusion in man.
Medicina Experimentalis - International Journal of Experimental Medicine 19: pp. 254-266. (1969)
75. Radó JP, Tako J, Szabo T, Banos C
Diuretic and antidiuretic effects of furosemide before and during the early period of pitressin therapy in diabetes insipidus.
Endokrinologie 54: pp. 26-35. (1969)
76. Radó JP, Tako J, Toth T, Endes P, Szabo T, Szanto Z
Increase in plasma renin level and aldosterone excretion in response to bethanidine sulfate (Esbatal) in a patient with renovascular hypertension.
Endokrinologie 54: pp. 253-264. (1969)
77. Radó JP, Borbely L, Szende L, Tako J
Extreme antidiuresis in response to chlorpropamide administered intravenously during angiotensin infusion in diabetes insipidus.
Medicina Experimentalis - International Journal of Experimental Medicine 19: pp. 245-253. (1969)
78. Szende L, Radó J
Diureticumok által okozott acut pancreatitis
Magyar Belorvosi Archivum 22: pp. 313-317. (1969)
79. Tako J, Radó J
[Adverse effects of diuretic drugs]
Orvosi Hetilap 110: pp. 891-895. (1969)

1970

80. Borbély L, Radó J, Szende L, Takó J
A "chlorpropamid antidiuresis" mechanizmusának vizsgálata diabetes insipidusban
Magyar Belorvosi Archivum 23: p. 26. (1970)
81. Radó J, Borbély L, Szende L, Takó J
A clopamid és a furosemid hatása a nátrium reabsorptióra a distális nephronban angiotensin infúzió alatt
Magyar Belorvosi Archivum 23: pp. 197-202. (1970)
82. Radó J
A koncentráló mechanizmus működésének változása diabetes insipidusban pitressin és diureticum hatására
Magyar Belorvosi Archivum 23: pp. 3-19. (1970)
83. Radó JP, Szende L, Borbely L, Banos C, Tako J, Fisher J
Different effects of frusemide administered during hypertonic saline infusion in healthy subjects and hypertensive patients.
Clinical Science 39: pp. 833-845. (1970)
84. Radó JP, Szende L, Borbely L, Tako J
Clinical value and mode of action of chlorpropamide in diabetes insipidus.
American Journal of the Medical Sciences 260: pp. 359-372. (1970)
85. Radó JP, Szende L, Tako J, Borbely L

- Studies on the sites of action of ethacrynic acid and furosemide during angiotensin infusion.
Journal of Clinical Pharmacology and the Journal of New Drugs 10: pp. 375-381. (1970)
86. Radó JP, Szende L, Borbely L
Effects of ethacrynic acid on specific renal functions without and during angiotensin infusion in man.
Archives Internationales de Pharmacodynamie et de Therapie 186: pp. 142-154. (1970)
87. Radó JP, Szende L, Borbely L
Investigation of the antidiuretic effect of high doses of intravenous chlorpropamide during excessive solute excretion induced by the combination of furosemide and clopamide in patients with diabetes insipidus.
Endokrinologie 56: pp. 196-205. (1970)
88. Radó JP, Borbely L, Szende L, Tako J
Studies on the mechanism of "chlorpropamide antidiuresis" in diabetes insipidus.
Endokrinologie 55: pp. 366-382. (1970)
89. Radó JP, Marosi J, Tako J
Concentrating power of the kidney after five years of pitressin-tannate therapy in a patient with diabetes insipidus untreated for 13 years. (Investigations during intravenous administration of hypertonic sodium chloride, lysine-vasopressin, clopamide and
Endokrinologie 55: pp. 359-365. (1970)
90. Radó JP, Borbely L, Szende L, Tako J
Relationship between the dose of chlorpropamide administered intravenously and the antidiuretic effect in diabetes insipidus.
Pharmacology 3: pp. 122-128. (1970)
91. Radó JP, Marosi J, Tako J
High doses of spironolactone (Aldactone, SC-14266, Verospirone) alone and in combination with triamterene and-or diuretics in the treatment of refractory edema associated with secondary hyperaldosteronism.
Endokrinologie 57: pp. 46-62. (1970)
92. Radó JP, Borbely L
Evidences for proximal tubular site of action of intravenous ethacrynic acid (Lyovac-Edecrin) obtained during antiotensin infusion in diabetes insipidus.
Endokrinologie 56: pp. 309-318. (1970)
93. Szam I, Radó JP, Borbely L, Szigeti L, Tako J
Clinico-pharmacological investigations with chlorpropamide in diabetes insipidus associated with diabetes mellitus.
Endokrinologie 56: pp. 109-117. (1970)
94. Szam I, Radó J, Borbely L, Szigeti L, Tako J
[Clinical and pharmacologic studies in diabetes insipidus complicated by diabetes mellitus]
Orvosi Hetilap 111: pp. 438-444. (1970)

1971

95. Radó JP, Borbely L
Enhancement of polyuria by glibenclamide in diabetes insipidus.
Lancet 2: p. 216. (1971)
96. Szende L, Radó J, Tako J

- [Clinico-pharmacological studies of furosemide]
Orvosi Hetilap 112: pp. 2580-2584. (1971)
97. Szende L, Radó J, Borbely L, Tako J
[Clinical value and action of chlorpropamide in diabetes insipidus, based on 12 cases]
Orvosi Hetilap 112: pp. 1333-1338. (1971)

1972

98. Radó J, Szende L, Tako J, Goth E, Fovenyi J
[Clinical value of the combination of vasopressin and chlorpropamide in cases of refractory diabetes insipidus]
Orvosi Hetilap 113: pp. 307-309. (1972)
99. Radó J, Szabó T, Takó J, Simon T, Gál M
Antidiuretikus hormon mobilisatio és hatás Haloperidollal kezelt schizophreniásokban
Ideggyógyászati Szemle / Clinical Neuroscience 25: p. 397. (1972)
100. Radó J, Szabó T, Szende L, Takó J, Fövényi J, Hutás I, Gartner P, Gergely R.
Clinicopharmacologiai vizsgálatok renális tubuláris acidosisal szövődött nephrogen diabetes insipidusban
Magyar Belorvosi Archivum 25: p. 72. (1972)
101. Radó JP, Banos C, Tako J
The furosemide wash-out pyelogram and the furosemide radioisotope renogram in the diagnosis of renovascular hypertension (preliminary report).
Nuklearmedizin-Nuclear Medicine 11: pp. 156-163. (1972)
102. Radó JP, Borbely L.
Glybenclamide enhancement of polyuria in patients with pituitary diabetes insipidus (preliminary report).
Endokrinologie 59: pp. 397-402. (1972)
103. Radó JP, Szende L, Tako J, Goth E, Fovenyi J.
Clinical value of the combination of vasopressin and chlorpropamide in a patient with "refractory" diabetes insipidus.
Endokrinologie 59: pp. 203-212. (1972)
104. Szende L, Radó JP, Tako J, Devenyi I.
Hyperkalemia and coma associated with renal tubular acidosis in an old patient with refractory edema due to the nephrotic syndrome: furosemide-bicarbonate therapy.
Journal of the American Geriatrics Society 20: pp. 102-115. (1972)
105. Szende L, Radó J, Tako J.
Clinicopharmacological study of Trofurit (furosemide).
Therapia Hungarica 20: pp. 131-132. (1972)
106. Szende L, Radó J, Takó J, Dévényi I.
Hyperkalaemiával járó renális tubuláris acidosis nephrosis szindrómában
Magyar Belorvosi Archivum 25: p. 283. (1972)

1973

107. Herman E, Goth E, Radó J.
[Successfully treated anorexia nervosa associated with hyperaldosteronism]
Orvosi Hetilap 114: pp. 1754-1756. (1973)
108. Radó J, Juhos E, Szende L, Marosi J, Tako J, Salamon F.

- [The effect of massive intravenous doses of furosemide in chronic kidney failure]
Orvosi Hetilap 114: pp. 1224-1228. (1973)
109. Radó J, Andor M, Marosi J, Takó J.
A chlorpropamid hypoglykaemia megelőzése diazoxiddal diabetes insipidusban és hypophysis elülsőlebeny insuffitentiában szenvedő betegen
Medicus Universalis 6: p. 13. (1973)
110. Radó J, Szende L, Borbély L, Bános CS, Takó J, Fischer J.
Egészséges egyének és hypertoniás betegek eltérő válasza sóinfúzióra és furosemidre
Magyar Belorvosi Archivum 26: p. 27. (1973)
111. Radó JP, Marosi J, Szende L, Tako J.
Clinical value of the combinations of carbamazepine (tegretol), chlorpropamide (diabinese) and vasopressin in the treatment of pituitary diabetes insipidus.
Endokrinologie 62: pp. 297-309. (1973)
112. Radó JP.
Clinical use of additive antidiuretic action of carbamazepine and chlorpropamide.
Hormone and Metabolic Research 5: p. 309. (1973)
113. Radó JP, Szabo T, Szende L, Tako J, Devenyi I, Hutas I, Gartner P, Gergely R.
Excessive decrease in free water clearance induced by furosemide and ethacrynic acid in nephrogenic diabetes insipidus associated with renal tubular acidosis.
Endokrinologie 61: pp. 413-429. (1973)
114. Radó JP, Szende L, Tako J, Halmos T.
Effects of intravenous diazoxide and chlorpropamide on renal function in man.
American Heart Journal 85: pp. 755-766. (1973)
115. Radó JP, Juhos E, Szende L, Marosi J, Tako J, Salamon F.
Acute renal effects of high doses of furosemide administered intravenously in patients with advanced chronic renal insufficiency.
Journal of Medicine 4: pp. 219-232. (1973)
116. Radó JP.
Falsely high fluorescence in cortisol determinations due to the carbamazepine.
Hormone and Metabolic Research 5: p. 63. (1973)
117. Radó JP.
Water intoxication during carbamazepine treatment
British Medical Journal (BMJ) 3: p. 479. (1973)
118. Radó JP, Szende L, Takó J, Góth E, Fövényi J.
Clinical Value of the Combination of Vasopressin and Chlorpropamide in a Patient with "refractory diabetes insipidus"
In: Pissiotis CA. Pissiotis CA (szerk.) Vasopressin II: Clinical Aspects. New York: 1973. pp. 69-78.
MSS Information Corporation

1974

119. Radó J, Marosi J, Szende L, Juhos É, Takó J, Fischer J
A chlorpropamid (Diabinese) és a carbamazepin (Tegretol) együttes alkalmazása a diabetes insipidus nehezen befolyásolható eseteiben
Magyar Belorvosi Archivum 27: p. 59. (1974)
120. Radó JP, Szende L, Tako J, Nagy O
Use of a simple fluorometric 11-hydroxycorticosteroids assay in the assessment of spironolactone-metabolite level in plasma and urine.

- Endokrinologie 64: pp. 22-32. (1974)
121. Radó JP, Simon T, Juhos E, Tako J, Nagy O
Interference of psychotropic drugs with cortisol determinations.
Hormone and Metabolic Research 6: pp. 530-531. (1974)
 122. Radó JP, Vegh L, Sawinsky I
Interference of triameterene with cortisol determination in urine.
Hormone and Metabolic Research 6: pp. 429-430. (1974)
 123. Radó JP, Szende L, Tako J
Drug-induced inhibition of the diuretic response to water loading in partial vasopressin responsive nephrogenic diabetes insipidus.
International Journal of Clinical Pharmacology, Therapy and Toxicology 10: pp. 64-69. (1974)
 124. Radó JP, Borbely L, Szende L, Fischer J, Tako J
Investigation of the diuretic effect of glibenclamide in healthy subjects and in patients with pituitary and nephrogenic diabetes insipidus.
Hormone and Metabolic Research 6: pp. 289-292. (1974)
 125. Radó JP, Szende L, Marosi J, Juhos E, Sawinsky I, Tako J
Inhibition of the diuretic action of glibenclamide by clofibrate, carbamazepine and 1-deamino-8-d-arginine-vasopressin (DDAVP) in patients with pituitary diabetes insipidus.
ACTA Diabetologica Latina 11: pp. 179-197. (1974)
 126. Radó JP, Szende L
Inhibition of clofibrate-induced antidiuresis by glybenclamide in patients with pituitary diabetes insipidus.
Journal of Clinical Pharmacology 14: pp. 290-295. (1974)
 127. Radó JP
Combination of carbamazepine and chlorpropamide in the treatment of "hyposponder" pituitary diabetes insipidus.
Journal of Clinical Endocrinology and Metabolism 38: pp. 1-7. (1974)
 128. Radó JP, Borbely L, Szende L, Tako J
Decreased antidiuretic response to lysine-vasopressin after acute administration of glibenclamide in healthy subjects.
ACTA Diabetologica Latina 11: pp. 18-21. (1974)
 129. Radó JP, Szende L, Marosi J
Influence of glyburide on the antidiuretic response induced by 1-deamino-8-D-arginine vasopressin (DDAVP) in patients with pituitary diabetes insipidus.
Metabolism-Clinical and Experimental 23: pp. 1057-1063. (1974)
 130. Szende L, Radó J, Takó J
Klinikopharmakologiai vizsgálatok Tendor-ral egy új vérnyomáscsökkentővel
Medicus Universalis 7: pp. 3-8. (1974)
 131. Tako J, Radó J
[Current trends and problems in the treatment of diabetes insipidus]
Orvosi Hetilap 115: pp. 427-430. (1974)

1975

132. Radó J, Szende L, Borbely L, Marosi J, Juhos E, Tako J
[The diuretic action of a new antidiabetic drug (glybenclamide)]
Orvosi Hetilap 116: pp. 249-253. (1975)
133. Radó JP, Marosi J, Fischer J, Tako J, Kiss N

- Relationship between the dose of 1-deamino-8-d-arginine vasopressin (ddavp) and the antidiuretic response in man.
Endokrinologie 66: pp. 184-195. (1975)
134. Radó JP, Marosi J
Prolongation of duration of action of 1-deamino-8-D-arginine vasopressin (DDAVP) by ineffective doses of clofibrate in diabetes insipidus.
Hormone and Metabolic Research 7: pp. 527-528. (1975)
135. Radó JP, Juhos E, Sawinsky I
Dose-response relations in drug-induced inappropriate secretion of ADH: effects of clofibrate and carbamazepine.
International Journal of Clinical Pharmacology and Biopharmacy 12: pp. 315-319. (1975)
136. Radó JP, Borbely L
Inhibition of the antidiuretic effect of 1-deamino-8d-arginine vasopressin (DDAVP) by glibenclamide in water-loaded healthy subjects.
Endokrinologie 66: pp. 88-93. (1975)
137. Radó JP
Evidence for permanent enhancement of residual ADH induced by antidiuretic agents (chlorpropamide, carbamazepine, clofibrate) in patients with pituitary diabetes insipidus.
Endokrinologie 64: pp. 217-222. (1975)
138. Radó JP, Borbély L
Inhibition of the antidiuretic effect of 1-deamino-8D-arginine vasopressin (DDAVP) by glibenclamide in water-loaded healthy subjects.
Hormone and Metabolic Research 7: p. 104. (1975)

1976

139. Radó J, Marosi J, Szende L, Borbely L, Tako J, Fischer J
[Studies of a new synthetic vasopressin derivative (DDAVP) in man]
Orvosi Hetilap 117: pp. 775-778. (1976)
140. Radó JP, Marosi J, Borbely L, Tako J
Individual differences in the antidiuretic response induced by single doses of 1-deamino-8-D-arginine-vasopressin (DDAVP) in patients with pituitary diabetes insipidus.
International Journal of Clinical Pharmacology and Biopharmacy 14: pp. 259-265. (1976)
141. Radó JP
Interference of bencyclan with 11-hydroxycorticosteroids determinations.
International Journal of Clinical Pharmacology and Biopharmacy 14: pp. 186-188. (1976)
142. Radó JP, Sawinsky I, Juhos E
Reversal of the suppressed potassium excretion during treatment with combinations of antikaliuretic drugs (spironolactone, canrenone, triamterene, amiloride) in patients with liver cirrhosis.
International Journal of Clinical Pharmacology and Biopharmacy 14: pp. 163-167. (1976)
143. Radó JP, Marosi J, Fischer J
Shortened duration of action of 1-deamino-8-D-arginine vasopressin (DDAVP) in patients with diabetes insipidus requiring high doses of peroral antidiuretic drugs.

- Journal of Clinical Pharmacology 16: pp. 518-524. (1976)
144. Radó JP
Change in antikaliuretic response to potassium-sparing diuretics in patients with cirrhotic ascites.
Journal of The American Geriatrics Society 24: pp. 340-343. (1976)
145. Radó JP, Juhos E
Effect of 1-deamino-5-D-arginine vasopressin (DDAVP) on plasma cortisol (hydrocortisone).
Journal of Clinical Pharmacology 16: pp. 333-337. (1976)
146. Radó JP, Juhos E
Opposite effects of spironolactone and amiloride on potassium excretion in a patient with ascites due to liver cirrhosis.
Endokrinologie 67: pp. 377-379. (1976)
147. Radó JP
Decreased antidiuretic response in diabetes insipidus during prolonged treatment with carbamazepine presumably due to enzym-induction.
Endokrinologie 67: pp. 322-330. (1976)
148. Radó JP, Marosi J
Lengthening of the duration of action of DDAVP by "ineffective" doses of clofibrate in patients with pituitary diabetes insipidus.
Endokrinologie 67: pp. 220-229. (1976)
149. Radó JP, Sawinsky I, Juhos E
Paradoxical reversal of the suppressed potassium secretion during treatment with combinations of antikaluretic agents (spironolactone, canrenone, triamterene, amiloride); a possible site of action in Henle's loop.
Hormone and Metabolic Research 8: pp. 250-251. (1976)
150. Radó JP, Marosi J, Szende L, Borbely L, Tako J, Fischer J
The antidiuretic action of 1-deamino-8-D-arginine vasopressin (DDAVP) in man.
International Journal of Clinical Pharmacology and Biopharmacy 13: pp. 199-209. (1976)
151. Radó JP, Marosi J, Borbely L, Tako J
Individual differences in the antidiuretic response induced by DDAVP in diabetes insipidus.
Hormone and Metabolic Research 8: pp. 155-156. (1976)
152. Radó JP, Szende L, Tako J, Nagy O, Kozma C
Application of a simple fluorometric method on absorption of canrenone.
International Journal of Clinical Pharmacology and Biopharmacy 13: pp. 123-126. (1976)
153. Radó JP, Szende L, Szucs L
Hyperkalemia unresponsive to massive doses of aldosterone in a patient with renal tubular acidosis.
Endokrinologie 68: pp. 183-188. (1976)
154. Radó JP, Szende L, Szucs L
Hyperkalemia unresponsive to massive doses of aldosterone and renal tubular acidosis in a patient with chronic interstitial nephritis: clinical and experimental studies.
Journal of Medicine 7: pp. 481-510. (1976)
155. Radó JP
Response to vasopressin analogues in diabetes insipidus
New England Journal of Medicine 295: p. 393. (1976)

156. Szam I, Radó J, Tako J
[Long-range therapy of hypertension]
Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete 31: pp. 321-324. (1976)
157. Szende L, Radó JP
[Letter: Significance of enzyme induction in decrease in the anti-diuretic effect of carbamazepine]
Nouvelle Presse Médicale 5: pp. 798-799. (1976)
158. Szende L, Marosi J, Radó J
[Letter: Is Halidor a hallucinogen?]
Orvosi Hetilap 117: p. 1309. (1976)

1977

159. Radó JP
Effect of mineralocorticoids on the paradoxical glucose-induced hyperkalemia in nondiabetic patients with selective hypoaldosteronism.
Research Communications in Chemical Pathology and Pharmacology 18: pp. 365-368. (1977)
160. Radó JP, Simatupang T, Boer P, Dorhoutmees E J
"Upright hyperkalemia" in selective hypoaldosteronism.
Endokrinologie 70: pp. 218-220. (1977)
161. Radó JP, Simatupang T, Boer P, Dorhout Mees E J
Postural plasma aldosterone response in "upright hyperkalemia" associated with selective hypoaldosteronism.
Biomedicine 27: pp. 209-211. (1977)
162. Radó JP
Effect of pharmacological doses of aldosterone on the hyperosmolality-induced hyperkalemia.
Hormone and Metabolic Research 9: p. 251. (1977)
163. Radó JP, Marosi J, Fischer J
Comparison of the antidiuretic effects of single intravenous and intranasal doses of DDAVP in diabetes insipidus.
Pharmacology 15: pp. 40-45. (1977)
164. Radó JP, Vegh L
Interference of beta-blocking drugs with cortisol determinations.
International Journal of Clinical Pharmacology and Biopharmacy 15: pp. 5-6. (1977)

1978

165. Radó JP
Regulation of plasma aldosterone by glucose-induced paradoxical hyperkalemia in the presence of suppressed renin-angiotensin system.
Endokrinologie 72: pp. 51-56. (1978)
166. Radó JP
1-desamino-8-D-arginine vasopressin (DDAVP) concentration test.
American Journal of the Medical Sciences 275: pp. 43-52. (1978)
167. Radó JP, Simatupang T, Boer P, Dorhout Mees E J
Pharmacologic studies in Bartter's syndrome: effect of DDAVP and indomethacin on renal concentrating operation. Part II.

International Journal of Clinical Pharmacology and Biopharmacy 16: pp. 22-26. (1978)

168. Simatupang TA, Radó JP, Boer P, Geyskes GG, Vos J, Dorhout Mees E J
Pharmacologic studies in Bartter's syndrome: opposite effects of treatment with antikaliuretic and antiprostaglandin drugs. Part I.
International Journal of Clinical Pharmacology and Biopharmacy 16: pp. 14-18. (1978)

1979

169. Miskovits G, Radó JP, Toth A, Zolnay E
Efficacy, safety and hypothalamic-pituitary-adrenal axis function in patients with asthma treated with cloprednol.
Respiration 38: pp. 345-352. (1979)
170. Radó JP
Glucose-induced paradoxical hyperkalemia in patients with suppression of the renin-aldosterone system: prevention by sodium depletion.
Journal of Endocrinological Investigation 2: pp. 401-406. (1979)
171. Radó JP, Boer P
Effect of DDAVP on plasma renin activity in man.
International Journal of Clinical Pharmacology and Biopharmacy 17: pp. 307-310. (1979)
172. Radó JP, Boer P
Regulations of plasma aldosterone in young hyperkalemic patients with stable chronic renal failure.
Endokrinologie 73: pp. 173-185. (1979)
173. Radó JP, Simatupang T, Boer P, Mees E J
Increase of serum potassium in the upright posture in selective hypoaldosteronism.
Hormone and Metabolic Research 11: pp. 47-51. (1979)
174. Radó JP, Boer P, Dorhout Mees EJ, Simatupang T
"Outpatient hyperkalemia" syndrome in renal and hypertensive patients with suppressed aldosterone production.
Journal of Medicine 10: pp. 145-157. (1979)

1980

175. Marosi J, Radó JP, Salamon F, Cseh Gy, Hajós Gy, Szántó S
Clinical observations in ectopic Cushing's syndrome caused by a mediastinal tumor; extraction of an adrenocorticotrophin-like substance from the neoplastic tissue and determination of its activity
In: Beers RF, Basett EG (szerk.)
Polypeptide Hormones: [Based on a 3-day conference held at the Johns Hopkins Medical Institutions]. 528 p.
New York: Raven Press, 1980. pp. 155-162.
(Miles international symposium series; 12)
176. Radó J
Vesehatású gyógyszerek (antidiuretikumok és diuretikumok) klinikai farmakológiai vizsgálata: Endocrin és renalis pharmacologia
1980.
Disszertáció /Kandidátus /
177. Radó J

Diureticumok

Gyógyszereink 30: pp. 49-65. (1980)

178. Radó JP, Juhos E, Dorhout Mees E J
Renal response to graded intravenous hypertonic NaCl infusion in healthy and hypertensive subjects: dose-related impairment in distal NaCl reabsorption.
American Heart Journal 100: pp. 183-190. (1980)
179. Radó JP
A possible role for insulin in the prevention of glucose-induced paradoxical hyperkalemia during sodium depletion.
Hormone and Metabolic Research 12: pp. 338-339. (1980)
180. Radó JP, Marosi J, Takó J, Szántó S, Salamon F
Effect of synthetic and standard ACTH on urinary hydrocortisone excretion as determined by fluorometry
In: Beers RF, Basett EG (szerk.)
Polypeptide Hormones: [Based on a 3-day conference held at the Johns Hopkins Medical Institutions]. 528 p.
New York: Raven Press, 1980. pp. 97-103.
(Miles international symposium series; 12.)

1981

181. Gercsak G, Hartai A, Faber K, Radó J
[Acute interstitial nephritis caused by a semisynthetic penicillin (methicillin)]
Orvosi Hetilap 122: pp. 2297-2300. (1981)
182. Radó J, Simatupang T, Boer P, Mees E J
[The role of prostaglandins in the pathogenesis of Bartter's syndrome]
Orvosi Hetilap 122: pp. 1519-1527. (1981)
183. Radó JP
Reversal of glucose-induced hyperkalemia by sodium restriction in "normaldosteronemic" diabetes mellitus.
Endokrinologie 78: pp. 244-252. (1981)
184. Radó JP
Glucose-induced hyperkalemia in normaldosteronemic diabetes associated with hyperthyroidism.
Endokrinologie 78: pp. 239-243. (1981)
185. Radó JP
Glucose-induced hyperkalemia in diabetic subjects.
Archives of Internal Medicine 141: pp. 1721-1722. (1981)
186. Radó JP
Reversal of glucose-induced hyperkalemia by sodium restriction in normaldosteronemic diabetes: evidence for elevated mineralocorticoid threshold.
Biomedicine 35: pp. 109-111. (1981)
187. Radó JP, Hartai A, Karpati E, Gercsak G, Molnar Z
Influence of posture on serum potassium changes during standard glucose tolerance test.
Research Communications in Chemical Pathology and Pharmacology 32: pp. 179-180. (1981)

1982

188. Molnár Zs, Radó J
Többszörös csigolyafracturával járó osteoporosist okozó larvált hyperthyreosis

- Magyar BelorvosI Archivum 35: pp. 256-260. (1982)
189. Radó J, Hartai A, Gercsak G, Jancso A, Ban K, Winkler G, Ghyczy E
Hypercalcemia-causing side effects of diuretics
Orvosi Hetilap 123: pp. 159-162. (1982)
Matarka
190. Radó J, Pató É, Fáber K
Kómával járó hypoglycaemia és tejsavacidosis kezeletlen cukorbeteg
Magyar Belorvosi Archivum 35: pp. 261-269. (1982)
191. Radó J, Molnár Zs, Hartai A, Gercsák Gy
Azosemid új diureticum
Magyar Belorvosi Archivum 35: p. 177. (1982)
192. Radó JP, Molnar Z, Hartai A, Gercsak G
Comparison of azosemide and furosemide in ascitic patients without and during
administration of spironolactone.
International Journal of Clinical Pharmacology, Therapy and Toxicology 20: pp.
532-537. (1982)
193. Radó JP
A possible role for human growth hormone (HGH) in the protection from glucose-
induced hyperkalemia in normaldosteronemic diabetes.
Endokrinologie 80: pp. 364-366. (1982)
194. Radó JP
A role for the upright posture in the development of glucose-induced
hyperkalemia; prevention by a mineralocorticoid.
Hormone and Metabolic Research 14: p. 551. (1982)
195. Radó JP, Banos C, Gercsak G, Molnar Z, Pato E, Csabuda M
Glucose-induced hyperkalemia developing in the upright position in captopril-
treated hypertensives.
Research Communications in Chemical Pathology and Pharmacology 38: pp. 161-
164. (1982)
196. Radó JP, van Wimersma Greidanus TB, Boer P, Mees EJ
Free water excretion due to suppressed vasopressin and stimulated aldosterone
during sodium restriction in hypoaldosteronemic renal failure.
Endokrinologie 79: pp. 266-280. (1982)
197. Radó JP, Hartai A
Simultaneous occurrence of hyperkalemia due to aldosterone suppression and
hyperfunctioning parathyroid adenoma.
Endokrinologie 79: pp. 259-265. (1982)
198. Radó JP
Glucose-induced paradoxical increase in HGH with potentiated decrease in serum
potassium in chronic renal failure.
Hormone and Metabolic Research 14: p. 105. (1982)

1983

199. Gercsak G, Pato E, Faber K, Juhos E, Radó J
[Disappearance of diabetes insipidus caused by a metastasis tumor in the anterior
pituitary gland]
Orvosi Hetilap 124: pp. 1017-1019. (1983)
200. Radó J, Szucs L
[Hyponatremia in malignant renovascular hypertension]
Orvosi Hetilap 124: pp. 2621-2628. (1983)

201. Radó J, Gercsak G, Pato E, Csabuda M, Molnar Z
[Captopril: a new method in the treatment of hypertension]
Orvosi Hetilap 124: pp. 1687-1691. (1983)
202. Radó J, Pato E
[Schwartz-Bartter syndrome following long-term DDAVP therapy in a patient with diabetes insipidus]
Orvosi Hetilap 124: pp. 1323-1326. (1983)
203. Radó J, Pató É, Gercsák Gy, Csabuda M
Bétareceptor blokkolók és captopril hatása a szérum kálium szintre és a renin-aldosteron rendszerre
Magyar Belorvosi Archivum 36: p. 249. (1983)
204. Radó J, Gercsák Gy, Pató É
A captopril hatása a veseműködésre gyógyszerrezisztens hypertóniában
Magyar Belorvosi Archivum 36: p. 288. (1983)
205. Radó J, Pató É
Hypoaldosteronismus syndroma (pseudohypoaldosteronismus) és u.n. "4 típusu" renalis tubularis acidosis polycystás vesebajban
Magyar Belorvosi Archivum 36: p. 145. (1983)
206. Radó JP
Glucose-induced hyperkalemia during captopril treatment.
Archives of Internal Medicine 143: p. 389. (1983)

1984

207. Gercsák Gy, Radó J
Határérték hypertonia
Orvosképzés 59: p. 392. (1984)
208. Radó J, Vönöczky K, Csabuda M, Karácsony É
Viz-intoxicatio
Magyar Belorvosi Archivum 37: pp. 197-203. (1984)
209. Radó J, Gercsák Gy
Cukor által okozott paradox hyperkaliaemia függőleges testhelyzetben captoprillal kezelt hypertóniásokon: Összefüggés plasma aldosteronnal, szérum insulinnal és vesefunkciókkal
Magyar Belorvosi Archivum 37: p. 76. (1984)
210. Radó JP
Glucose induced paradoxical serum potassium elevation exclusively in the upright posture in metoprolol treated hypertensives.
Research Communications in Chemical Pathology and Pharmacology 46: pp. 159-160. (1984)
211. Radó JP
Prediction of hyperkalemia associated with prolonged treatment with captopril by glucose-induced acute serum potassium changes.
Experimental and Clinical Endocrinology 84: pp. 143-147. (1984)
212. Radó JP, Banos C, Gercsak G, Molnar Z
Effect of body posture on the serum potassium response to glucose in healthy subjects, diabetics and hyperthyroid patients.
Experimental and Clinical Endocrinology 83: pp. 275-282. (1984)
213. Radó JP, Gercsak GY, Banos C S
Effect of posture and a mineralocorticoid on the glucose-induced hypokalemia in man.

- Biomedicine & Pharmacotherapy 38: pp. 212-213. (1984)
214. Radó JP, Gercsak G, Banos C
Relationships between glucose-induced elevation of serum potassium in the upright posture, hormonal changes and renal functions in captopril-treated hypertensives.
Hormone and Metabolic Research 16: p. 57. (1984)

1985

215. Radó J, Gercsak G
[Increased edema susceptibility during diuretic treatment]
Orvosi Hetilap 126: pp. 3099-3101. (1985)
216. Radó J, Gercsak G
[Life-threatening hyperkalemia alternating with hypokalemia in kidney diseases]
Orvosi Hetilap 126: pp. 2661-2664. (1985)
217. Radó J, Pato E, Czigner J, Faber K
[Pseudoresistance to DDAVP in diabetes insipidus]
Orvosi Hetilap 126: pp. 2043-2046. (1985)
218. Radó J, Csabuda M
[A successfully treated case of spironolactone-induced hyperkalemic quadriplegia]
Orvosi Hetilap 126: pp. 1967-1970. (1985)
219. Radó JP, Csabuda M, Banos C
Influence of body posture on aldosterone suppression after antihypertensive drugs (captopril and metoprolol).
Hormone and Metabolic Research 17: pp. 615-616. (1985)
220. Radó JP
Posture as a contributing factor to beta-blockade-induced hyperkalaemia.
European Journal of Clinical Pharmacology 28: pp. 359-360. (1985)

1986

221. Radó J, Csanyi P, Gercsak G, Osvath J
[Water intoxication in mental patients (study of the effects of psychotropic drugs and smoking)]
Orvosi Hetilap 127: pp. 2993-2999. (1986)
222. Radó J
[Progressive hyperkalemia during chronic captopril therapy (pharmacological hypoaldosteronism)]
Orvosi Hetilap 127: pp. 899-902. (1986)
223. Radó J
Captopril monoterápia és kombinált kezelés: Kerekasztal konferencia Balatonfüred 1986
Cardiologia Hungarica 17:(2) pp. 121-134. (1986)
224. Radó J, Pató É
Spironolacton által okozott neuropsychiatriai rendellenességek
Magyar Belorvosi Archivum 39: pp. 42-49. (1986)
225. Radó J, Csabuda M, Pató É, Gercsák Gy
Metoprolol és captopril hatása a szérum kálium szintre
Magyar Belorvosi Archivum 39: pp. 101-109. (1986)
226. Radó J
A szintétikus ACTH humán farmakológiája és diagnosztikus használata

- Orvosképzés 61: pp. 63-80. (1986)
227. Radó J
A plasma aldosteron változása gyógyszer (metoprolol,captopril) és függőleges testhelyzet hatására
Kísérletes Orvostudomány 38: p. 235. (1986)
228. Radó JP, Gercsak G, Banos C
Interplay of various factors in glucose-induced hyperkalemia during captopril treatment.
International Journal of Clinical Pharmacology, Therapy and Toxicology 24: pp. 69-76. (1986)

1987

229. Radó J
Endokrin tényezők szerepe a plasma kálium szabályozásában
Orvosképzés 62: p. 361. (1987)
230. Radó J, Zdravkova Sz, Gercsák Gy
Hyperkalaemiás bélparalízis
Medicus Universalis 20:(2) pp. 75-77. (1987)
231. Radó JP
Drug-induced electrolyte disturbances
Giornale Italiano di Chim Clin 12: p. 173. (1987)

1988

232. Csanyi P, Radó JP, Hormay M
Acute renal failure due to cephamandole.
British Medical Journal (BMJ) 296: p. 433. (1988)
233. Csanyi P, Hormay M, Radó J
[Cefamandole-induced acute kidney failure]
Orvosi Hetilap 129: pp. 2531-2533. (1988)
234. Honti J, Szam I, Radó J
[Hann syndrome: remission of diabetes insipidus by functional failure of the anterior pituitary gland]
Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete 43: pp. 414-415. (1988)
235. Pato E, Radó J
[Severe bone damage in a patient with primary hypoparathyroidism treated as an epileptic with anticonvulsants]
Orvosi Hetilap 129: pp. 2637-2640. (1988)
236. Radó J, Gercsak G, Horvath F
[Diuretic-induced pseudo-Bartter syndrome in idiopathic edema]
Orvosi Hetilap 129: pp. 1703-1705. (1988)
237. Radó J
[Electrolyte disorders caused by drugs]
Orvosi Hetilap 129: pp. 25-31. (1988)
238. Radó J
Monotherapy and combined treatment with captopril.
ACTA Physiologica Hungarica 72 Suppl: pp. 23-35. (1988)
239. Radó J
Angiotensin convertáló enzyngátló és bétablokkoló kezelés hatása idiopathiás oedémában

- Magyar Belorvosi Archivum 41: p. 297. (1988)
240. Radó JP
Successful treatment of hyperkalemic quadriplegia associated with spironolactone.
International Journal of Clinical Pharmacology, Therapy and Toxicology 26: pp. 339-345. (1988)

1989

241. Radó J, Taller A
[Partial diabetes insipidus and ascitic liver cirrhosis in a patient]
Orvosi Hetilap 130: pp. 2045-2048. (1989)
242. Radó J, Csanyi P
[Hyponatremia caused by water intoxication induced by diuretics]
Orvosi Hetilap 130: pp. 25-26. (1989)
243. Radó J, Juhász E, Pataki E
Klinikai farmakologiai vizsgálatok kaptoprillal, különös tekintettel az idős korra
Gyógyszereink 39: pp. 139-145. (1989)
244. Radó JP
Endocrinological aspects of potassium metabolism.
ACTA Physiologica Hungarica 74: pp. 95-102. (1989)
245. Vonoczky K, Radó J
[The effect of carbamazepine on water metabolism in epileptics]
Orvosi Hetilap 130: pp. 267-268. (1989)

1990

246. Radó JP, Taller A
Simultaneous occurrence of diabetes insipidus and ascites due to liver cirrhosis: clinical and pathophysiological studies.
Experimental and Clinical Endocrinology 95: pp. 369-373. (1990)

1991

247. Csányi P, Radó J
A vérnyomáscsökkentő gyógyszerek interakciói
Gyógyszereink 41: pp. 22-44. (1991)
248. Haris Ágnes, Radó János
Az erythromycin mellékhatásai, különös tekintettel a májra
Gyógyszereink 41: pp. 251-256. (1991)
249. Radó J, Zdravkova S
[Lithium-induced chronic water-metabolism disorder (nephrogenic diabetes insipidus)]
Orvosi Hetilap 132: pp. 1987-1990. (1991)

1992

250. Aranyi J, Radó J
[Rhabdomyolysis in a medical student induced by body-building exercise (rhabdomyolysis following acute muscular exertion)]
Orvosi Hetilap 133: pp. 1965-1967. (1992)
251. Haris Á, Radó J

- Az antiepileptikumok által okozott csontkárosodás újabb adatok megvilágításában
Gyógyszereink 42: pp. 112-121. (1992)
252. Radó J, Pato E
[Circadian rhythm of blood pressure in hypertension treated with enalapril and other drugs]
Orvosi Hetilap 133: pp. 3299-3303. (1992)
253. Radó János, Haris Ágnes, Pató Éva
Antiepileptikum osteomalacia és renalis tubuláris acidosis sclerosis tuberosában
Orvosi Hetilap 133:(5) pp. 293-296. (1992)
Matarka

1993

254. Kovács A, Radó J
A hyperinsulinaemiával és insulinresistentiával járó hypertonia kezelése
Gyógyszereink 43: pp. 76-85. (1993)
255. Pató É, Radó J
A foszfor szerepe a vesebetegség progressziójában
Magyar Belorvosi Archivum 46: pp. 357-366. (1993)
256. Pató É, Radó J, Kerényi K, Megyeri G
Az adenoma bizonyításának szokatlan nehézségei két primer parathyreosis esetben Uzsoki Kórház Év 1993, Szerk.:Radó J;Szegedy L; 79-93 old (1993)
Egyéb /Nem besorolt /
[Cikk munkahely kiadványában]
257. Radó J, Aranyi J, Deak G, Retai G
[Pseudophaeochromocytoma (hypertensive crisis as a result of beta receptor hypersensitivity?)]
Orvosi Hetilap 134: pp. 919-922. (1993)
258. Radó JP, Haris A
Metabolic bone disease (anticonvulsant osteomalacia) and renal tubular acidosis in tuberous sclerosis.
Internal Medicine 32: pp. 574-579. (1993)

1994

259. Haris A, Radó J
[Atrial natriuretic factor: a "physiological diuretic"]
Orvosi Hetilap 135: pp. 339-345. (1994)
260. Radó J, Pato E
[Clinical spectrum of distal renal tubular acidosis and its study with bicarbonate loading]
Orvosi Hetilap 135: pp. 2695-2699. (1994)
261. Radó J, Pato E, Haris A, Balogh I
[Effect of calcitriol, a vitamin D compound, in bone disease associated with distal renal tubular acidosis]
Orvosi Hetilap 135: pp. 2319-2323. (1994)

1995

262. Radó J, Csabuda M, Kiss L
[The effect of captopril on the acidification function of the kidney in hypertension]

- Orvosi Hetilap 136: pp. 1167-1169. (1995)
263. Radó J, Szende L
[Simultaneous familial occurrence of distal renal tubular acidosis, polycystic kidney and nephrogenic diabetes insipidus]
Orvosi Hetilap 136: pp. 995-1001. (1995)
264. Radó J, Pato E, Ilias L, Ivanyi T, Racz K, Laczi F
Ismétlődő súlyos vízmérgezések egy idős betegben (Adatok az "inappropriate antidiuretic hormone" syndroma és az atrialis natriureticus factor kapcsolatához)
Orvosi Hetilap 136: pp. 189-193. (1995)
265. Radó J
Renalis tubuláris acidosis és szövődménye a nephrogen diabetes insipidus 1995.
Disszertáció /Habilitációs anyag

1996

266. Haris A, Radó J
[Potassium-sparing diuretics (spironolactone, triamterene, amilorid)]
Orvosi Hetilap 137: pp. 1907-1914. (1996)
267. Haris Ágnes, Radó János
A spiramicin májfunkciókra gyakorolt hatásának prospectiv tanulmányozása klinikai beteganyagon
Gyógyszereink 46:(1) pp. 18-21. (1996)
268. Pato E, Radó J, Toth A, Aranyi J
[Water intoxication in pulmonary tuberculosis complicated by aspergillosis]
Orvosi Hetilap 137: pp. 751-753. (1996)

1997

269. Arányi J, Radó J
Teljes ízérzésvesztés terbinafin hatására ACE-gátlóval kezelt betegben
Hypertonia és Nephrologia 1: pp. 146-148. (1997)
270. Haris A, Radó J
[Hyponatremia]
Orvosi Hetilap 138: pp. 3087-3095. (1997)
271. Pato E, Radó J
[ACE inhibitor therapy of hemodialyzed patients]
Orvosi Hetilap 138: pp. 1903-1907. (1997)
272. Radó J, Toth A, Haris A
[Role of aldosterone in potassium secretion in chronic renal failure associated with hypertension (transtubular potassium gradient)]
Orvosi Hetilap 138: pp. 2517-2520. (1997)
273. Radó J, Haris A, Szebenyi B
[Adult-onset sex-linked familial hypophosphatemic osteomalacia]
Orvosi Hetilap 138: pp. 1683-1688. (1997)
274. Radó J
A diureticus terápiáról
Gyógyszerpiac: Gyógyszerforgalmazás Szakmai Folyóirata 5: pp. 12-16. (1997)
275. Radó J
Renalis tubularis acidosis
Hypertonia és Nephrologia 1: pp. 57-65. (1997)
276. Radó J, Tóth A, Mayer I
Hypokalaemiás tetraplegia polydipsiás betegben

- Hypertonia és Nephrologia 1: pp. 47-50. (1997)
277. Radó JP, Haris A, Szebenyi B
 Familial adult onset X-linked hypophosphataemic osteomalacia (report of a family; clinical and experimental studies).
 ACTA Physiologica Hungarica 85: pp. 199-214. (1997)

1998

278. Haris A, Toth A, Radó JP
 High-dose phosphate treatment leads to hypokalemia in hypophosphatemic osteomalacia.
 Experimental and Clinical Endocrinology & Diabetes 106: pp. 431-434. (1998)
279. Radó J
 [Nephrogenic diabetes insipidus]
 Orvosi Hetilap 139: pp. 559-563. (1998)
280. Radó J
 Gyógyszer és betegség interakció a szérum kálium szint szabályozásában 1998.
 Disszertáció /MTA Doktora /
281. Radó J, Arányi J
 Tüdőoedéma haemodialízis alatt ACE-gátló okozta veseelégtelenségben
 Hypertonia és Nephrologia 2: pp. 87-91. (1998)
282. Radó J
 Diureticumok vesebetegségekben
 Hypertonia és Nephrologia 2: pp. 118-126. (1998)
283. Radó J
 Diureticumok antihypertensiv hatásmechanizmusa
 Hypertonia és Nephrologia 2: pp. 3-7. (1998)
284. Radó J, Haris Á, Szebenyi B
 Successful treatment of familial x-linked hypophosphatemic osteomalacia with phosphate and high dose calcitriol
 European Journal of Internal Medicine 9: pp. 185-186. (1998)
285. Tóth Andor, Haris Ágnes, Radó János
 Hypokalaemia foszfátkezelés alatt hypophosphataemiás osteomaláciában szenvedő betegen
 Hypertonia és Nephrologia 2:(3) pp. 154-156. (1998)

1999

286. Haris A, Radó JP
 Patterns of potassium wasting in response to stepwise combinations of diuretics in nephrotic syndrome.
 International Journal of Clinical Pharmacology and Therapeutics 37: pp. 332-340. (1999)
287. Radó J, Haris A
 [Hyperkalemias]
 Orvosi Hetilap 140: pp. 2611-2618. (1999)
288. Radó J
 Eukalaemiás diuresis: Glibenclamid egy újfajta diureticum koncepciója
 Hypertonia és Nephrologia 3: pp. 310-313. (1999)
289. Radó J, Haris Á
 Káliumkiválasztási minták diureticumok lépcsőzetes kombinációi hatására oedémás vesebeteggekben

- Hypertonia és Nephrologia 3: pp. 184-193. (1999)
290. Radó J, Tóth A
Conn-syndroma diagnózisa ACE-gátlóval kezelt hypertóniában
Hypertonia és Nephrologia 3:(3) pp. 150-153. (1999)
291. Radó JP, Haris A
Patterns of potassium (K) wasting in response to stepwise combinations of diuretics in nephrotic syndrome.
Nephrology Dialysis Transplantation 14 Suppl 4: pp. 12-13. (1999)
292. Tóth A, Haris Á, Radó J
Hypokalaemia phosphat kezelés alatt hypophosphataemiás osteomaláciában is szenvedő hypertóniás betegben
Hypertonia és Nephrologia 3: pp. 58-60. (1999)

2000

293. Haris A, Radó J
[Transtubular potassium gradient in the diagnosis of potassium metabolism disorders]
Orvosi Hetilap 141: pp. 385-391. (2000)
294. Haris Á, Radó J
A transtubuláris kálium grádiens jelentősége és alkalmazása vesebetegségekben
Hypertonia és Nephrologia 4: pp. 93-99. (2000)
295. Matyus J, Szébenyi B, Redl P, Mikita J, Gaspar L, Haris A, Radó J, Kakuk G
[Hypophosphatemic oncogenic osteomalacia]
Orvosi Hetilap 141: pp. 2785-2788. (2000)
296. Radó J
Az angiotenzin vesehatásai emberben: Az angiotenzin infusio, az ACE-gátlók és receptor antagonisták vesehatásainak összevetése
Hypertonia és Nephrologia 4: pp. 3-13. (2000)
297. Radó J
Levelek a Szerkesztőhöz: Szerkesztőségi Kommentár dr. Mátyus János: Hazai Orvosi Szakirodalom Leveléhez
Hypertonia és Nephrologia 4:(5) pp. 272-273. (2000)

2001

298. Radó J
Izombénulás kálium anyagcsere zavar következtében: A hypokalaemiás és hyperkalaemiás paralysis előfordulásának összehasonlító elemzése az irodalom és saját tapasztalatok alapján
Hypertonia és Nephrologia 5: pp. 202-208. (2001)
299. Radó J
A "furosemid-renographia" felfedezése és jelentősége
Hypertonia és Nephrologia 6:(1) pp. 16-24. (2001)
300. Radó J
A furosemid vese-scintigraphia helye a húgyuti obstrukciók kivizsgálási algoritmusában
Magyar Radiológia 75: pp. 154-161. (2001)

2002

301. Radó J
[Let's read the domestic literature. ACE-inhibitors and spironolactone-induced hyperkalemia]
Orvosi Hetilap 143: p. 1868; author reply 1868. (2002)
302. Radó J
A diureticus kezelés indikációi és gyakorlati kivitelezése
Hippocrates (BP) 4: pp. 14-17. (2002)
303. Radó J
Tévhittek (csapdák) a diureticus kezelésben
Hypertonia és Nephrologia 6: pp. 86-96. (2002)
304. Radó J
Egy új vasodilatator-diureticum (dopamin receptor agonista fenoldopam) vesehatásainak összehasonlítása az angiotensin rendszerre ható gyógyszerekével és a pitvari natriureticus faktoréval
Hypertonia és Nephrologia 6:(3) pp. 174-176. (2002)
305. Radó J
Malignus hypertonia
In: Kornya László (szerk.)
Betegség enciklopédia I-II. 2564 p.
Budapest: Springer Kiadó, 2002. p. 663.
306. Radó J
Oncogen osteomalacia
In: Kornya László (szerk.)
Betegség enciklopédia I-II. 2564 p.
Budapest: Springer Kiadó, 2002. p. 672.
307. Radó J
Renovasularis hypertonia
In: Kornya László (szerk.)
Betegség enciklopédia I-II. 2564 p.
Budapest: Springer Kiadó, 2002. p. 691.
308. Radó J
Vizmérgezés
In: Kornya László (szerk.)
Betegség enciklopédia I-II. 2564 p.
Budapest: Springer Kiadó, 2002. p. 696.
309. Radó J
Renalis tubularis acidosis
In: Kornya László (szerk.)
Betegség enciklopédia I-II. 2564 p.
Budapest: Springer Kiadó, 2002. p. 688.

2003

310. Radó J
Renális tubuláris acidosis
In: Rosivall L, Kiss I (szerk.)
Nephrologia. Elmélet és klinikum, dialysis, transplantation. 1349 p.
Budapest: Medintel Kiadó, 2003. p. 373.
311. Radó J
Tubulopáthiák-renális tubuláris acidosis

- In: Rosivall L, Kiss I (szerk.)
Nephrologia. Elmélet és klinikum, dialysis, transplantation. 1349 p.
Budapest: Medintel Kiadó, 2003. p. 569.
312. Radó J
Diureticus therápia I.: Elmélet
Hypertonia és Nephrologia 7: pp. 153-161. (2003)
313. Radó J
Diureticus kezelés
Lege Artis Medicinae 13: pp. 120-125. (2003)
314. Radó J
Néhány adat a diureticumok történetéhez: Szerkesztői Levél
Hypertonia és Nephrologia 7:(3-4) pp. 204-206. (2003)

2004

315. Radó J
A vesefunkciók vizsgálata
In: Kakuk György (szerk.)
Klinikai nephrologia: a vese belgyógyászati betegségeinek kézie. 1201 p.
Budapest: Medicina kiadó, 2004. pp. 46-57.
316. Radó J
A tubuláris funkciók izolált zavarai
In: Kakuk György (szerk.)
Klinikai nephrologia: a vese belgyógyászati betegségeinek kézie. 1201 p.
Budapest: Medicina kiadó, 2004. p. 353.
317. Radó J
Aminoaciduriák In: Kakuk György (szerk.)
Klinikai nephrologia: a vese belgyógyászati betegségeinek kézie. 1201 p.
Budapest: Medicina kiadó, 2004. p. 353.
318. Radó J
Renális glucosuria
In: Kakuk György (szerk.)
Klinikai nephrologia: a vese belgyógyászati betegségeinek kézie. 1201 p.
Budapest: Medicina kiadó, 2004. p. 355.
319. Radó J
Phosphaturia
In: Kakuk György (szerk.)
Klinikai nephrologia: a vese belgyógyászati betegségeinek kézie. 1201 p.
Budapest: Medicina kiadó, 2004. p. 355.
320. Radó J
Hypouricaemia
In: Kakuk György (szerk.)
Klinikai nephrologia: a vese belgyógyászati betegségeinek kézie. 1201 p.
Budapest: Medicina kiadó, 2004. p. 358.
321. Radó J
Renalis tubuláris acidosis
In: Kakuk György (szerk.)
Klinikai nephrologia: a vese belgyógyászati betegségeinek kézie. 1201 p.
Budapest: Medicina kiadó, 2004. p. 359.
322. Radó J
Fanconi syndroma

- In: Kakuk György (szerk.)
Klinikai nephrologia: a vese belgyógyászati betegségeinek kézikönyve. 1201 p.
Budapest: Medicina kiadó, 2004. p. 367.
323. Radó J
Bartter-szindróma -hypokalaemiás tubuláris kórképek
In: Kakuk György (szerk.)
Klinikai nephrologia: a vese belgyógyászati betegségeinek kézikönyve. 1201 p.
Budapest: Medicina kiadó, 2004. p. 371.
324. Radó J
Nephrogen diabetes insipidus
In: Kakuk György (szerk.)
Klinikai nephrologia: a vese belgyógyászati betegségeinek kézikönyve. 1201 p.
Budapest: Medicina kiadó, 2004. p. 375.
325. Radó J
A haemolyticus uraemiás szindróma és a thromboticus thrombocytopeniás purpura (HUS/TTP)
In: Kakuk György (szerk.)
Klinikai nephrologia: a vese belgyógyászati betegségeinek kézikönyve. 1201 p.
Budapest: Medicina kiadó, 2004. p. 292.
326. Radó J
Sav-bázis és ionzavarok krónikus veseelégtelenségben
In: Kakuk György (szerk.)
Klinikai nephrologia: a vese belgyógyászati betegségeinek kézikönyve. 1201 p.
Budapest: Medicina kiadó, 2004. p. 644.
327. Radó J
Diureticus terápia
In: Kakuk György (szerk.)
Klinikai nephrologia: a vese belgyógyászati betegségeinek kézikönyve. 1201 p.
Budapest: Medicina kiadó, 2004. p. 1115.
328. Radó J
Diuretikus terápia II.: Diuretikumok alkalmazása
Hypertonia és Nephrologia 8: pp. 3-19. (2004)

2005

329. Radó J
Diuretikumok alkalmazásának speciális problémái diabetes mellitusban I. rész
Diabetologia Hungarica 13:(4) pp. 283-288. (2005)
330. Radó J
Diuretikumok
Nefrológiai Útmutató-Különszám *: pp. 133-139. (2005)
331. Radó J
A fagyáspontcsökkenéstől az osmolalitásig: Korányi Sándor Emlékelőadás 2004 alapján
Hypertonia és Nephrologia 9: pp. 4-13. (2005)
332. Radó J Andreoli Th.E., Ritz E., Rosivall L.:
Nephrology, Hypertension, Dialysis, Transplantation
Hypertonia és Nephrologia 9:(3-4) pp. 220-221. (2005)

2006

333. Radó J

- Diuretikumok alkalmazásának speciális problémái diabetes mellitusban II. rész
Diabetologia Hungarica 14:(1) pp. 51-58. (2006)
334. Radó J, Apor P
Szakirodalmi válogatások a vizintoxikációról.: Vizintoxikáció sportolás során, kórházban, börtönben, gyermekbántalmazás következtében, gyógyszerek hatására
Hypertonia és Nephrologia 10:(1) pp. 44-49. (2006)
335. Radó J
A halhatatlan Korányi Sándor elfelejtett sorai a hazai szerzők idézéséről:
Orvostörténelem
Hypertonia és Nephrologia 10:(1) pp. 50-52. (2006)

2007

336. Radó J
A tudomány vonzásában: Életmű gyógyszerhatásokról: a "mélyreásó" és az interdiszciplináris kutatás dilemmája az idézettség és az impakt faktor megvilágításában
Hypertonia és Nephrologia 11:(3) pp. 137-152. (2007)
337. Radó J
Humán farmakológiai kutatásaink desmopressinnel és más készítményekkel neurohypophyseális és nephrogen diabetes insipidusban:
I. Neurohypophyseális Diabetes Insipidus Hypertonia és Nephrologia 11:(4) pp. 181-198. (2007)
338. Radó J
Hyperkalaemia: Kommentár
Orvostovábbképző Szemle 14:(1) pp. 93-95. (2007)
339. Radó J
Humán farmakológiai kutatásaink desmopressinnel és más készítményekkel neurohypophyseális és nephrogen diabetes insipidusban II.: Nephrogen diabetes insipidus
Hypertonia és Nephrologia 11:(5) pp. 244-256. (2007)

2008

340. Haris Ágnes, Radó János
A víz- és elektrolitháztartás zavarai: Differenciáldiagnosztika és terápia Budapest: Medicina kiadó, 2008. 395 p.

2009

341. Alföldi S , Radó J , Reusz Gy
A hypertonia és nephrologia folyóirat története
I. Hypertonia és Nephrologia 13:(2) pp. 94-95. (2009)
342. Radó J
A tudomány vonzásában II.: Csapatmunkában vagy egyedül kutassunk: személyi részesedés a eredményben
Hypertonia és Nephrologia 13:(1) pp. 22-26. (2009)
/Esszé /
343. Radó J
Egy felfedezés magyar sorsa- a diuretikus renográfia
Lege Artis Medicinae 19:(2) p. 150. (2009)

344. Radó J
A hypertonia és nephrologia folyóirat története II.: Kortörténeti háttér
Hypertonia és Nephrologia 13:(3) pp. 134-135. (2009)
345. Radó J
Sóhajtó vízajtó, avagy a vízhatók szerepe magasvérnyomás-betegségben
Hypertonia és a Kardiiovaszkuláris Rendszer 1:(3) pp. 23-24. (2009)

2010

346. Radó J
A tudomány vonzásában III.: 55 éves életművem: mire jutottam
Hypertonia és Nephrologia 14:(2) pp. 73-77. (2010)

2011

347. Radó J
Scylla és Charybdis - A hypertonia kezelése
Hypertonia és Nephrologia 15:(1) p. 4. (2011)
348. Radó J
Vízajtók kombinációja rezisztens hypertoniában
Hypertonia és Nephrologia 15:(1) pp. 36-39. (2011)
349. Radó J
Tanárom, Gömöri Pál
Hypertonia és Nephrologia 15:(3) pp. 130-133. (2011)
350. Radó J
Uj referálórovat indul Kitekintő címmel: A szerkesztő levele
Hypertonia és Nephrologia 15:(3) p. 100. (2011)
351. Radó J, Kovács A
Diuretikum által okozott vízmérgezés
Hypertonia és Nephrologia 15:(2) pp. 81-85. (2011)
352. Radó J
Diabetes mellitus és (nephrogen) diabetes insipidus együttes előfordulása
Hypertonia és Nephrologia 15:(4) pp. 183-187. (2011)
353. Radó J
Az ember vízháztartása
Magyar Tudomány 2011:(12) pp. 1440-1446. (2011)
354. Radó J, Alföldi S, Reusz Gy A
Hypertonia és Nephrologia folyóirat története
In: Kiss I, Farsang Cs (szerk.)
A Magyar Hypertonia Társaság Éve 1993-2011. 136 p.
Budapest: Literatura Medica Kiadó Kft., 2011. pp. 83-85.
355. Székács Béla, Radó János, Kiss István
Az időskori hypertonia és kezelése
Orvostovábbképző Szemle Május:(Klnsz) pp. 35-38. (2011)

2012

356. Radó J
A tudomány vonzásában IV. Túl korán sem szabad közölni?: Magyar szerzők prioritását megmenti egy délamerikai radiológus
Hypertonia és Nephrologia 16:(2) pp. 78-82. (2012)
357. Radó J

A víz-és elektrolitháztartás zavarai: Kommentár
Orvostovábbképző Szemle 19:(10) pp. 13-15. (2012)

358. Radó J
Az endokrinológiai kutatások története az Uzsoki utcai kórházban és annak előzményei
In: Rácz Károly, Tóth Miklós (szerk.)
Fejezetek a magyar endokrinológia történetéből. 475 p.
Budapest: Semmelweis Kiadó, 2012. pp. 267-275.
359. Radó J
A diuretikus kezelés hazai története: I.rész Fodor Imre
Hypertonia és Nephrologia 16:(5) pp. 222-227. (2012)

2013

360. Radó János
Mit tettünk az elmúlt évben nagyjaink emlékének ápolásáért?
Hypertonia és Nephrologia 17:(5-6) pp. 207-208. (2013)
361. Radó János
Diuretikumok: (Vízajtók)
Hypertonia és a Kardiovaszkuláris Rendszer 6:(3) pp. 13-14. (2013)

2015

362. Radó J
Korányi Sándorról egy követője
Hypertonia és a Kardiovaszkuláris Rendszer 8:(1) pp. 18-19. (2015)

2016

363. Radó J
Magyar víruskutatás és a NASA-nephrológiai vonatkozásokkal: Varicella zosterben szenvedő betegekben végzett klinikai megfigyeléseink és laboratoriumi (virologiai) vizsgálataink
Hypertonia és Nephrologia 20:(2) pp. 93-96. (2016)

July 26, 2018

Contributions to psychotropic drug development with special reference to carbamazepine by János Radó

28 *articles*

I. Carbamazepine: Antidiuretic action: 20 articles

II. Carbamazepine: Water intoxication: 5 articles

III. Carbamazepine: Interaction with cortisol determination: 1 article

IV. Interference of psychotropic drugs with cortisol determination: 2 articles

I. Carbamazepine: Antidiuretic Action (20 articles)

1. Radó J: Az endokrinológiai kutatások története az Uzsoki utcai kórházban és annak előzményei. In: Rácz Károly, Tóth Miklós (szerk.). Fejezetek A Magyar Endokrinológia Történetéből. 475 P. Budapest: Semmelweis Kiadó, 2012. pp. 267-275.
2. Radó J: Az ember vízháztartása. Magyar Tudomány 2011:(12) pp. 1440-1446. (2011)
3. Haris Ágnes, Radó János: A Víz- és Elektrolitháztartás Zavarai: Differenciáldiagnosztika és Terápia. Budapest: Medicina Könyvkiadó, 2008. 395 p.
4. Radó J: Humán farmakológiai kutatásaink desmopressinnel és más készítményekkel neurohypophyseális és nephrogen diabetes insipidusban: I. Neurohypophyseális Diabetes Insipidus. Hypertonia és Nephrologia 11:(4) pp. 181-198. (2007)
5. Radó J: Humán farmakológiai kutatásaink desmopressinnel és más készítményekkel neurohypophyseális és nephrogen diabetes insipidusban II.: Nephrogen diabetes insipidus. Hypertonia és Nephrologia 11:(5) pp. 244-256. (2007)
6. Radó J: A fagyáspontcsökkenéstől az osmolalitásig: Korányi Sándor Emlékelőadás 2004 alapján. Hypertonia és Nephrologia 9: pp. 4-13. (2005)
7. Radó J: Vizmérgezés In: Kornya László (szerk.). Betegség Enciklopédia I-II. 2564 p. Budapest: Springer Tudományos Kiadó, 2002. p. 696.
8. Haris A, Radó J: Hyponatremia. Orvosi Hetilap 138: pp. 3087-3095. (1997)
9. Vonoczky K, Radó J: The effect of carbamazepine on water metabolism in epileptics. Orvosi Hetilap 130: pp. 267-268. (1989)
10. Radó JP: Decreased antidiuretic response in diabetes insipidus during prolonged treatment with carbamazepine presumably due to enzym-induction. Endokrinologie 67: pp. 322-330. (1976)
11. Szende L, Radó JP: Letter: Significance of enzyme induction in decrease in the anti-diuretic effect of carbamazepine. Nouvelle Presse Médicale 5: pp. 798-799. (1976)

12. Radó JP, Juhos E, Sawinsky I: Dose-response relations in drug-induced inappropriate secretion of ADH: effects of clofibrate and carbamazepine. *International Journal of Clinical Pharmacology and Biopharmacy* 12: pp. 315-319. (1975)
13. Radó JP: Evidence for permanent enhancement of residual ADH induced by antidiuretic agents (chlorpropamide, carbamazepine, clofibrate) in patients with pituitary diabetes insipidus. *Endokrinologie* 64: pp. 217-222. (1975)
14. Radó J, Marosi J, Szende L, Juhos É, Takó J, Fischer J: A chlorpropamid (Diabinese) és a carbamazepin (Tegretol) együttes alkalmazása a diabetes insipidus nehezen befolyásolható eseteiben. *Magyar Belorvosi Archivum* 27: p. 59. (1974)
15. Radó JP, Szende L, Tako J: Drug-induced inhibition of the diuretic response to water loading in partial vasopressin responsive nephrogenic diabetes insipidus. *International Journal of Clinical Pharmacology, Therapy and Toxicology* 10: pp. 64-69. (1974)
16. Radó JP, Szende L, Marosi J, Juhos E, Sawinsky I, Tako J: Inhibition of the diuretic action of glibenclamide by clofibrate, carbamazepine and 1-deamino-8-d-arginine-vasopressin (DDAVP) in patients with pituitary diabetes insipidus. *Acta Diabetologica Latina* 11: pp. 179-197. (1974)
17. Radó JP: Combination of carbamazepine and chlorpropamide in the treatment of "hyposponder" pituitary diabetes insipidus. *Journal of Clinical Endocrinology and Metabolism* 38: pp. 1-7. (1974)
18. Tako J, Radó J: Current trends and problems in the treatment of diabetes insipidus. *Orvosi Hetilap* 115: pp. 427-430. (1974)
19. Radó JP, Marosi J, Szende L, Tako J: Clinical value of the combinations of carbamazepine (tegretol), chlorpropamide (diabinese) and vasopressin in the treatment of pituitary diabetes insipidus. *Endokrinologie* 62: pp. 297-309. (1973)
20. Radó JP: Clinical use of additive antidiuretic action of carbamazepine and chlorpropamide. *Hormone and Metabolic Research* 5: p. 309. (1973)

II. carbamazepine: Water Intoxication /5 articles/

21. Radó J, Apor P: Szakirodalmi válogatások a vizintoxikációról.: Vizintoxikáció sportolás során, kórházban, börtönben, gyermekbántalmazás következtében, gyógyszerek hatására. *Hypertonia és Nephrologia* 10:(1) pp. 44-49. (2006)
22. Radó J: Electrolyte disorders caused by drugs. *Orvosi Hetilap* 129: pp. 25-31. (1988)
23. Radó JP: Drug-induced electrolyte disturbances. *Giornale Italiano di Chim Clin* 12: p. 173. (1987)
24. Radó J, Csanyi P, Gercsak G, Osvath J: Water intoxication in mental patients (study of the effects of psychotropic drugs and smoking). *Orvosi Hetilap* 127: pp. 2993-2999. (1986)
25. Radó JP: Water intoxication during carbamazepine treatment. *British Medical Journal (BMJ)* 3: p. 479. (1973)

III. Carbamazepine: Interference with Cortisol Determinations (falsely high fluoresce) /1 article/

26. Radó JP: Falsely high fluorescence in cortisol determinations due to the carbamazepine. *Hormone and Metabolic Research* 5: p. 63. (1973)

IV. Carbamazepine: Interference of Psychotropic Drugs with Cortisol Determinations: imiparine, trimiparine, levopromazin, diazepam, diethazine, tolperison, bencyclane /2 articles/

27. Radó JP, Simon T, Juhos E, Tako J, Nagy O: Interference of psychotropic drugs with cortisol determinations. *Hormones and Metabolic Research* 6: pp. 530-531. (1974)

28. Radó JP: Interference of bencyclan with 11-hydroxycorticosteroids determinations. *International journal of Clinical Pharmacology and Biopharmacy* 14: pp. 186-188. (1976)

September 8, 2016

János Radó: The use of modern antidiuretic agents in the treatment of permanent lithium-induced nephrogenic diabetes insipidus

Abstract

Recent views about lithium therapy (“Lithium has been firmly established as the first-choice drug for preventing mood episodes in bipolar disorders, meeting all requirements of the Evidence-Based Medicine” [Rybakowski 2017]) made it worthwhile to seek further solutions for the alleviation of the side effects resulting from this therapy, first of all in the disturbance of water metabolism, occurring almost in every case of the patient population during long-term therapy. These views prompted us to publish our data concerning the use of modern antidiuretic agents in the treatment of “vasopressin resistant” lithium induced polyuria (permanent nephrogenic diabetes insipidus). We found that the administration of very high doses of Desmopressin resulted in clinically relevant antidiuresis, enhanced by Indomethacine and abolished by Calcitonin. Piroxicam, another nonsteroidal anti-inflammatory compound, also seemed to be antidiuretic, though in a less extent than indomethacine. The message of our writing is:

in such an important form of psychiatric treatment as Lithium is, a serious disturbance of water metabolism can be alleviated by the clever use of modern antidiuretic interventions.

Introduction

Lithium was introduced into clinical medicine (again) by Cade in 1949, for the treatment of certain psychiatric disorders. This type of therapy spread worldwide, became the “gold standard” and then gave its place to other psychotropic, and later neuropsychopharmacologic compounds (Ban 2017). Differing from the fate of many other drugs, however, lithium did not disappear totally from the palette. From time to time, it appears from the dark as a “gold standard in its time,” and as a possibility to treat “refractory conditions.” In addition, lithium was declared many times not only a remedy of acute conditions, but as a prophylactic measure for the prevention of acute episodes of the bipolar disorder. The writer of these opinions met several patients whose Lithium treatment was going to be stopped by his or her psychiatrist, but they all were very unsatisfied with this decision. I think that the fact that the lithium carbonate molecule was too “simple” as compared to the modern drugs with more complicated chemical structures, and that therapy with Lithium was burdened with the need to determine blood levels several times in each case, as well as the number of serious side effects, not mentioning the known “corporate corruptions” in the industry producing and promoting more modern medicines (Blackwell 2017), all may have played a role in the decreasing use of Lithium.

Excellent experts of lithium therapy stress the significance of this treatment. “Although a number of drugs with mood-stabilizing properties already exist, none has so far surpassed lithium as far as prophylactic efficacy in bipolar illness is concerned, not even to mention a duration of such prophylaxis” (Rybakowsky 2017). “The evidence base for lithium in the long-term treatment of bipolar disorders has strengthened. With no other drug available having such ample and consistent evidence for its efficacy lithium remains the most valuable treatment option in this indication” (Severus 2014). Further opinions about Lithium therapy can be found in collated documents in the INHN webpages under the heading Lithium controversy (Blackwell 2014.) In any case, use of lithium proved to be a valuable way to treat certain psychiatric diseases, with the probable capability to prevent acute episodes. Therefore, further studies concerning both the effects and side

effects of lithium are not useless efforts even in the “molecular genetic era” of neuropsychopharmacology (Ban 2017).

Our Studies Concerning the Effects of Modern Antidiuretic Agents

One of the side effects of lithium is a disorder in renal concentrating operation (Forrest 1974; Glick 1984). The disturbance in water metabolism is appearing almost in every patient treated with lithium on a long-term basis (Allen 1989). The abnormality is frequently mild, manifesting in increased urine volume and polydipsia of various degree because of the decreased water reabsorption in the distal nephron. (Boccalandro 2004; Cohen 2002; Haris and Radó 2008; Kazama 2007). Sometimes, however, marked polyuria, resembling “diabetes insipidus” can develop. As this polyuria is “vasopressin resistant” by definition it is named “nephrogenic diabetes insipidus” (Bedford 2008; Kalra 2016; Radó 1978, 1998; Thompson 1997). We have dealt with these abnormalities for several years and during our studies we found a 61-year-old women patient suffering from affective bipolar disorder in whom nephrogenic diabetes insipidus developed during lithium therapy lasting more than 10 years. Her serum calcium, potassium and glucose levels were normal, 10 ug dDAVP into both nostrils was ineffective and the water deprivation test was negative. Therefore, diabetes mellitus, central diabetes insipidus and psychic polyuria have been excluded from the polyuric disorders, as well as the calcium or potassium abnormality induced nephrogenic diabetes (Radó 1991, 1993). As the polyuria did not cease after discontinuation of lithium it was named “permanent lithium induced nephrogenic diabetes insipidus” (Guirguis 2000; Neithercut 1990; Simon 1977). Although nephrogenic diabetes insipidus is said to be “vasopressin resistant,” based on our and others’ previous investigations (Boccalandro 2004; Moses 1984; Radó 1978/b, 1995, 2004, 2007, 2011; Stasior 1991; Weinstock and Moses 1990), we did not exclude the use of certain vasopressin derivatives in this condition.

In our above-mentioned patient, polyuria developed during Lithium treatment; the average 24hr urine volume was 5483 ml, while the 24hr glomerular filtration rate (endogenous creatinine clearance) was only 31.5 ml/min. Alleviating polyuria is a very important immediate task in such patients: having a less disturbed night’s rest. As mentioned above, despite the theoretical vasopressin resistant condition we gave excessive supramaximal doses of a very powerful antidiuretic compound, desmopressin (1-deamino-8-d-arginine –vasopressin, dDAVP). This vasopressin derivative molecule

has an extremely strong antiuretic capability combined with a uniquely long duration of action (Radó 1975a,b, 1976a,b,c,d, 1977, 1978a). dDAVP was also given in certain cases of congenital and acquired nephrogenic diabetes insipidus for antidiuretic purposes (Boccalandro 2004; Moses 1984; Radó 1995). The administered doses were generally less than given by us. Nonsteroidal anti-inflammatory compounds have also been successfully administered in some cases of similar conditions. These drugs were administered also in Lithium induced polyuria (Allen 1989; Radó 1991, 1993, 1995; Weinstock and Moses 1990; Vierhapper 1990). However, in several cases of these disorders with excessive polyuria, administration of nonsteroidal drugs failed or the effect was not satisfactory as shown in our patient presented here. The combination of dDAVP and nonsteroidal drugs also have been tried (Weinstock and Moses 1990). In such cases we used a combination of nonsteroidal drugs with excessive - supramaximal doses of dDAVP. A way to administer these two drugs is reported here.

As our patient suffered too from very severe arthritic and osteogenic pains, Calcitonin was also given. During these studies we discovered that co-administration of Calcitonin with dDAVP can abolish the antidiuretic effect of the latter (Radó 1991,1993). Surprisingly, the original condition of the nephrogenic diabetes insipidus is restored when adding Calcitonin to the continued administration of dDAVP. One of our main purposes is to describe this interaction between dDAVP and Calcitonin.

Investigations Performed During Maintained Lithium Therapy

We studied our patient both during maintained lithium carbonate treatment and again several months after the discontinuation of lithium. During maintained lithium therapy the investigated parameters can be seen in Figures 1, 2 and 3. Standard methods were used in the laboratory determinations as well as in the statistics. The patient was allowed to drink water “ad libitum.” Daily sodium intake was 100 mmol, potassium intake was 40 mmol. dDAVP was given 30-30 ug into both nostrils 5 times a day, at 8 am, 12 am, 4 pm, 8 pm, and 12 pm.

Urine was collected in 24hr clearance periods. After a 7-day “no drug” period, indomethacine (75 mg per day) was given for six days. After a wash-out period, dDAVP was administered for five consecutive days. After that, indomethacine and dDAVP were given in combination for a 6-day period. (Duration of investigational periods are indicated

with “N” in the figures.) The combination of calcitonin and dDAVP was studied in a 11-day period (daily 100 IU calcitonin was given).

Results are Summarized in Figures 1-3 and in the Table

We can see in Figure 1 that indomethacine (administered alone) as compared to “no drug” did not cause significant change in urine volume and osmolality.

However, dDAVP (administered alone) as compared to “no drug” significantly decreased ($p<0.05$) free water excretion expressed in the percentage of glomerular filtration rate ($\text{CH}_2\text{O} \times 100/\text{GFR}$) and increased ($p<0.05$) urine osmolality.

In response to dDAVP (administered alone) as compared to indomethacine (administered alone), urine volume (1 asterisk= $p<0.05$) and free water excretion decreased (3 asterisks= $p<0.001$) while urine osmolality increased ($p<0.001$).

After administration of the combination of indomethacine and dDAVP as compared to dDAVP (administered alone), urine volume ($p<0.001$) and free water excretion ($p<0.001$) decreased while urine osmolality increased ($p<0.001$).

Figure 1




Figure 1. The effects of various interventions (no drug, indomethacine, dDAVP (desmopressine), indomethacine and dDAVP) on specific renal functions were investigated in a patient with permanent lithium induced nephrogenic insipidus during maintained Lithium carbonate treatment. $P > 0.05$ = comparison with NO DRUG. ASTERISKS above dDAVP = comparison with INDO. ASTERISKS above INDO + dDAVP = comparison with dDAVP.

In Figure 2 we can see that dDAVP (administered alone) decreased urine volume ($p < 0.001$) and free water excretion ($p < 0,01$), while increased ($p < 0.05$) urine osmolality as compared to “no drug” was seen. However, when calcitonin was combined with dDAVP urine volume ($p < 0.05$) and free water excretion ($p < 0.001$) increased and urine osmolality decreased (not significant) as compared to dDAVP (administered alone).

Figure 2




Figure 2. The effects of various interventions (no drug, dDAVP (desmopressine), Calcitonin and dDAVP) on specific renal functions were investigated in a patient with permanent Lithium induced nephrogenic insipidus during maintained lithium carbonate treatment. dDAVP induced a marked antidiuresis which has been abolished by Calcitonin despite further administration of dDAVP. ASTERISKS = comparison of CALCITONIN + dDAVP to dDAVP.

In Figure 3 changes of free water excretion (expressed in the percentage of glomerular filtration rate) can be seen. dDAVP (administered alone) caused a decrease, while co-administration of indomethacine and dDAVP potentiated this effect. Indomethacine (administered alone) was practically without any effect. Calcitonin abolished the effect of dDAVP.

Figure 3




Figure 3. The effect of various interventions (no drug, dDAVP /desmopressine/, dDAVP and indomethacine, indomethacine, dDAVP and Calcitonin) on free water excretion expressed in the percentage of glomerular filtration was investigated in a patient with permanent lithium induced nephrogenic insipidus during maintained Lithium carbonate treatment. CH₂Ox100/GFR ml/min mean values and standard error of the mean are given.

TABLE

<i>DRUG</i>	<i>URINE VOLUME</i> (ml/min)	<i>Cosmx100/GFR</i> (ml/min)	<i>CH₂OX100/GFR</i> (ml/min)
NO	4778 _± 335	4.17 _± 0.21	2.78 _± 0.22
INDO	4350 _± 180	4.76 _± 0.31	2.50 _± 0.32
<u>dDAVP'</u>	3480 _± 299 ^X	4.13 _± 0.16	1.16 _± 0.13 ^{XXX}
<u>INDO+dDAVP</u>	2875 _± 161 ^{xxx}	4.71 _± 0.40	0.44 _± 0.22 ^{xxx Y}
<u>CALCIT+dDAVP</u>	5363 _± 283	4.59 _± 0.38	2.52 _± 0.27 ^{yyy}

Values are expressed as mean±SEM. x=p<0.05; xxx = p< 0.001 as compared to "no drug" - Y= p< 0.05; YYY=p<0.001 as compared to the single drug.

Abbreviations:

dDAVP=1-deamino-8D-arginine vasopressin=desmopressin.

INDO=indomethacine. CALCIT= calcitonin.

Cosm =osmolal clearance; C_{H_2O} = free water clearance; GFR=glomerular filtration rate.

As shown in the table above, changes in urine volume, osmolal clearance and free water excretion (expressed in the percentage of glomerular filtration) can be seen numerically. Indomethacine (administered alone) was practically without any effect, while desmopressine (administered alone) caused significant decrease both in urine volume and free water excretion, enhanced markedly by the co-administration of indomethacine. (In osmolal clearance no significant change occurred.).

We can summarize the results of the first part of our present studies by reporting that administration of excessive doses of Desmopressin resulted in clinically relevant antidiuresis, enhanced by Indomethacine and abolished by Calcitonin.

After performing these investigations, administration of lithium carbonate was discontinued.

Investigations Performed after Stopping Lithium Therapy

Polyuria remained and practically did not change during the next three years. Therefore, the diagnosis is: “permanent” lithium induced nephrogenic diabetes insipidus. Another interesting observation was that the glomerular filtration rate increased from the 31-47 ml/min value, found during lithium therapy, to 130 ml/min two months after the discontinuation of lithium and permanently remained at this level. The increase of glomerular filtration apparently did not enhance the polyuria. Polyuria was, however, partially sensitive to Desmopressin.

After stopping lithium therapy, two months later the patient was studied again. This time the effect of dDAVP (administered alone) – “as baseline” – was compared with that of the combinations of dDAVP and indomethacine, as well as dDAVP and piroxicam. (To have an ideal baseline, discontinuation of dDAVP was not possible because it would have been unethical and the patient definitely opposed it.) Urine volume, free water excretion, osmolal clearance, urine and serum osmolality, as well as glomerular filtration rate were determined.

It can be seen in Figure 4 that indomethacine plus dDAVP as compared to dDAVP (administered alone) was antidiuretic (urine volume [$p < 0.001$] and free water excretion [$p < 0.001$] decreased and urine osmolality [$p < 0.001$] increased) without any consistent change in osmolal clearance, glomerular filtration rate and serum osmolality. Piroxicam plus dDAVP as compared to dDAVP (administered alone) was also antidiuretic (urine volume [$p < 0.01$] and free water excretion [$p < 0.01$] decreased and urine osmolality [$p < 0.1$] increased) without any consistent change in osmolal clearance, glomerular filtration rate and serum osmolality. These results support the contention that indomethacine is not the only nonsteroidal anti-inflammatory compound which can be used in the antidiuretic therapy. However, piroxicam seemed to be less antidiuretic than indomethacine, by ca 20-30 %. It should be mentioned, that another nonsteroidal drug (aspirin) had no antidiuretic capability (Vierhapper 1990).

Figure 4




Figure 4. Two months after discontinuation of lithium carbonate treatment the effects of various interventions (dDAVP /desmopressine/, piroxicam and dDAVP, indomethacine and dDAVP) on specific renal functions were investigated in a patient with permanent lithium induced nephrogenic insipidus.

Conclusion

The message of our present writing is that in such an important form of psychiatric treatment as lithium is, a serious side effect, the disturbance of water metabolism, can be alleviated by clever use of modern antidiuretic interventions.

References:

Allen HM, Jackson RL, Winchester MD et al. Indomethacin in the treatment of Lithium induced nephrogenic diabetes insipidus. *Archives of Internal Medicine* 1989; 149:1123-26.

Ban TA. Neuropsychopharmacology in Historical Perspective. Education in the Field in the Post-Neuropsychopharmacology Era. Prologue. *inhn.org. Education*. September 18, 2017.

Bedford JJ, Weggery S, Ellis G, McDonald FJ, Joyce PR, Leader JP, Walker RJ. Lithium-induced nephrogenic diabetes insipidus: renal effects of Amiloride. *Clin J Am Soc Nephrol* 2008; 3:1324-31.

Blackwell B. Lithium Controversy. A historical autopsy. *inhn.org.controversies*. June 19, 2014.

Blackwell B. Barry Blackwell. Corporate Corruption In: The Psychopharmaceutical Industry (Revised). *inhn.org.controversies*. March 16, 2017.

Boccalandro C, De Mattia F, Guo DC, Xue L, Orlander P, King TM, Gupta P, Deen PM, Lavis VR, Milewicz DM. Characterization of an aquaporin-2 water channel gene mutation causing partial nephrogenic diabetes insipidus in a Mexican family: Evidence of increased frequency of the mutation in the town of origin. *J Am Soc Nephrol* 2004; 15:1223-31.

Cade JP. Lithium salts in the treatment of psychotic excitement. *Med J Australia* 1949; 2:349-52.

Cohen M, Post GS. Water Transport in the Kidney and Nephrogenic Diabetes Insipidus *J Vet Intern Med* 2002; 16:510–7.

Felsenfeld AJ, Levine BS. Calcitonin, the forgotten hormone: does it deserve to be forgotten? *Clin Kidney J* 2015; 8:180–7.

Forrest JN, Cohen AD, Torretti J, Himmelhoch JM, Epstein FH. On the mechanism of Lithium-induced diabetes insipidus in man and the rat. *Journal of Clinical Investigation* 1974; 53:1115-23.

Glick, IS, Janowsky D, Salzman C, Shader R. APPENDIX B Lithium: A clinical update 1984. A Model Psychopharmacology Curriculum for Psychiatric Residents An Ad Hoc Committee of the American College of Neuropsychopharmacology. *inhn.org.collated*. February 9, 2017.

Guirguis AF, Taylor HC. Nephrogenic diabetes insipidus etc. *Endocrine Practice* 2000; 6:324-8.

Haris Á, Radó J. A víz-és elektrolitháztartás zavarai. Budapest: Medicina; 2008

Kalra S, Zargar AH, Jain SM, Sethi B, Chowdhury S, Singh AK, Thomas N, Unnikrishnan AG, Ballani Thakkar P, Malve H. Diabetes insipidus: The other diabetes. *Indian J Endocr Metab* 2016; 20:9-21.

Kazama I, Arata T, Michimata M, Hatano R, Suzuki M, Miyama N, Sanada S, Sato A, Satomi S, Ejima Y, Sasaki S, Matsubara M. Lithium effectively complements vasopressin V2 receptor antagonist in the treatment of hyponatraemia of SIADH rats *Nephrology Dialysis Transplantation* 2007; 22:68-76.

Kittikulstuth W, Friedman PA, van Hoek A, Gao Y, Kohan DE. Identification of adenylyl cyclase isoforms mediating parathyroid hormone- and calcitonin stimulated cyclic AMP accumulation in distal tubule cells. *BMC Nephrology* 2017; 18:292.

Moses AM, Scheinman SJ, Oppenheim A. Marked hypotonic polyuria resulting from nephrogenic diabetes insipidus with partial sensitivity to vasopressin. *J Clin Endocrinol Meta.* 1984; 59:1044-9.

Neithercut WD, Spooner RJ, Hendry A, Dagg JH. Persistent nephrogenic diabetes insipidus, tubular proteinuria, aminoaciduria and parathyroid hormone resistance following long term lithium administration. *Postgrad Med J* 1990; 66: 479-82.

Radó JP. 1-desamino-8-D-arginine vasopressin (DDAVP) concentration test. *Am J Med Sci* 1978; 275:43-52.

Radó JP. Nephrogenic diabetes insipidus. *Orv Hetil* 1998; 139:559-63.

Radó JP. Nephrogen diabetes insipidus. In: Kakuk G. szerk. *Klinikai nephrologia*. Budapest: Medicina; 2004, p. 375.

Radó JP. Humán farmakológiai kutatásaink desmopressinnel és más készítményekkel neurohypophyseális és nephrogen diabetes insipidusban: I. Neurohypophyseális diabetes insipidus és II. nephrogen diabetes insipidus. *Hypertonia és Nephrologia* 2007; 11:181-98 and 244-56.

Radó JP. Diabetes mellitus és (nephrogen) diabetes insipidus együttes előfordulása *Hypertonia és Nephrologia* 2011 15:183-7.

Radó JP, Marosi J. Prolongation of duration of action of 1-deamino-8-D-arginine vasopressin (DDAVP) by ineffective doses of clofibrate in diabetes insipidus. *Horm Metab Res* 1975b; 7:527-8.

Radó JP, Marosi J, Borbely L, Tako J. Individual differences in the antidiuretic response induced by single doses of 1-deamino-8-D-arginine-vasopressin (DDAVP) in patients with pituitary diabetes insipidus. *Int J Clin Pharmacol Biopharm* 1976d; 14:259-65.

Radó JP, Marosi J, Borbely L, Tako J. Individual differences in the antidiuretic response induced by DDAVP in diabetes insipidus. *Horm Metab Res* 1976a; 8:155-6.

Radó JP, Marosi J, Fischer J. Shortened duration of action of 1-deamino-8-D-arginine vasopressin (DDAVP) in patients with diabetes insipidus requiring high doses of peroral antidiuretic drugs. *J Clin Pharmacol* 1976c; 16:518-24.

Radó JP, Marosi J, Fischer J. Comparison of the antidiuretic effects of single intravenous and intranasal doses of DDAVP in diabetes insipidus. *Pharmacology* 1977; 15:40-5.

Radó JP, Marosi J, Fischer J, Tako J, Kiss N. Relationship between the dose of 1-deamino-8-darginine vasopressin (ddavp) and the antidiuretic response in man. *Endokrinologie* 1975a; 66:184-95.

Radó JP, Marosi J, Szende L, Borbely L, Tako J, Fischer J. The antidiuretic action of 1-deamino-8-D-arginine vasopressin (DDAVP) in man. *Int J Clin Pharmacol Biopharm* 1976b; 13:199-209.

Radó JP, Simatupang T, Boer P, Dorhout Mees EJ. Pharmacologic studies in Bartter's syndrome: effect of DDAVP and indomethacin on renal concentrating operation. Part II. *Int J Clin Pharmacol Biopharm* 1978b; 16:22-6.

Radó JP, Szende L. Simultaneous familial occurrence of distal renal tubular acidosis, polycystic kidney and nephrogenic diabetes insipidus] *Orvosi Hetilap* 1995; 136:995-1001.

Radó JP, Zdravkova S. Lithium-induced chronic water-metabolism disorder (nephrogenic diabetes insipidus). *Orv Hetil.* 1991;132:1987-90.

Radó JP, Zdravkova S. Effect of Indomethacine and Calcitonin During Administration of 1-Deamino-8-D-Arginin-Vasopressin (dDAVP) on Free Water Clearance in Nephrogenic Diabetes Insipidus (NDI). XIIth International Congress of Nephrology. June 13–18, 1993 Jerusalem, Israel.

Rybakowski J. Final comment: Half a Century of Inspiring Lithium Controversy. Barry Blackwell: *The Lithium controversy: A historical autopsy*. Collated by Olaf Fjetland. inhn.org.collated. September 30, 2017.

Severus E, Taylor MJ, Sauer C, Pfennig A, Ritter P, Bauer M, Geddes JR. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. *International Journal of Bipolar Disorders* 2014; 2:15.

Simon NM, Garber E, Arieff AJ. Persistent nephrogenic diabetes insipidus after lithium carbonate. *Ann Int Med* 1977; 86:446-7.

Stasior DS, Kikeri D, Duel B, Seifter JL. Nephrogenic diabetes insipidus responsive to indomethacine plus dDAVP. *New Eng J Med* 1991; 324:850-1.

Thompson CJ, France AJ, Baylis PH. Persistent Nephrogenic diabetes insipidus following lithium therapy. *Scottish Medical Journal* 1997; 42:16-7.

Vierhapper H. Indomethacine in the treatment of lithium-induced nephrogenic diabetes insipidus. *Arch Int Med* 1990; 150:2419.

Weinstock RS Moses AM. Desmopressin and indomethacine therapy for nephrogenic diabetes insipidus in patients receiving lithium carbonate. *South Med J* 1990; 83:1475-7.

Acknowledgment. The author expresses his sincere thanks to Dr. Zdravkova Sznyeska, nephrologist, for her contribution in collecting data and handling the statistical analysis.

January 25, 2018

Barry Blackwell's comment

I want to thank János Radó for his thoughtful final contribution to the collated lithium file. This is a fairy tale ending to a long saga which provides a detailed and inventive management of a serious side effect that may make a significant contribution to the safe use of a simple ion that remains the best, safest and least expensive treatment for the prevention of recurrent episodes of bipolar disorder. Schou and Cade would have been pleased.

May 10, 2018

János Radó's reply to Barry Blackwell's comment

I am delighted by the nice words of Barry Blackwell. This honor presented to me is extraordinary indeed, considering that it comes from one of the greatest persons in the field of treatment of bipolar disorder with lithium.

There could not be a higher praise for me than “Schou and Cade would have been pleased.”

I felt that my merit is much lower than the one contributed to me by Barry Blackwell; that is the reason for which I was unable to reply to his comments for a long time.

January 8, 2020

Gordon Johnson's comment

Uncertainty concerning lithium's effects on renal function are widespread and may adversely affect clinical management. As Radó notes lithium is the drug of first choice in long term prophylactic treatment in bipolar disorder requiring clinical and laboratory monitoring.

Thirst and increase of urine volume (polyuria) are two of the most frequently reported side effects. These changes are attributed to decreased responsiveness of the renal tubules to the antidiuretic hormone. This impairment of urinary concentrating ability

is considered a reversible pharmacological effect. Polyuria has been reported in up to 50% of patients; with polyuria greater than 3 litres per 24 hours in 20% of patients on long term lithium therapy (Boton, Gauria and Battle 1987). Such increased urine volume carries a potential risk of toxicity to the patients because of sodium depletion, excessive fluid loss or reduced fluid intake. Progressive impairment may occur in some patients leading to a diabetes insipidus syndrome.

In 5 to 10 % of patients the impairment of concentrating ability may be irreversible or only partly reversible upon lithium discontinuation (Bendz 1983).

In contrast glomerular function remains relatively unscathed (Johnson, Glenn, Hunt et al 1984). There is an inverse correlation between maintenance plasma lithium levels and urinary concentrating ability and plasma levels should be kept at the lowest level consistent with adequate therapeutic effect. As renal tubular concentrations of lithium may be 10-20 times that in plasma what are moderate differences in plasma level will be considerably amplified at the tubular level.

Radó reports a case study in a patient with irreversible diabetes insipidus associated with lithium maintenance treated in a cross over study with high dose pitressin analogue alone and in combination with indomethacin or calcitonin. Excessive doses of desmopressin alone had an antidiuretic effect with decreased urine volume and increased osmolality. The nonsteroidal drug indomethacin enhanced the effect while calcitonin abolished it.

The mechanisms involved remain unexplained. No adverse effects were noted. The diabetes insipidus persisted following lithium discontinuation and remained unchanged over three years. A small improvement in glomerular filtration was noted. This also remained unchanged over the three years.

This is an interesting report of effective treatment paradigm in severe lithium induced diabetes insipidus and warrants further investigation.

Risk factors associated with impaired renal function in patients on lithium are

1. Current or previous episodes of lithium intoxication
2. Lithium dose and plasma levels
3. Concomitant psychotropic medication
4. Cardiovascular disease

5. Age decline in GFR

There is no consistent evidence that differences in lithium preparations or dosage regimens effect renal function differentially. The clinical benefits obtained in the majority of patients far outweigh the identifiable risks of renal impairment.

References:

Bendz H. Kidney function in lithium treated patients. Acta Psychiat Scand 1983; 68:303

Bendz H, Aurell M, Balldin J, Mathe A, Sjodin I. Kidney damage in long term lithium patients: A cross sectional study of patients with 15 years or more on lithium. Nephrol Dial Transplant 1994; 9:1250-4.

Boton R, Gauria M, Battle D. Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. Amer. J Kidney Dis 1987; 10:329-45.

Johnson G. Lithium early development, toxicity and renal function Neuropsychopharmacology 1998; 19:200-5

Johnson G, Glenn E, Hunt G, Duggin G, Horvath JS, Tiller DJ. Renal function and lithium treatment: initial and follow up tests in Manic -Depressive patients. J. Affective Disorders 1984; 6: 249-63.

July 5, 2018

János Radó's reply to Gordon Johnson's comment

I would like to thank Gordon Johnson for his comments on my final comment on the collated document of Barry Blackwell's Lithium controversy project. I am especially grateful for his comments because it was from his reports that we learned the natural history of renal function changes in patients under lithium therapy (Johnson, Glenn, Hunt et al. 1984; Johnson 1998).

In some patients treated for 10-20 years urinary concentrating ability studied during administration of vasopressin decreased below plasma osmolality (300mosm/Kg). This observation was confirmed later by many investigators. Thus, the development of nephrogenic diabetes insipidus as a consequence of long-term lithium treatment is no longer a rarity. In some cases withdrawal of lithium resulted in improved renal function, while in others lithium-induced nephrogenic diabetes insipidus remained irreversible, e.g., "permanent" (Radó and Zdravkova 1991,1993). Even in these cases therapy is not

absolutely hopeless. Several therapeutic options are available, by which the patient's rest during night can be somewhat secured by decreasing the polyuria with thiazide diuretics, indomethacine, amiloride, desmopressin and, most importantly, combinations of them (Croft, Bedford, Leader and Walker 2018; Mizuno, Fujimoto, Sugiyama et al. 2003; Radó 2018, 2019; Stasior, Kikeri, Duel and Seifter 1991; Weinstock and Moses 1990).

Although lithium-induced permanent nephrogenic diabetes insipidus is "by definition" a vasopressin-resistant condition, vasopressin resistance in many cases is not absolute (Canfield, Tamarappoo, Moses et al.1997; Moses, Scheinman and Oppenheim 1984). When we started our studies with desmopressin a "supramaximal" dose was 300 mcg given intranasally. In these early human pharmacology investigations 320 mcg was given as a quasi "single dose" during one hour to patients with neurohypophyseal (central) diabetes insipidus (Radó 1975). When we used desmopressin for nephrogenic diabetes insipidus 300 mcg was given during 24 hrs (Radó and Zdravkova 1991,1993). In the meantime, however, it became known that desmopressin may be effective also in hematologic disorders. In these disorders, in certain cases, desmopressin was given in very extreme doses

The industry produced desmopressin preparations containing very high concentrations of desmopressin which acted on the blood clotting mechanism for bleeding disorders. By using such a preparation (Octim Nasal Spray Ferring Pharmaceuticals Ltd) administration of 300 mcg (150 mcg into each nostril) as a single dose is easily feasible.

To the best of my knowledge this preparation has not been tried, up to now, in the combination therapy (with indomethacine or other compounds) of the lithium-induced permanent nephrogenic diabetes insipidus. Nevertheless, Gordon Johnson's statement, based on his studies, is valid also at present: "the results confirm the safety of lithium administration in the majority of patients." This wise sentence has been corroborated since many times (Aiff, Attman P, Aurell et al. 2014; Blackwell 2014; Bendz Schön, Attman and Aurell 2010; Croft, Bedford, Leader and Walker 2018; Radó 2018, 2019; Rybakowski 2017; Severus 2014; Shine, McKnight, Leaver and Geddes 2015).

References:

Aiff H, Attman P, Aurell M, Bendz H, Schön S, Svedlund J. The impact of modern treatment principles may have eliminated lithium-induced renal failure. *Journal of Psychopharmacology*. 2014; 28(2):151-4.

Bedford JJ, Weggery S, Ellis G, McDonald FJ, Joyce PR, Leader JP, Walker RJ. Lithium-induced nephrogenic diabetes insipidus: renal effects of Amiloride. *Clin J Am Soc Nephrol* 2008a; 3:1324-31.

Bendz H, Schön S, Attman P, Aurell M. Renal failure occurs in chronic lithium treatment but is uncommon. *Kidney International* 2010; 77:219-224.

Blackwell B. Lithium Controversy. A historical autopsy. inhn.org/controversies. June 19, 2014.

Canfield MC, Tamarappoo BK, Moses AM, Verkman AS, Holtzman EJ. Identification and characterization of aquaporin-2 water channel mutations causing nephrogenic diabetes insipidus with partial vasopressin response. *Hum Mol Genet*. 1997; 6(11):1865-71.

Croft, PK, Bedford, J. J., Leader, JP, Walker RJ: Amiloride modifies the progression of lithium-induced renal interstitial fibrosis. *Nephrology (Carlton)*. 2018; 23(1):20-30.

Johnson G. Lithium--early development, toxicity, and renal function. *Neuropsychopharmacology* 1998; 19:200-5.

Johnson G, Glenn E, Hunt G, Duggin G, Horvath JS, Tiller DJ. Renal function and lithium treatment: initial and follow-up tests in manic-depressive patients. *J. Affective Disorders* 1984; 6 249-63.

Johnson G. Comment on János Radó's (January 25, 2018) final comment. (Barry Blackwell Lithium Controversy. inhn.org/controversies. July 5, 2018.

Mizuno H, Fujimoto S, Sugiyama Y, Kobayashi M, Ohro Y, Uchida S, Sasaki S, Togari H. Successful treatment of partial nephrogenic diabetes insipidus with thiazide and desmopressin. *Horm Res*. 2003; 59(6):297-300.

Moses AM, Scheinman SJ, Oppenheim A. Marked hypotonic polyuria resulting from nephrogenic diabetes insipidus with partial sensitivity to vasopressin. *J Clin Endocrinol Metab*.1984; 59:1044-9.

Radó J. Final comment on Barry Blackwell: The lithium controversy. A historical autopsy. Collated by Olaf Fjetland. Use of modern antidiuretic agents in the treatment of permanent lithium-induced nephrogenic diabetes insipidus (Administration of excessive doses of desmopressin resulted in clinically relevant antidiuresis, enhanced by indomethacine and abolished by calcitonin). inhn.org/collated. January 25, 2018.

Radó JP, Marosi J, Fischer J, Tako J, Kiss N. Relationship between the dose of 1-deamino-8-d-arginine vasopressin (ddavp) and the antidiuretic response in man. *Endokrinologie* 1975; 66:184-95.

Radó JP, Zdravkova S. Lithium-induced chronic water-metabolism disorder (nephrogenic diabetes insipidus)]. *Orv Hetil*. 1991; 132:1987-90.

Radó JP, Zdravkova S. Effect of Indomethacine and Calcitonin During Administration of 1-Deamino-8-D-Arginin-Vasopressin (dDAVP) on Free Water Clearance in Nephrogenic

Diabetes Insipidus (NDI). XIIth International Congress of Nephrology. June 13–18, 1993 Jerusalem, Israel.

Radó J. Renal Toxicity of Lithium in Historical Perspective with Special Reference To Nephrogenic Diabetes Insipidus and its Treatment. *inhn.org.controversies*. May 2, 2019.

Rybakowski J. Final comment: Half a Century of Inspiring Lithium Controversy. Barry Blackwell: The Lithium controversy: A historical autopsy. Collated by Olaf Fjetland. *inhn.org.collated*. August 17, 2017.

Shine B, McKnight RF, Leaver L, Geddes JR. Long term effects of lithium on renal, thyroid, and parathyroid function: retrospective analysis of laboratory data. *The Lancet* 215; 386:461-8.

Severus E, Taylor MJ, Sauer C, Pfennig A, Ritter P, Bauer M, Geddes JR. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. *Int J Bipolar Disord*. 2014; 2:15.

Stasior DS, Kikeri D, Duel B, Seifter JL. Nephrogenic diabetes insipidus responsive to indomethacine plus dDAVP. *New Eng J Med* 1991; 324:850-1.

Weinstock RS, Moses AM. Desmopressin and indomethacine therapy for nephrogenic diabetes insipidus in patients receiving lithium carbonate. *South Med J* 1990; 83:1475-7.

July 11, 2019

János Radó: Additional information

Calcitonin in lithium-induced nephrogenic diabetes insipidus

In our previous studies the favorable antidiuretic action of Desmopressin was counteracted by the concomitant administration of Calcitonin in Lithium-induced permanent nephrogenic diabetes insipidus (Radó 2018). However, the exact mechanism of the abolishment of Desmopressin-induced antidiuresis by Calcitonin was not clear. As the opinions in the literature are rather divided concerning the basic water metabolic action of Calcitonin, further considerations may have significance.

Calcitonin is a “tricky” hormone, having both diuretic and antidiuretic properties. *Diuretic effect* of Calcitonin was an observation mainly in the older literature (Carney, and Thompson 1981; Keeler, Walker and Copp 1970) and is in harmony with our published data on a water mobilizing action (Radó 1991, 1993, 2018). On the other hand, *a water retaining action* was found by the de Rouffignac group (Elalouf, Roinel and de Rouffignac 1986) in response to *human* Calcitonin in rats during microculture studies

simulating the changes induced by Desmopressin. The results of these investigations were later confirmed by elegant, sophisticated methods (Bouley 2011) *indicating that Calcitonin has a vasopressin-like action, indeed*. Calcitonin was even recommended - though purely on theoretical basis - for the treatment of nephrogenic diabetes insipidus, i.e., in a vasopressin resistant condition (Bouley et al. 2011).

An alternative explanation to the complicated water effects of Calcitonin may be provided by supposing that both Desmopressin and have an effect on the same renal tubular site on the vasopressin (V2) receptor, but the effect of Calcitonin is weaker than that of Desmopressin. So, Calcitonin, by occupying the receptors, can have a competitive antagonism with the Desmopressin molecule. *Further studies are necessary to confirm or exclude the possible competitive antagonism between Desmopressin and Calcitonin.*

References:

Bouley R, Lu HA, Nunes P, Da Silva N, McLaughlin M, Chen Y, Brown D. Calcitonin Has a Vasopressin-like Effect on Aquaporin-2 Trafficking and Urinary Concentration. *J Am Soc Nephrol* 22: 2011.

Carney S, Thompson L. Acute effect of calcitonin on rat renal electrolyte transport. *Am J Physiol* 240: F12–F16, 1981.

Elalouf JM, Roinel N, de Rouffignac C. Effects of human calcitonin on water and electrolyte movements in rat juxtamedullary nephrons: inhibition of medullary K recycling. *Pflugers Arch.* 1986; 406(5):502-8.

Keeler, R. Walker, V. Copp D. H. Natriuretic and diuretic effects of salmon calcitonin in rats. *Canadian Journal of Physiology and Pharmacology*, 1970, Vol. 48, No. 12 : pp. 838-41.

Radó JP, Zdravkova S. Lithium-induced chronic water-metabolism disorder (nephrogenic diabetes insipidus). *Orv Hetil.* 1991; 132:1987-90.

Radó JP, Zdravkova S. Effect of Indomethacine and Calcitonin During Administration of 1-Deamino-8-D-Arginin-Vasopressin (dDAVP) on Free Water Clearance in Nephrogenic Diabetes Insipidus (NDI). XIIth International Congress of Nephrology. June 13–18, 1993, Jerusalem, Israel.

Radó J. Use of modern antidiuretic agents in the treatment of permanent lithium induced nephrogenic diabetes insipidus. (Administration of excessive doses of desmopressin resulted in clinically relevant antidiuresis, enhanced by indomethacine and abolished by calcitonin). *inhn.org.controversies*. January 25, 2018. (János Radó's final comment on Barry Blackwell: The lithium controversy. A historical autopsy. Collated by Olaf Fjetland).

September 13, 2018

Hector Warnes' comment on János Radó's additional information

About 10% of patients on long-term lithium prophylaxis (more than 10 years) may develop a “Lithium induced nephrogenic diabetes insipidus” (Khanna 2006). I had two cases in my clinical praxis of bipolar patients who had severe polydipsia and polyuria. They woke up four or five times at night to urinate large volumes (more than 3 L/24 hrs; less 300 osmolality). I consulted a nephrologist who wisely advised me to change the medication because of the abnormal creatinine clearance and the glomerular filtration rate. The condition is caused by complete or partial resistance of the kidneys to arginine vasopressin, the antidiuretic hormone. It is considered a serious adverse effect, because of the risk of developing dehydration (sodium may decrease to less than 170 mmol/L). It has also been observed during treatment with clozapine, in patients with hypokalemia and hypercalcemia, and it has been identified as a rare genetic cause of the disorder.

I am not sure that lithium is the first line of treatment in bipolar disorder even though there is a group of bipolar patients (approximately 40%) who are responsive to lithium prophylaxis.

I would not take it lightly if the patient developed nephrogenic diabetes insipidus because of the kidney risks involved unless lithium has been the only mood stabilizing drug that kept the patient symptom free for many years. We are also aware that an important percentage of patients suffering from medical, neurological or psychiatric disorders are not compliant with the instructions given by their doctors.

Reference:

Khanna A. Acquired nephrogenic diabetes insipidus. *Semin Nephrol* 2006; 26:244-8.

January 17, 2019

János Radó's reply to Hector Warnes' comments

Many thanks to Hector Warnes for his recent very interesting comments on my additional final comment of September 13, 2018.

I absolutely agree with Hector Warnes that: “I would not take it lightly if the patient developed nephrogenic diabetes insipidus because of the kidney risks involved

unless lithium has been the only mood stabilizing drug that kept the patient symptom free for many years.”

In some patients treated more than 10 years with lithium urinary concentrating ability decreases below plasma osmolality. Development of nephrogenic diabetes insipidus as a consequence of long-term lithium treatment is not a rarity anymore. In the two patients with severe disturbance in the renal concentrating operation of Hector Warnes it was a really wise decision to stop lithium therapy. In some cases withdrawal of lithium results in improvement in renal function, while in others lithium-induced nephrogenic diabetes insipidus remains irreversible (Radó and Zdravkova 1991,1993). Even in these cases of “lithium-induced permanent nephrogenic diabetes insipidus” therapy is not absolutely hopeless, there are several therapeutic options available, by which the rest of the patient during night can be somewhat secured by decreasing the polyuria. Thiazide diuretics, indomethacine, amiloride, desmopressin and most importantly combinations of them are our armamentarium in the alleviation of polyuria and polydipsia (Croft, Bedford, Leader and Walker 2018; Mizuno, Fujimoto, Sugiyama et al. 2003; Radó 2018; Radó 2019; Stasior, Kikeri, Duel and Seifter 1991; Weinstock and Moses 1990).

It was the conclusion of our previous work that in such an important form of psychiatric treatment as lithium is, a serious side effect, the disturbance of water metabolism, can be alleviated by clever use of modern antidiuretic interventions. (Radó 2018)

References:

- Kalita-De Croft P, Bedford JJ, Leader JP, Walker RJ. Amiloride modifies the progression of lithium-induced renal interstitial fibrosis. *Nephrology (Carlton)*. 2018; 23(1):20-30.
- Mizuno H, Fujimoto S, Sugiyama Y, Kobayashi M, Ohro Y, Uchida S, Sasaki S, Togari H. Successful treatment of partial nephrogenic diabetes insipidus with thiazide and desmopressin. *Hormone Research* 2003; 59(6):297-300.
- Radó J. Use of modern antidiuretic agents in the treatment of permanent lithium-induced nephrogenic diabetes insipidus (Administration of excessive doses of desmopressin resulted in clinically relevant antidiuresis, enhanced by indomethacine and abolished by calcitonin). *inhn.org.collated*. January 25, 2018.
- Radó JP, Zdravkova S. Lithium-induced chronic water-metabolism disorder (nephrogenic diabetes insipidus)]. *Orv Hetil*. 1991; 132,1987-90.
- Radó J. Renal Toxicity of Lithium in Historical Perspective with Special Reference To Nephrogenic Diabetes Insipidus and its Treatment. *inhn.org.controversies*. May 2. 2019.

Radó JP, Zdravkova S. Effect of Indomethacine and Calcitonin During Administration of 1-Deamino-8-D-Arginin-Vasopressin (dDAVP) on Free Water Clearance in Nephrogenic diabetes Insipidus (NDI). XIIth International Congress of Nephrology. June 13–18, 1993 Jerusalem, Israel.

Stasior DS, Kikeri D, Duel B, Seifter JL. Nephrogenic diabetes insipidus responsive to indomethacine plus dDAVP. *New Eng J Med* 1991; 324:850-1.

Weinstock RS Moses AM. Desmopressin and indomethacine therapy for nephrogenic diabetes insipidus in patients receiving lithium carbonate. *South Med J* 1990; 83:1475-7.

August 15, 2019

János Radó: Renal Toxicity of Lithium in Historical Perspective with Special Reference to Nephrogenic Diabetes Insipidus and its Treatment

Abstract

Renal toxicity of lithium is a highly important subject which may jeopardize the use of an agent needed by millions suffering from recurrent episodes of bipolar disorder. Lithium may cause profound changes in the previously normal kidney functions and structure leading to end stage kidney disease. The recent use of lower serum lithium levels, however, almost eliminated the risk of lithium-induced renal failure.

In the present report we deal with disturbances of the normal concentrating operation of the kidney; lithium-induced concentrating defect and nephrogenic diabetes insipidus (NDI); and treatment of the lithium-induced disorders.

Treatment of the lithium-induced NDI consists of the thiazides, indomethacine and other non-steroid anti-inflammatory compounds as well as the administration of large doses of desmopressin, amiloride and combinations thereof. Administration of very high doses of desmopressin has resulted in clinically relevant antidiuresis, enhanced by indomethacine. Amiloride is a very special antikaluretic diuretic drug which can abolish several lithium-induced abnormalities. In such an important form of psychiatric treatment as lithium, a serious disturbance of water metabolism can be alleviated by the clever use of modern antidiuretic interventions.

Introduction

“Lithium is a simple ion that remains the best, safest and least expensive treatment for the prevention of recurrent episodes of bipolar disorder” (Blackwell 2018). However, long term administration of lithium has been associated with nephrotoxic effects, altering the structure or/and function of the kidney. Although chronic lithium therapy can cause advanced renal disease, most cases of nephrotoxicity are limited only to narrowed renal concentrating operation. Even in cases with the lithium-induced most severe disturbance of water metabolism, i.e., NDI, there are some therapeutic measures which can alleviate, to some extent, the patient’s suffering. Decreasing the polyuria may secure some rest for the patients during the night. Treatment options for the lithium-induced NDI were not fully considered in a recent review of lithium nephrotoxicity (Davis, Desmond and Berk

2018). More extensive analysis of these options is the purpose of the present article, with special reference to historical points of views.

Lithium Induced Nephropathy

General toxicity was a concern even for John Cade, the discoverer of the lithium therapy in 1947 (Cade 1949). The strongest propagator of this treatment, Morgens Schou, was also frightened of the side effects, considering that his loved brother's health was at stake (Schou 1958). Gordon Johnson investigated the influence of lithium treatment on the endogenous creatinine clearance and found that "overall, glomerular filtration rate fell within the established normal range" (Johnson 1984). However, Hestbech, Hansen and Amdisen (1977); Bendz (1983); Bendz, Aurell, Balldin et al. 1994; Bendz, Schön, Attman and Aurell (2010); and Boton, Gauria and Battle (1987) found chronic renal lesions following long-term treatment with lithium. Chronic lithium therapy produces progressive interstitial fibrosis, hyperplastic changes in the medullary collecting ducts, distal tubule dilatation and microcyst formation (Croft, Bedford, Leader and Walker 2018). Renal failure occurs in chronic lithium treatment but is uncommon (Bendz Schön, Attman and Aurell 2010; Johnson 1998). Davis, Desmond and Berk (2018) developed a search strategy using the most valuable electronic databases to identify the most pertinent questions of lithium-induced nephropathy. They confirmed that there was no correlation between the duration of therapy and decreases in eGFR. At least 20 years or more is necessary for the development of lithium-induced end stage kidney disease. Nevertheless the incidence of the latter is not more than 0,2-0,7 % (according to Shine, McKnight, Leaver and Geddes [2015], 0,5-1%). Not only duration of therapy but other factors may also be relevant to the development lithium-induced nephropathy, such as age, female gender, other diseases favoring nephropathy (diabetes mellitus and hypertension), use of nephrotoxic drugs, prior episodes of acute lithium toxicity, etc. (Davis, Desmond and Berk 2018; Johnson 2018). However, Aiff, Attman P, Aurell et al. (2014) stress that the recent use of lower serum lithium levels almost eliminated the risk of lithium-induced renal failure.

Disturbances in the Renal Concentrating Operation

In healthy people urine concentration can exceed that of plasma which is ca 290 mOsm/Kg. The osmolal concentration of the urine can be as high as 1200 mOsm/Kg during prolonged thirst. During water conservation the renal medullary interstitial tissue

is hypertonic, due to the accumulated sodium and urea in consequence of the active sodium reabsorption in the ascending limb of the loop of Henle transporting the sodium into the medullary interstitium. Its osmolality is as high as that of the concentrated urine. The presence of vasopressin-induced increase of collecting tubular permeability allows diffusion of water back into the medullary interstitium down the established medullary osmotic gradient resulting in maximally concentrated urine. Lithium diminishes the osmotic gradient in the renal medulla reflected in a marked reduction in both osmolyte and urea content. Decrease in the renal medullary interstitial hypertonicity results in lower urinary concentration, polyuria and polydipsia. Amiloride, by increase in medullary osmolytes, restores the renal medullary interstitial hypertonicity, resulting in normalization of the renal concentrating mechanism and less and more concentrated urine. (Bedford, Leader, Jing et al. 2008b)

During ad libitum fluid as intake in healthy people the average urine osmolality is ca 600 mOsm/Kg. During water diuresis however, the urinary osmolality is ca 100 mOsm/Kg or less. The lowest value I observed in my human pharmacology studies was 40 mOsm/Kg after water loading. In prolonged polyuria the osmotic concentration in the renal medulla decreases due to the “washout” effect with the consequence of reduced concentrating power.

In some patients with neurohypophyseal (central) diabetes insipidus the value of urine osmolality can be as high as 300 mOsm/Kg or more, though in most cases it is as in water diuresis. The osmolal concentration of the urine increases at least 9 % in response to vasopressin (Miller Moses test), so differentiation from the NDI - at least in the full cases - is simple. In congenital NDI the urine osmolality figures are the same as in central DI but are not responding to the antidiuretic hormone (ADH, vasopressin).

The diagnosis may be difficult in patients with the partial form of the diseases. Fortunately, sophisticated molecular genetic studies provide exact methods for successful differentiation. The identification, characterization and mutational analysis of the two different genes, the arginine vasopressin receptor 2 gene (AVPR2) and the vasopressin-sensitive water channel gene (aquaporin 2 [AQP2]), provide the basis for understanding the two hereditary forms of renal diabetes insipidus: the X-linked NDI (relatively frequent) and the non x-linked NDI (very rare) (Fujiwara and Bichet 2005). The two types of NDI result from mutation in the structure either of the V2 receptor or AQP2 which causes impaired arginine-vasopressin induced signal transduction (Canfield,


Tamarappoo, Moses et al. 1997). “All families with hereditary diabetes insipidus (the X-linked NDI and the non x-linked NDI) should have their molecular defect identified” (Fujiwara and Bichet 2005).

The concentrating process normally starts with the binding of arginine-vasopressin to the V2 receptors on the basolateral surface of the principal cells in the collecting duct. It stimulates adenyl cyclase and influences the content of the intracellular vesicles, the AQP2 protein which is the “water channel” to be inserted in the apical membrane in the luminal site of the principal cell in the collecting duct. Vasopressin stimulation results in the 20-fold increase in water permeability of responsive principal cells.

Although the mechanisms of the development of inherited and acquired forms of diabetes insipidus are entirely different, therapy of the two types is surprisingly similar. In the patients with the full (complete) form of the inherited disease the vasopressin resistance may be absolute. However, many patients with congenital NDI suffer only in a partial form of the disease (Boccalandro, De Mattia, Guo et al. 2004). In such patients administration of large doses of DDAVP can alleviate somewhat the suffering. It is interesting that within one family huge interindividual variations can be observed in the degree of vasopressin resistance. On this basis the effectiveness of large doses of DDAVP can be significantly different within one family. Figure 1 shows our personal observations in such a family.

In a five-member congenital NDI family who were investigated during thirst and administration of lysin-vasopressin urine, osmolality values were 207 mOsm/Kg, 236 mOsm/Kg, 296 mOsm/Kg, 322 mOsm/Kg, and 405 mOsm/Kg. (Radó, Szende 1995). In Figure 1 only data of four members are depicted.

Figure 1



Investigational data of the congenital NDI family (Mother /I/1 F.I./ and three siblings). The effect of thirst and administration of lysine-vasopressin (doses are indicated above the figure) without or with infusion of hypertonic saline. It can be seen that in the first two members urine osmolality remains definitely lower than that of plasma. In the third member urine osmolality reaches that of plasma, while in the fourth member surpasses it.

Free water clearance (CH_2O) increases during hypertonic sodium chloride infusions while in response to administration of lysine-vasopressin it decreases. Only in the fourth family member is free water clearance turned into free water reabsorption (TcH_2O). Changes are similar in the free water clearance expressed in the percentage of glomerular filtration rate ($CH_2O \times 100 / GFR$). Osmolal clearance (C_{osm}) as well as $C_{osm} \times 100 / GFR$ markedly increased during hypertonic sodium chloride infusion in the first member of the family. Parallel changes were seen in urine flow (V) and free water clearance.

The values of the glomerular filtration rate (GFR) were normal in three members of the family.

The lowest numbers indicate the duration of the individual clearance periods.

Lithium – Induced Concentrating Defect

The lithium-induced disturbance in renal concentrating operation begins shortly after the introduction of the drug. Lithium entering the principal cells of the collecting duct through the sodium epithelial channel abolishes the formation of cyclic AMP and by that the vasopressin mediated insertion of the water channel protein aquaporin 2 into the apical membrane of the cells. Down regulation of AQP2 reduces water reabsorption because of decreasing water permeability of the tubules. Lithium therapy reduces also the organic osmolyte content of the renal medulla (Bedford, Leader, Jing et al. 2008b). Dissipation of the high solute content of the renal medulla, the decrease in renal medullary hypertonicity, is the other cause of the lithium polyuria. Amiloride restores renal medullary osmolytes and hypertonicity improving by that the renal concentrating operation (Bedford, Weggery, Ellis et al. 2008a; Bedford, Leader, Jing et al. 2008b).

The concentrating defect progressively increases during further administration of lithium. In Gordon Johnson's patient material (after 12 hr thirst and administration of pitressin) the average maximal urine concentration was of about 400 mOsm/kg in 11 patients treated two years with lithium, while it was only 200 mOsm/kg in three patients treated 10-20 years (Johnson 1984).

The concentrating defect can be demonstrated at least in 50% of all patients. It is questionable whether in any patient the renal concentrating operation can remain intact during administration of lithium for several decades. Also a difficult question where is the limit between "narrowed" concentration and NDI. NDI can be only "functional" or in all cases lithium induced morphological structural alterations are present. On the basis of modern studies we may account perhaps in all patients lithium-induced "remodeling" of cells in the cortical and medullary renal tubules. "The cellular effects of lithium treatment are broad and complex" (Nielsen, Hoffert, Knepper et al. 2008).

Lithium-induced NDI

Nephrogenic diabetes insipidus is a clinical condition characterized with vasopressin-resistant polyuria and polydipsia. One of the most frequent causes of acquired NDI is chronic administration of lithium; it develops after 10 years of treatment with lithium in more than 10% of the patients. Disturbance of water metabolism is the most characteristic alteration in lithium- induced NDI; *increased sodium excretion and hyperchloremic metabolic acidosis is also present*. Decreased abundances of vasopressin

governed aquaporin 2 and 3 water channels in the collecting duct is responsible for the insufficient tubular water reabsorption. Increased sodium excretion is caused by the reduced expression of the epithelial sodium channel in the cortical and outer medullary collecting duct. Lithium-induced increased expression of H⁺ATPase in the collecting duct is associated with the impaired excretion of acid. (There are other mechanisms too, also leading to renal tubular acidosis.) Nielsen, Hoffert, Knepper et al. (2008) performed “*proteomic analysis*” of lithium-induced NDI and found previously unknown mechanisms for aquaporin down regulation as well as cellular proliferation. *Their model system was the inner medullary collecting duct isolated from lithium treated rats.* Their most important finding was that lithium treatment affected proteins involved in cell death, apoptosis and cell proliferation. Several *signaling pathways* were activated by lithium treatment, as well as the increased intracellular accumulation of beta-catenin and phosphorylated glycogen synthase kinase type 3beta. The authors remark that similar targets may have lithium in the brain. *It should be stressed again that the author’s conclusion is “that the cellular effects of lithium treatment are broad and complex, and as such a single pathway leading to reduced AQP2 expression and subsequent polyuria is unlikely.”*

Treatment of Lithium-induced NDI

Before the era of Modern Pharmacology congenital NDI could be treated only by providing water. “Adjuvant” therapy was the restriction of sodium and protein in the patient’s diet, thus decreasing the excreted osmols and water

Chlorothiazide, the first thiazide diuretic, was introduced into clinical medicine in 1958. Crawford, Kennedy and Hill discovered in 1960 that in patients with central diabetes insipidus the high urine volume can be halved by the administration of the new drug. In our several studies we could corroborate the original results of these authors and extended those with other classes of diuretics (Radó, Bános, Marosi et al. 1968). The thiazide diuretic acts by inhibiting sodium reabsorption in the distal convoluted tubule which interferes with urine dilution, on the one hand, and (indirectly) enhances sodium reabsorption in the proximal tubules on the other. This latter mechanism decreases the delivery of the filtrate to the distal nephron and enhances there the reabsorption of sodium and water reducing by that the excreted volume of urine (Earley and Orloff 1962; Oiso et al. 2013). Modern studies proved that the antidiuretic effect of hydrochlorothiazide in

lithium-induced NDI is associated with upregulation of the aquaporin 2, the Na-Cl cotransporter and the epithelial sodium channel (Kim, Lee, Oh et al. 2004). In the paradoxical thiazide antidiuresis finally sodium reabsorption (and water reabsorption) is increasing both in the proximal and distal nephron.

Thiazides can be combined with amiloride, indomethacine, DDAVP etc. Congenital NDI was treated successfully with a thiazide combined with large doses of DDAVP (Mizuno, Fujimoto, Sugiyama et al. 2003)

Indomethacine, a prostaglandin synthetase inhibitor was also found to have antidiuretic properties in NDI. The efficiency is dependent upon inhibition of prostaglandin synthesis. Prostaglandins antagonize the effect of vasopressin. Indomethacine therefore increases concentrating capacity. *According to Oiso et al. (2013) indomethacine probably acts by inhibiting the retrieval of aquaporin 2 water channels from the apical membrane of the principal cells.* Simon, Garber and Arieff used indomethacine in lithium-induced NDI in 1977; Libber, Harrison and Spector administered it in 1986; Allen, Jackson, Winchester et al. in 1989; Vierhapper in 1990; Radó and Zdravkova in 1991 and 1993; and Thompson, France and Baylis in 1997. We administered indomethacine together with desmopressin in a patient with Bartter syndrome, and found a dramatic antidiuretic effect (Radó, Simatupang, Boer et al. 1978). In our recent study (Radó 2018) we found that indomethacine had a more pronounced antidiuretic effect than piroxicam, another non-steroid anti-inflammatory compound.

For *Desmopressin (1-Deamino-8-D-Arginine Vasopressin: DDAVP)*, structural alterations of the vasopressin molecule resulted in increased antidiuretic potency, longer duration of action and lacking pressor effect due to decreased vasoconstrictor activity. In our studies carried out over 40 years we have demonstrated a relationship between the dose and both the magnitude and the duration of the antidiuretic effect (Radó et al. 1975c, 1976c). Robertson and his coworkers (Oiso et al. 2013) wrote about our early investigations that “in patients with neurohypophyseal diabetes insipidus rapid infusion of 1 /ug DDAVP increased urine osmolality to a maximum of 700-800 mOm/Kg; further increases in dosage only prolonged the duration of action from an average of 26 hours after 1 /ug to 46 hours after 8 /ug.” Our further studies revealed large interindividual variability in the magnitude and duration of the antidiuretic response of DDAVP, which was contributed -at least in part- to the interindividual differences in renal concentrating power (Radó et al. 1976a). The long duration of action of DDAVP is attributed mainly to

its slow metabolic (enzymatic) degradation, and both shortened duration of action (Radó et al. 1976b) and lengthened duration of action (Radó et al 1975b) were reported under varying pharmacological circumstances. Comparison of the antidiuretic effects of single intravenous and intranasal doses of DDAVP in diabetes insipidus was also an important part of our investigations (Radó, Marosi and Fischer 1977). Intranasal administration of DDAVP was at that time a comfortable way of administration and proved to be reliable. Today DDAVP therapy can be carried out by oral melting tablets. We have elaborated a diagnostic procedure for the differentiation of the various concentrating defects by intranasal administration of DDAVP, the “DDAVP concentrating test” (Radó 1978).

“Vasopressin-like” antidiuretic action has been reported after administration of carbamazepine, even leading to water intoxication (Radó 1973). Clofibrate has also a similar effect. The development of a drug-induced inappropriate secretion of antidiuretic hormone syndrome has been described after combined administration of carbamazepine and clofibrate (Radó, Juhos and Sawinsky 1975a). Combination of carbamazepine and chlorpropamide was effective in the treatment of “hypo-responder” diabetes insipidus (Radó et al 1974a). Antidiuretic effect of small doses of DDAVP could be enhanced by the coadministration of carbamazepine or/and clofibrate and can be inhibited by glyburide (Radó 1974b,c).

Indomethacine and DDAVP was used for the first time in lithium induced NDI in 1990 by Weinstock and Moses and in 1991 by Stasior, Kikeri, Duel and Seifter. We used successfully excessive doses of DDAVP combined with indomethacine or piroxicam for the alleviation of polyuria in lithium induced NDI (Radó and Zdravkova 1993; Radó 2018)

Amiloride is a potassium retaining (antikaluretic) diuretic. Polyuria and polydipsia due to lithium-induced NDI decreases during administration of amiloride. Amiloride improved responsiveness to arginine-vasopressin stimulated translocation of AQP 2 to the apical membrane of the principal cell and increased AQP2 excretion as well as maximal urinary osmolality (Bedford Leader, Jing et al. 2008b). Inhibiting the lithium-induced epithelial sodium channel in the collecting duct with amiloride reduces the lithium induced down-regulation of the aquaporin 2 expression. Amiloride reduces transcellular lithium transport, intracellular lithium concentration and lithium-induced inactivation of GSK-3-beta (Kalra, Zargar, Sunil et al. 2016). Amiloride therapy alleviated also the chronic lithium therapy produced progressive interstitial fibrosis and

hyperplastic changes in the medullary collecting ducts (Croft, Bedford, Leader and Walker 2018).

A Vasopressin–analogue (DDAVP) in NDI a “Vasopressin-Resistant” Condition? Yes, In Large Doses in NDI.

Per definition, NDI is a vasopressin-resistant condition. In two congenital cases of Moses, Scheinman and Oppenheim (1984), however, NDI responded to large doses of DDAVP. Though 25-50 times as resistant to DDAVP nasal spray as Radó’s patients with central diabetes insipidus (Radó 1975c) these patients could be treated effectively with large doses of the nasal spray. Our dosage protocol is in total agreement with the calculation of Moses, Scheinman and Oppenheim. We gave 250-300 /ug DDAVP nasal spray to our lithium induced NDI patient, which is ca 25 times more than a normal 10 /ug dose (Radó 2018). In our patient with lithium- induced NDI (Radó 2018) 24 hr urine osmolality before treatment was 175 mOsm/Kg, while under treatment with excessive doses of DDAVP plus indomethacine it was 280 mOsm/Kg. Others have similar experiences (Oiso et al. 2013; Mizuno, Fujimoto, Sugiyama et al. 2003; Stasior, Kikeri, Duel and Seifter 1991; Weinstock and Moses 1990).

Conclusions

Lithium is important for the world’s millions of patients with recurrent episodes of bipolar disorder -- based on the works of Ban 2017, Blackwell 2014 and 2018, Rybakowski 2017, Severus 2014 and others. Lithium remains a key treatment, although its use needs monitoring and a safety-conscious approach is needed (Shine, McKnight, Leaver and Geddes 2015). The burden of the not too uncommon side effect, the lithium-induced NDI can be alleviated somewhat by the clever use of modern antidiuretic agents (indomethacine combined with excessive doses of desmopressin), including also the use of amiloride, and thiazides.

References:

Aiff H, Attman P, Aurell M, Bendz H, Schön S, Svedlund J. The impact of modern treatment principles may have eliminated lithium-induced renal failure. *Journal of Psychopharmacology*. 2014; 28:151-4.

Allen HM, Jackson RL, Winchester MD, Deck LV, Allon M. Indomethacin in the treatment of lithium-induced nephrogenic diabetes insipidus. *Archives of Internal Medicine* 1989; 149; 1123-26.

- Ban TA: Neuropsychopharmacology in Historical Perspective. Education in the Field in the Post-Neuropsychopharmacology Era. Prologue. inhn.org/education. September 18, 2017.
- Bedford JJ, Weggery S, Ellis G, McDonald FJ, Joyce PR, Leader JP, Walker RJ. Lithium-induced nephrogenic diabetes insipidus: renal effects of Amiloride. *Clin J Am Soc Nephrol* 2008a; 3: 1324–31.
- Bedford JJ, Leader JP, Jing R, Walker RJ, Klein JD, Sands JM, Walker RJ. Amiloride restores renal medullary osmolytes in lithium-induced nephrogenic diabetes insipidus. *Am. J. Physiol. Renal. Physiol.* 2008b; F812-F820.
- Bendz H. Kidney function in lithium treated patients. *Acta Psychiat Scand* 1983; 68: 303.
- Bendz H, Aurell M, Balldin J, Mathe A, Sjodin I. Kidney damage in long term lithium patients: A cross sectional study of patients with 15 years or more on lithium. *Nephrol Dial Transplant* 1994; 9:1250- 4.
- Bendz H, Schön S, Attman P, Aurell M. Renal failure occurs in chronic lithium treatment but is uncommon. *Kidney International* 2010; 77:219-24.
- Blackwell B. Lithium Controversy. A historical autopsy. inhn.org/controversies. June 19, 2014.
- Blackwell B. Final reply to János Radó's final comment. inhn.org/controversies. May 10, 2018.
- Boccalandro C, De Mattia F, Guo DC, Xue L, Orlander P, King TM, Gupta P, Deen PM, Lavis VR, Milewicz DM. Characterization of an aquaporin-2 water channel gene mutation causing partial nephrogenic diabetes insipidus in a Mexican family: Evidence of increased frequency of the mutation in the town of origin. *J Am Soc Nephrol* 2004; 15:1223-31.
- Boton R, Gauria M, Battle D. Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. *Amer. J Kidney Dis* 1987; 10: 329-45.
- Cade JP. Lithium salts in the treatment of psychotic excitement. *Med J Australia* 1949; 2: 349 -52.
- Canfield MC, Tamarappoo BK, Moses AM, Verkman AS, Holtzman EJ. Identification and characterization of aquaporin-2 water channel mutations causing nephrogenic diabetes insipidus with partial vasopressin response. *Human Molecular Genetics* 1997; 6: 1865-71.
- Crawford JD, Kennedy GC, Hill LE. Clinical results of treatment of diabetes insipidus with drugs of the chlorothiazide series. *N Engl J Med* 1960; 262: 739-42.
- Croft PK, Bedford JJ, Leader JP, Walker RJ. Amiloride modifies the progression of lithium-induced renal interstitial fibrosis. *Nephrology (Carlton)*. 2018 Jan; 3(1):20-30. doi: 10.1111/nep.12929.
- Davis J, Desmond M, Berk M. Lithium and nephrotoxicity: a literature review of approaches to clinical management and risk stratification. *BMC Nephrology* 2018; 19:305.

- Fujiwara TM, Bichet DG. Molecular Biology of hereditary diabetes insipidus. *J Am Soc Nephrol* 2005; 16:2836-46.
- Earley LE, Orloff J. The mechanism of antidiuresis associated with the administration of hydrochlorothiazide to patients with vasopressin resistant diabetes insipidus. *J Clin Invest* 1962; 41:1988-97.
- Hestbech J, Hansen HE, Amdisen A. Chronic renal lesions following long-term treatment with lithium. *Kidney Int* 1977; 12:205-13.
- Johnson G. Lithium early development, toxicity and renal function *Neuropsychopharmacology* 1998; 19:200-5
- Johnson G, Glenn E, Hunt G, Duggin G, Horvath JS, Tiller DJ. Renal function and lithium treatment: initial and follow up tests in Manic -Depressive patients. *J. Affective Disorders* 1984; 6: 249-63.
- Johnson G. Comment on János Radó's (January 25, 2018) final comment (Barry Blackwell: The Lithium Controversy. A historical autopsy). *inhn.org.collated*. July 5, 2018.
- Kalra S, Zargar AH, Sunil MJ, Bipin S, Chowdhury S, Singh AK, Thomas N, Unnikrishnan AG, Thakkar PB, Malve H. Diabetes insipidus: The other diabetes. *Indian J Endocr Metab* 2016; 20:9-21.
- Kim GH, Lee JW, Oh YK, Chang HR, Joo KW, Na KY, Earm JH, Knepper MA, Han JS. Antidiuretic effect of hydrochlorothiazide in lithium-induced nephrogenic diabetes insipidus is associated with upregulation of aquaporin 2, Na-Cl cotransporter and epithelial sodium channel. *J Am Soc Nephrol* 2004; 15:2836-43.
- Libber S, Harrison M, Spector D. Treatment of Nephrogenic diabetes insipidus with prostaglandin synthesis inhibitors. *J Pediatr* 1986; 108:305-11.
- Mizuno H, Fujimoto S, Sugiyama Y, Kobayashi M, Ohro Y, Uchida S, Sasaki S, Togari H. Successful treatment of partial nephrogenic diabetes insipidus with thiazide and desmopressin. *Horm Res*. 2003; 59:297-300.
- Moses AM, Scheinman SJ, Oppenheim A. Marked hypotonic polyuria resulting from nephrogenic diabetes insipidus with partial sensitivity to vasopressin. *J Clin Endocrinol Meta*.1984; 59:1044-9.
- Nielsen J, Hoffert JD, Knepper MA, Agre P, Nielsen S, Fenton RA. Proteomic analysis of lithium-induced nephrogenic diabetes insipidus: Mechanisms for aquaporin 2 down-regulation and cellular proliferation. *PNAS* 2008; 105:3634-9.
- Osio Y, Robertson GL, Norgard JP, Juul KV. Treatment of neurohypophyseal diabetes insipidus. *J Clin Endocrinol Metab* 2013; 98:3958-67.
- Radó J. Final comment (Use of modern antidiuretic agents in the treatment of permanent lithium-induced nephrogenic diabetes insipidus [Barry Blackwell: The lithium controversy. A historical autopsy]). *inhn.org.collated*. January 25, 2018.
- Radó JP. Water intoxication during carbamazepine treatment. *Brit Med J*. 1973; 3:479.
- Radó JP. Combination of carbamazepine and chlorpropamide in the treatment of "hyposponder" diabetes insipidus. *J Clin Endocrinol Metab* 1974; 1:38.

Radó JP. 1-desamino-8-D-arginine vasopressin (DDAVP) concentration test. *Am J Med Sci* 1978; 275: 43-52.

Radó JP, Bános Cs, Marosi J, Borbély L, Takó. Investigation on diuretic and antidiuretic properties of furosemide in diabetes insipidus. *Endokrinologie* 1968; 53:253-60.

Radó JP, Juhos É, Sawinsky I. Dose-response relations in drug-induced inappropriate secretion of ADH: Effects of clofibrate and carbamazepine. *Int J Clin Pharmacol* 1975a; 12:315-19.

Radó JP, Marosi J. Prolongation of duration of action of 1-deamino-8-D-arginine vasopressin (DDAVP) by ineffective doses of clofibrate in diabetes insipidus. *Horm Metab Res* 1975b; 7: 527-8.

Radó JP, Marosi J, Borbely L, Tako J. Individual differences in the antidiuretic response induced by single doses of 1-deamino-8-D-arginine-vasopressin (DDAVP) in patients with pituitary diabetes insipidus. *Int J Clin Pharmacol Biopharm* 1976a; 14: 259-65.

Radó JP, Marosi J, Fischer J. Shortened duration of action of 1-deamino-8-D-arginine vasopressin (DDAVP) in patients with diabetes insipidus requiring high doses of peroral antidiuretic drugs. *J Clin Pharmacol* 1976b; 16: 518-24.

Radó JP, Marosi J, Fischer J. Comparison of the antidiuretic effects of single intravenous and intranasal doses of DDAVP in diabetes insipidus. *Pharmacology* 1977; 15: 40-5.

Radó JP, Marosi J, Fischer J, Tako J, Kiss N. Relationship between the dose of 1-deamino-8-d-arginine vasopressin (DDAVP) and the antidiuretic response in man. *Endokrinologie* 1975c; 66: 184-95.

Radó JP, Marosi J, Szende L, Borbely L, Tako J, Fischer J. The antidiuretic action of 1-deamino-8-D-arginine vasopressin (DDAVP) in man. *Int J Clin Pharmacol Biopharm* 1976c; 13: 199-209.

Radó JP, Szende L, Marosi J. Influence of glyburide on the antidiuretic response induced by 1-deamino-8-d-arginine vasopressin in patients with pituitary diabetes insipidus. *Metabolism* 1974b; 23:1057-1063.

Radó JP, Simatupang T, Boer P, Dorhout Mees EJ. Pharmacologic studies in Bartter's syndrome: effect of DDAVP and indomethacin on renal concentrating operation. Part II. *Int J Clin Pharmacol Biopharm* 1978; 16:22-6.

Radó JP, Szende L. Simultaneous familial occurrence of distal renal tubular acidosis, polycystic kidney and nephrogenic diabetes insipidus. *Orvosi Hetilap* 1995; 136:995-1001.

Radó JP, Szende L, Marosi J, Juhos É, Sawinsky I, Takó J. Inhibition of the diuretic action of glibenclamide by clofibrate, carbamazepine and 1-deamino-8-D-arginin vasopressin (DDAVP) in patients with pituitary diabetes insipidus. *Acta Diabetologia Latina* 1974c;11:179-97.

Radó JP, Zdravkova S. Lithium-induced chronic water-metabolism disorder (nephrogenic diabetes insipidus)]. *Orv Hetil.* 1991;132, 1987-90.

Radó JP, Zdravkova S. Effect of Indomethacine and Calcitonin During Administration of 1-Deamino-8-D-Arginin-Vasopressin (dDAVP) on Free Water Clearance in Nephrogenic

Diabetes Insipidus (NDI). XIIth International Congress of Nephrology. June 13–18, 1993 Jerusalem, Israel.

Rybakowski J. Final comment: Half a Century of Inspiring Lithium Controversy. Barry Blackwell: The Lithium controversy: A historical autopsy. Collated by Olaf Fjetland. inhn.org. collated. September 30, 2017.

Schou M. Lithium studies. 1. Toxicity Acta Pharmacol Toxicol 1958;15:70-84.

Shine B, McKnight RF, Leaver L, Geddes JR. Long term effects of lithium on renal, thyroid, and parathyroid function: retrospective analysis of laboratory data. The Lancet 2015; 386:461-8.

Severus E, Taylor MJ, Sauer C, Pfennig A, Ritter P, Bauer M, Geddes JR. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. International Journal of Bipolar Disorders 2014; 2:15.

Simon NM, Garber E, Arieff AJ. Persistent nephrogenic diabetes insipidus after lithium carbonate. Ann Int Med 1977; 86:446-7.

Stasior DS, Kikeri D, Duel B, Seifter JL. Nephrogenic diabetes insipidus responsive to indomethacine plus dDAVP. New Eng J Med 1991; 324: 850-1.

Thompson CJ, France AJ, Baylis PH. Persistent nephrogenic diabetes insipidus following lithium therapy. Scottish Medical Journal 1997; 42: 16-7.

Vierhapper H. Indomethacine in the treatment of lithium-induced nephrogenic diabetes insipidus. Arch Int Med 1990; 150: 2419.

Weinstock RS Moses AM. Desmopressin and indomethacine therapy for nephrogenic diabetes insipidus in patients receiving lithium carbonate. South Med J 1990; 83: 1475-7.

May 2, 2019

Janusz Rybakowski's commentary

The paper written by János Radó provides a detailed description of one of the frequent renal side-effects of lithium: an impairment of renal concentrating ability which, in rare cases, can have its apogee in lithium-induced nephrogenic diabetes insipidus. As to diabetes insipidus, the author discusses the available treatments of this condition pointing to the clever use of modern antidiuretic interventions. This may provide clinicians employing lithium in patients with mood disorders and encountering such a side effect, a variety of options for its management.

However, from nearly a half-century perspective of the practice of lithium treatment, I can voice an opinion that lithium-induced impairment of renal concentrating

ability, leading infrequently to nephrogenic diabetes insipidus, may not be a major kidney problem connected with the long-term lithium therapy. This side-effect of lithium can be observed as early as after several weeks of lithium therapy and, in most cases, disappears completely after lithium discontinuation; it can also be effectively treated according to Dr. Radó's guidelines. During long-term lithium treatment, many patients present some degree of impairment of renal concentrating ability, however, in most cases it does not have significant clinical importance and does not lead to lithium discontinuation. The most important kidney side-effect is lithium nephropathy, developing mostly after 10 or more years of lithium treatment and, in some cases, can result in renal failure and make a real case for termination of lithium therapy. In good responders to long-term lithium, it may have a detrimental effect to the illness since a replacement of lithium with another mood stabilizer is usually not so effective.

My experience with lithium therapy dates back to 1970 when I started such treatment at the Department of Psychiatry, Medical Academy, Poznan, Poland. Two years later I described, first in Polish medical literature, a case of lithium-induced diabetes insipidus. This side effect occurred after several weeks of lithium therapy and disappeared following lithium discontinuation (Rybakowski and Daszynska 1972).

In recent years our group has performed a number of studies on kidney function in long-term lithium-treated patients. In the study published in 2012, 80 patients with a bipolar mood disorder (26 male, 54 female), aged 60 ± 11 years, receiving lithium for 5-38 (16 ± 9) years, were investigated. Decreased estimated glomerular filtration rate (eGFR) values <60 ml/min/1.73/m² were found in 23% of patients, significantly more frequently in men than in women (38% vs. 16%). Specific gravity of the urine, equal to or below 1.005, was recorded in 21% of men and 14% of women (Rybakowski, Abramowicz, Drogowska et al. 2012).

Since the inhibition caused by lithium of the glucocorticoid synthase kinase-3beta (GSK-3 β) makes it the main mechanism of lithium action, we were interested whether the functional -50 C/T polymorphism of the GSK-3 β gene could be associated with kidney function in 78 long-term lithium-treated bipolar patients. We found such an association with a lithium effect on urine concentrating capacity. Patients homozygous for C allele had significantly higher urine specific gravities (1.019 ± 0.008) compared to the remaining genotypes (1.013 ± 0.007) ($p = 0.035$), with no influence attributed to the duration of lithium treatment. Other parameters of kidney function (serum creatinine,

eGFR, serum NGAL and urinary β 2-MG levels) were not different between genotypes (Rybakowski, Abramowicz, Szczepankiewicz et al. 2013).

As previously mentioned, the main reasons for lithium discontinuation in long-term lithium-treated patients are the symptoms of lithium-induced nephropathy. However, such a discontinuation, especially in “excellent lithium responders” (ELR), is associated with a high risk of relapse and a treatment-resistant course. We assessed kidney function during a five-year follow-up in the ERL with the glomerular filtration rate (GFR) < 50 ml/min/1.73 m². Three males and one female were included. At the beginning, their age was 61 ± 0.8 years and duration of lithium treatment was 27 ± 9 years. Kidney parameters (serum creatinine, GFR and urine specific gravity) were assessed at least three times during the five-year follow-up period. In three patients having the initial GRF between 47–48 ml/min/1.73 m², the kidney parameters did not show significant changes and the patients continued lithium treatment. The patient with the lowest GFR (32 ml/min/1.73 m²) had a 14% decrease in GFR and a 10% increase in serum creatinine. However, urinary specific gravity increased during this time from 1.003 to 1.007. In this patient, the dose of lithium was decreased by one-third and he was placed under strict nephrological observation. Therefore, based on the results and in the ELR with the GFR not much lower than 50 ml/min/1.73 m², we suggest continuing lithium with a yearly check on kidney parameters. In the ELR with a much lower GFR, a reduction of lithium dose and nephrological observation along with more frequent monitoring would be recommended (Abramowicz, Permoda-Osip, Nowak et al. 2017).

We also described five patients (two men and three women, aged 64-79 years) with ultra-long-term lithium treatment (40-45 years) and good response to such treatment. Their serum lithium level was maintained within the range of 0.60-0.65 mmol/l, except for one male, having 0.7-0.8 mmol/l. One man had stage 3 chronic kidney disease and the other stage 2/3 chronic kidney disease. All three women had asymptomatic stage 2 chronic kidney disease. However, no progression has been observed within the last five years. The urine specific gravity in all patients was above 1.005. In all patients the cognition and professional activity were at the level of healthy subjects with comparable age and years of education. Their functioning in family and social roles was good. The beginning of lithium prophylaxis had usually been made within the first three years of the illness. Therefore, we could conclude that in patients with favorable response to lithium, such a longitudinal administration of the drug can produce satisfactory performance in

vocational and psychosocial areas and the management of potential adverse effects can be adequate (Permoda-Osip, Abramowicz, Kraszewska et al. 2016).

In conclusion, from a long-term lithium administration perspective, the issue of lithium-induced diabetes insipidus is much less important than lithium-induced nephropathy. However, Dr. Radó should be congratulated for his excellent review of treatment possibilities for this lithium-induced side effect. In my opinion, the extensive therapeutic experience of Dr. Radó with lithium-induced diabetes insipidus deserves an updating publication in a regular bipolar disorder journal and I would encourage him to submit such a paper to the International Journal of Bipolar Disorders.

References:

Abramowicz A, Permoda-Osip A, Nowak B, Olejniczak P, Rybakowski JK. Five-year observation of chronic renal insufficiency during lithium treatment. A case study of four patients. *Pharmacother Psychiatry Neurol* 2017; 33: 169-79.

Permoda-Osip A, Abramowicz M, Kraszewska A, Suwalska A, Chlopocka-Wozniak M, Rybakowski JK. Kidney, thyroid and other organ functions after 40 years or more of lithium therapy: a case series of five patients. *Ther Adv Psychopharmacol* 2016; 6: 277-82.

Rybakowski J, Daszyńska M. Case of diabetes insipidus in the course of treatment with lithium carbonate (article in Polish). *Pol Tyg Lek* 1972; 25: 1527-8.

Rybakowski JK, Abramowicz M, Drogowska J, Chłopocka-Woźniak M, Michalak M, Czekalski S. Screening for the markers of kidney damage in men and women on long-term lithium treatment. *Med. Sci Monit* 2012; 18: CR656-60.

Rybakowski JK, Abramowicz M, Szczepankiewicz A, Michalak M, Hauser J, Czekalski S. The association of glycogen synthase kinase-3beta (GSK-3 β) gene polymorphism with kidney function in long-term lithium-treated bipolar patients. *Int J Bipolar Disord* 2013; 1: 8.

June 20, 2019

János Radó's reply to Janusz Rybakowski's commentary

Many thanks to Professor Rybakowski for his comment, which is as comprehensive as a comment could be. We are grateful for the perfect evaluation of the clinical significances of the different lithium-induced renal abnormalities.

Professor Rybakowski stresses that the most important kidney side effect is lithium-nephropathy resulting in renal failure and makes a real case for termination of

lithium therapy. It is sometimes a tragic event for the excellent responding long-term treated patient because of the high risk to relapse.

We have to congratulate the Rybakowski Group for their wise recommendations in lithium therapy (lowering plasma lithium levels, more intensive role of nephrologists, etc.) by which they are able to continue lithium treatment (in their excellent responding patients) even with lithium-induced nephropathy.

However, our field is lithium-induced permanent nephrogenic diabetes insipidus and other associated abnormalities. In such a patient with advanced lithium-induced renal tubular acidosis severe metabolic bone disease also developed (Radó 2018). Bone pain could not be easily eliminated. Calcitonin was administered with a surprising result. The antidiuretic action of desmopressin was abolished and the polyuria was restored. It is interesting that a basically (probably) antidiuretic molecule behaved as a “diuretic.” We proposed the possibility of a competitive antagonism between desmopressin and calcitonin (Radó 2018)

By the way, I read recently with great enthusiasm Professor Rybakowski’s excellent 2018 review article on Challenging the negative perception of lithium and optimizing its long term administration. The significance of this work is characterized by a remark of Domenico De Berardis at the end of the publication: “The underutilization of lithium is a plague and ...malpractice. Your paper should be read by all psychiatrists and residents.”

I appreciate very deeply Professor Rybakowski’s commentary on my “Review of the literature” (Radó 2019).

References:

Radó J. Final comment (Use of modern antidiuretic agents in the treatment of permanent lithium-induced nephrogenic diabetes insipidus [Barry Blackwell: The lithium controversy. A historical autopsy]). inhn.org/collated. January 25, 2018.

Radó J. Addition to final comment: Calcitonin in lithium-induced nephrogenic diabetes insipidus (Barry Blackwell: The lithium controversy. A historical autopsy) inhn.org/collated. September 13, 2018.

Radó J. Renal Toxicity of Lithium in Historical Perspective with Special Reference To Nephrogenic Diabetes Insipidus and its Treatment. inhn.org/controversies. May 2, 2019.

Radó J. Desmopressin may counteract polyuria in lithium-induced nephrogenic diabetes insipidus (Review of the literature). inhn.org/archives. July 18, 2019.

Rybakowski J. Challenging the negative perception of lithium and optimizing its long term administration. *Frontiers in Molecular Neuroscience*. October 2018.

June 27, 2019

Janusz Rybakowski's response to János Radó's reply

I was greatly flattered by the appraisal of my comment by János Radó. It seems that the bottom line for both of us is to efficiently alleviate possible renal obstacles to long-term lithium treatment, be it nephrogenic diabetes insipidus or lithium-induced nephropathy. We concur with the notion that lithium should be used more frequently and, by doing so, it would be able to help the larger number of patients.

While lithium is the drug of choice for preventing recurrences in bipolar (and probably also unipolar) mood disorder, the fringe benefits of lithium therapy should also be emphasized. These are connected with anti-suicidal, antiviral and neuroprotective properties of this ion. Among all mood-stabilizing drugs, lithium is the most powerful for preventing suicidal behavior (Cipriani, Hawton, Stockton and Geddes 2013). The antiviral effect of lithium was demonstrated by showing a reduction of labial herpes frequency in long-term lithium-treated patients (Rybakowski and Amsterdam 1991). Finally, neuroprotective effects of lithium have been demonstrated such as increasing cerebral volume, decreasing risk of dementia as well as promising results in Alzheimer's disease (Rybakowski, Suwalska and Hajek 2018). Interestingly, the effect of lithium in dementia might be connected with its action against herpes viruses (Rybakowski 2019). A recent paper of Van Gestel, Franke, Petite et al. (2019) could also be recalled showing that lithium-treated bipolar patients show the features of decreased brain aging.

It should be hoped that disseminating knowledge on the efficient managing of lithium-induced renal side effects could contribute to more common application of this therapeutic ion in mood disorders.

References:

Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. *Br Med J* 2013;346:f3646.

Van Gestel H, Franke K, Petite J, Slaney C, Garnham J, Helmick C, Johnson K, Uher R, Alda M, Hajek T. Brain age in bipolar disorders: Effects of lithium treatment. *Aust N Z J Psychiatry* 2019 Jun 27: 4867419857814. [Epub ahead of print].

Rybakowski JK, Amsterdam JD. Lithium prophylaxis and recurrent labial herpes infections. *Lithium* 1991;2:43-7.

Rybakowski JK, Suwalska A, Hajek T. Clinical perspectives of lithium's neuroprotective effect. *Pharmacopsychiatry* 2018;51:194-99.

Rybakowski JK. Commentary: Corroboration of a major role for Herpes Simplex Virus Type 1 in Alzheimer's disease. *Front Aging Neurosci* 2019;10:433.

November 14, 2019

János Radó: Desmopressin may counteract polyuria in lithium-induced nephrogenic diabetes insipidus

Review of the literature

Abstract

Lithium is a simple ion that remains the best, safest and least expensive treatment for the prevention of recurrent episodes of bipolar disorder. However, in many patients administration of lithium is associated with renal side effects. The most frequent side effect is a defect in urinary concentration which may lead to permanent lithium-induced nephrogenic diabetes insipidus. In the older literature this problem was treated with great attention; in the most recent publications, however, lithium-induced nephrogenic insipidus is hardly mentioned. Patients suffer from a disturbed night therefore it is an eminent goal to secure them some rest.

In our previous work administration of excessive doses of desmopressin resulted in clinically relevant antidiuresis in lithium-induced nephrogenic insipidus enhanced by indomethacine (Radó and Zdravkova 1991; Radó 2018a,b; Radó 2019). The purpose of the present paper is to review the literature concerning the use of desmopressin in lithium-induced nephrogenic diabetes insipidus.

Introduction

Lithium is a simple ion that remains the best, safest and least expensive treatment for the prevention of recurrent episodes of bipolar disorder (Blackwell 2018). This concept is supported by many reports, among them those of Ban (2017); Gupta, Kripafani, Khastgir and Reilly (2013); Rybakowski (2017); and Severus, Taylor, Sauer et al. (2014). However, its use has gradually declined and many less-established drugs are preferred. It is underused because of its low therapeutic index, the need for regular blood tests and perceptions about its adverse effects, including renal problems (Gupta, Kripafani, Khastgir, Reilly 2013)

The most frequent renal problem encountered is the disturbance in water metabolism due to lithium-induced insufficiency in renal concentrating operation resulting in polyuria and polydipsia. Daily urine volume increases, in many cases more than 3-5 liters a day (Johnson 2018; Warnes 2019), but we have seen a patient, in whom

in a stage of her long history it was more than 10 liters. Patients suffer from a disturbed night. Therefore, it is an eminent goal to secure some rest for them. In the older literature this problem seemed to be very important (Johnson, Glenn, Hunt et al. 1984; Johnson 1998; Radó and Zdravkova 1991) and was treated with great attention. In the most recent publications, however, lithium-induced nephrogenic insipidus is hardly mentioned (Gupta and Khastgear 2017; Davis, Desmond and Berk 2018). The recommended drugs are mostly a thiazide diuretic (Mizuno, Fujimoto, Sugiyama et al. 2003), indomethacine (Weinstock and Moses 1990) and amiloride (Croft, Bedford, Leader and Walker 2018).

A Short Pharmacology of Desmopressin

Structural alterations of the vasopressin molecule resulted in 1-deamino-8-D-arginine vasopressin (DDAVP) or desmopressin, with increased antidiuretic potency, longer duration of action and lacking a pressor effect due to decreased vasoconstrictor activity. In our studies carried out over 40 years we have demonstrated a relationship between the dose and both the magnitude and the duration of the antidiuretic effect (Radó, Marosi, Fischer et al. 1975a; Radó, Marosi, Szende et al. 1976c). Robertson and his coworkers (Oiso, Robertson, Norgard and Juul 2013) wrote about our early investigations that “in patients with neurohypophyseal diabetes insipidus rapid infusion of 1 micgr desmopressin increased urine osmolality to a maximum of 700-800 mOm/Kg; further increases in dosage only prolonged the duration of action from an average of 26 hours after 1 micgr to 46 hours after 8 micgr.”

Our further studies revealed large interindividual variability in the magnitude and duration of the antidiuretic response of desmopressin, which was contributed - at least in part - to the interindividual differences in renal concentrating power (Radó, Marosi, Borbely and Tako 1976a). The long duration of action of desmopressin is attributed mainly to its slow metabolic (enzymatic) degradation and both shortened duration of action (Radó, Marosi and Fischer 1976b) and lengthened duration of action (Radó and Marosi 1975b) were reported under varying pharmacological circumstances.

The effect of desmopressin was inhibited by glyburide, an antidiabetic compound, probably by competitive antagonism (Radó, Szende and Marosi 1974a; Radó, Szende, Marosi et al. 1974b) A similar antagonism by calcitonin was discovered later (Radó 2018ab). Comparison of the antidiuretic effects of single intravenous and intranasal doses of desmopressin in diabetes insipidus was also an important part of our investigations

(Radó, Marosi and Fischer 1977). Intranasal administration of desmopressin was at that time a comfortable way of administration and proved to be reliable and today desmopressin therapy can be carried out by ingesting dissolving tablets (Walle, Stockner, Raes and Nørgaard 2007).

We have elaborated a diagnostic procedure for the differentiation of the various concentrating defects by intranasal administration of desmopressin, the “desmopressin concentrating test” (Radó 1978). When we started our studies with desmopressin a “supramaximal” dose was 300 microgr given intranasally. In these early human pharmacology investigations 320 mcg was given as a quasi “single dose” during one hour to patients with neurohypophyseal (central) diabetes insipidus (Radó and Marosi 1975b). When we used desmopressin for nephrogenic diabetes insipidus 300 microgr was given during 24 hrs. (Radó and Zdravkova 1991). In the meantime, however, it became known desmopressin may also be effective in hematologic disorders; for these disorders, in certain cases, desmopressin was given in very extreme doses. The industry produced desmopressin preparations containing very high concentrations of desmopressin intended to act on the blood clotting mechanism for bleeding disorders. By using such a preparation (Octim Nasal Spray Ferring Pharmaceuticals Ltd) administration of 300 micrgr (150 micrgr into both nostrils) as a single dose is easily feasible. To the best of my knowledge this preparation has not been tried, up to now, in the therapy of the lithium-induced permanent nephrogenic diabetes insipidus.

Desmopressin Administered Alone in Nephrogenic Diabetes Insipidus

Although nephrogenic diabetes insipidus is said to be “vasopressin resistant,” on the basis of ours and others’ previous investigations we did not exclude the use of certain vasopressin derivatives in this condition because vasopressin resistance in many cases is not absolute (Canfield, Tamarappoo, Moses et al. 1997; Fujiwara and Bichet 2005; Khanna 2006; Oiso, Robertson, Norgard and Juul 2013; Moses, Scheinman and Oppenheim 1984). Large doses of desmopressin were successfully given to patients with congenital nephrogenic diabetes insipidus for antidiuretic purposes (Boccalandro, De Mattia, Guo et al. 2004; Canfield, Tamarappoo, Moses et al. 1997; Khanna 2006; Oiso, Robertson, Norgard and Juul 2013; Moses, Scheinman and Oppenheim 1984). The effectiveness of relatively large doses of vasopressin (and also excessive doses of desmopressin) can be significantly different even within one family with congenital

nephrogenic diabetes insipidus (Radó and Szende 1995; Radó 2019). Probably the degree of resistance to vasopressin (desmopressin) may differ among the family members: one family member was treated successfully with desmopressin for decades and the case was published because the (congenital nephrogenic) diabetes insipidus was later associated with diabetes mellitus (Radó 2011). In our previous work we found that in a patient with lithium-induced permanent nephrogenic diabetes insipidus in response to excessive desmopressin doses free water excretion (expressed in the percentage of glomerular filtration rate ($\text{CH}_2\text{O} \times 100/\text{GFR}$)) significantly decreased and urine osmolality significantly increased (Radó 2018a).

A very special observation

Müller, Marr, Ankermann et al. (2002) investigated two unrelated families in which two children had inherited primary nocturnal enuresis and nephrogenic diabetes insipidus; they had mutations in the aquaporin-2 gene. The mutant proteins were inactive, suggesting that administration of desmopressin could not concentrate the urine in these patients. However, treatment with desmopressin resolved primary nocturnal enuresis completely.

Combination of Desmopressin with Other Antidiuretic Agents in Nephrogenic Diabetes Insipidus

Mizuno, Fujimoto, Sugiyama et al. (2003) treated a seven-year-old boy suffering from congenital nephrogenic diabetes insipidus who had demonstrated a partial response to desmopressin. Neither a low salt diet and a thiazide nor a large dose of desmopressin was effective in reduction of daily urine volume. However combination of thiazide and a large dose of desmopressin resulted in a decrease in urine volume and disappearance of nocturia.

Indomethacine and desmopressin was used for the first time in lithium induced nephrogenic diabetes insipidus in 1990 by Weinstock and Moses. They found in their two patients that indomethacine alone was practically ineffective, but in combination with large doses of desmopressin urine volume decreased by 47% and 63% respectively, while urine osmolalities increased by 200% and 227% respectively.

Stasior, Kikeri, Duel and Seifter (1991) reported a patient with lithium-induced nephrogenic diabetes insipidus who was responsive to desmopressin in the presence of

indomethacine, but not to desmopressin or indomethacine alone. A single dose of 6 micgr desmopressin subcutaneously (not a too large dose!) without indomethacine caused an increase in urine osmolality from 187 mOsm/Kg to 270 mOsm/Kg (44%). However, in response to the same dose of desmopressin in the presence of indomethacine urine osmolality increased from 106 mOsm/Kg to 384 mOsm/Kg (262%).

In our patient urine volume and free water clearance significantly decreased while urine osmolality significantly increased after administration of the combination of indomethacine and desmopressin as compared to desmopressin administered alone (Radó 2018a).

In our further studies piroxicam plus desmopressin, as compared to desmopressin (administered alone), was also antidiuretic: urine volume and free water excretion decreased while urine osmolality increased without any consistent change in osmolal clearance, glomerular filtration rate and serum osmolality. These results support the contention that indomethacine is not the only nonsteroidal anti-inflammatory compound which can be used in the antidiuretic therapy. However, piroxicam seemed to be less antidiuretic than indomethacine by 20-30%.

Antidiuretic properties have been demonstrated for chlorpropamide, carbamazepine and clofibrate which potentiate the effect of desmopressin (Radó 2019). From these compounds probably only carbamazepine may be useful in a limited extent in the treatment of the lithium-induced nephrogenic insipidus. Statins (Bonfrate, Procino, Wang et al. 2015; Milano, Carmoniso, Gerbino and Procino 2017); metformin (Efe, Klein, LaRocque et al. 2016); sildenafil and calcitonin (Milano, Carmoniso, Gerbino and Procino 2017); prasugrel (Zhang, Peti-Peterdi, Brandes et al. 2017); and clopidrogel (Zhang, Peti-Peterdi, Heiney et al. 2015) were also shown to have some antidiuretic capabilities. Only calcitonin was combined with desmopressin (Radó 2018 a,b). In our hands, however, it was not an antidiuretic factor.

Administration of excessive doses of desmopressin resulted in clinically relevant antidiuresis, enhanced by indomethacine and abolished by calcitonin (Radó 2018a). Calcitonin is a “tricky” hormone, having both diuretic and antidiuretic properties. Diuretic effect of calcitonin was an observation found mainly in the older literature and is in harmony with our published data on a water mobilizing action (Radó 1991, 1993, 2018a). On the other hand, water retaining action was found (Elalouf, Roinel and de

Rouffignac 1986) in response to human calcitonin in rats during micropuncture studies simulating the changes induced by desmopressin. Calcitonin was recommended as a possible treatment for hereditary nephrogenic diabetes insipidus by Milano, Carmoniso, Gerbino and Procino (2017).

Combinations of hydrochlorothiazide with indomethacine, amiloride with thiazide diuretics have additive antidiuretic effects (Milano, Carmoniso, Gerbino and Procino 2017). All could have been combined - at least theoretically - with desmopressin to have a really potentiated antidiuretic intervention for the treatment of lithium-induced nephrogenic diabetes insipidus.

Conclusion

It is important to save lithium treatment for millions of people suffering from bipolar disorder and other psychiatric abnormalities in an age when its use has gradually declined and many less-established drugs are preferred (Gupta, Kripafani, Khastgir, Reilly 2013.) This can be done (at least partly) by demonstrating that treatment of lithium-induced permanent nephrogenic diabetes insipidus is not so hopeless as it appears from some recent articles dealing with lithium induced nephrotoxicity. Our therapeutic armamentarium include several drugs, thiazide diuretics, nonsteroid anti-inflammatory drugs, amiloride and desmopressin. In this article we dealt with desmopressin administered alone and in combination with other drugs in the treatment of congenital, as well as lithium-induced nephrogenic diabetes insipidus. On the basis of the available literature desmopressin alone and in combination with other antidiuretic drugs seemed to be an effective means in counteracting lithium-induced polyuria.

References:

Ban TA: Neuropsychopharmacology in Historical Perspective. Education in the Field in the Post-Neuropsychopharmacology Era. Prologue. inhn.org/education. September 18, 2017.

Blackwell B. Lithium Controversy. A historical autopsy. inhn.org/controversies. June 19, 2014.

Blackwell B. Final reply to János Radó's final comment. inhn.org/controversies. May 10, 2018.

Boccalandro C, De Mattia F, Guo DC, Xue L, Orlander P, King TM, Gupta P, Deen PM, Lavis VR, Milewicz DM. Characterization of an aquaporin-2 water channel gene mutation causing partial nephrogenic diabetes insipidus in a Mexican family: Evidence

- of increased frequency of the mutation in the town of origin. *J Am Soc Nephrol* 2004; 15:1223-31.
- Bonfrate L, Procino G, Wang DQ-H, Svelto M, Portincasa P. A novel therapeutic effect of statins in nephrogenic diabetes insipidus. *J Cell Mol Med* 2015;19:265-82.
- Canfield MC, Tamarappoo BK, Moses AM, Verkman AS, Holtzman EJ. Identification and characterization of aquaporin-2 water channel mutations causing nephrogenic diabetes insipidus with partial vasopressin response. *Human Molecular Genetics* 1997; 6: 1865-171.
- Croft PK, Bedford JJ, Leader JP, Walker RJ. Amiloride modifies the progression of lithium-induced renal interstitial fibrosis. *Nephrology (Carlton)*. 2018 Jan;23(1):20-30.
- Davis J, Desmond M, Berk M. Lithium and nephrotoxicity: a literature review of approaches to clinical management and risk stratification. *BMC Nephrology* 2018; 19:305.
- Efe O, Klein JD, LaRocque LM, Ren H, Sands JM. Metformin improves urine concentration in rodents with nephrogenic diabetes insipidus. *JCI Insight*. 2016 Jul 21;1(11).
- Elalouf JM, Roinel N, de Rouffignac C. Effects of human calcitonin on water and electrolyte movements in rat juxtamedullary nephrons: inhibition of medullary K recycling. *Pflugers Arch*. 1986; 406:502-8.
- Fujiwara TM, Bichet DG. Molecular Biology of hereditary diabetes insipidus. *J Am Soc Nephrol* 2005; 16:2836-46.
- Gupta S, Kripafani M, Khastgir U, Reilly J. Management of the renal adverse effects of lithium. *Advances in psychiatric treatment*. 2013; 19, 457–66.
- Gupta S, Khastgear U. Drug information update. Lithium and chronic kidney disease: debate and dilemmas. *BJPsych Bulletin* 2017;41:216-20.
- Johnson G. Lithium early development, toxicity and renal function *Neuropsychopharmacology* 1998; 19:200-5
- Johnson G, Glenn E, Hunt G, Duggin G, Horvath JS, Tiller DJ. Renal function and lithium treatment: initial and follow up tests in Manic-Depressive patients. *J. Affective Disorders* 1984; 6: 249-63.
- Johnson G. Comment on János Radó's final comment. In: Blackwell B. *The Lithium Controversy. A historical autopsy*. inhn.org.collated. July 5, 2018.
- Khanna A. Acquired nephrogenic diabetes insipidus. *Semin Nephrol* 2006;26: 244-8.
- Milano S, Carmoniso M, Gerbino A, Procino G. Hereditary nephrogenic diabetes insipidus: Pathophysiology and possible treatment. An Update. *Int J Mol Sci*. 2017 Nov 10;18(11).
- Mizuno H, Fujimoto S, Sugiyama Y, Kobayashi M, Ohro Y, Uchida S, Sasaki S, Togari H. Successful treatment of partial nephrogenic diabetes insipidus with thiazide and desmopressin. *Horm Res*. 2003;59(6):297-300.

- Moses AM, Scheinman SJ, Oppenheim A. Marked hypotonic polyuria resulting from nephrogenic diabetes insipidus with partial sensitivity to vasopressin. *J Clin Endocrinol Metab.* 1984; 59:1044–9.
- Müller D, Marr N, Ankermann T, Eggert P, Deen PMT. Desmopressin for nocturnal enuresis in nephrogenic diabetes insipidus. *Lancet* 2002;359 (9305) 495-7.
- Oiso Y1, Robertson GL, Nørgaard JP, Juul KV. Clinical review: Treatment of neurohypophyseal diabetes insipidus. *J Clin Endocrinol Metab.* 2013 Oct;98(10):3958-67.
- Radó JP. 1-desamino-8-D-arginine vasopressin (desmopressin) concentration test. *Am J Med Sci* 1978; 275: 43-52.
- Radó J. Diabetes mellitus és (nephrogen) diabetes insipidus együttes előfordulása. *Hypertonia és Nephrologia* 2011;15:183-7.
- Radó J. Final comment (Use of modern antidiuretic agents in the treatment of permanent lithium-induced nephrogenic diabetes insipidus. In Blackwell B: The lithium controversy. A historical autopsy inhn.org/controversies. inhn.org/collated. January 25, 2018a.
- Radó J. Addition to final comment. Calcitonin in lithium-induced nephrogenic diabetes insipidus. In Blackwell B. The lithium controversy. A historical autopsy. inhn.org/collated Sept.13, 2018b.
- Radó J. Renal Toxicity of Lithium in Historical Perspective with Special Reference To Nephrogenic Diabetes Insipidus and its Treatment. inhn.org/collated May 2, 2019.
- Radó JP, Marosi J. Prolongation of duration of action of 1-deamino-8-D-arginine vaso(desmopressin) by ineffective doses of clofibrate in diabetes insipidus. *Horm Metab Res* 1975b; 7: 527-8.
- Radó JP, Marosi J, Borbely L, Tako J. Individual differences in the antidiuretic response induced by single doses of 1-deamino-8-D-arginine-vasopressin (desmopressin) in patients with pituitary diabetes insipidus. *Int J Clin Pharmacol Biopharm* 1976a; 14: 259-65.
- Radó JP, Marosi J, Fischer J. Shortened duration of action of 1-deamino-8-D-arginine vasopressin (desmopressin) in patients with diabetes insipidus requiring high doses of peroral antidiuretic drugs. *J Clin Pharmacol* 1976b; 16: 518-24.
- Radó JP, Marosi J, Fischer J. Comparison of the antidiuretic effects of single intravenous and intranasal doses of desmopressin in diabetes insipidus. *Pharmacology* 1977; 15: 40-5.
- Radó JP, Marosi J, Fischer J, Tako J, Kiss N. Relationship between the dose of 1-deamino-8-d-arginine vasopressin (desmopressin) and the antidiuretic response in man. *Endokrinologie* 1975a; 66: 184-95.
- Radó JP, Marosi J, Szende L, Borbely L, Tako J, Fischer J. The antidiuretic action of 1-deamino-8-D-arginine vasopressin (desmopressin) in man. *Int J Clin Pharmacol Biopharm* 1976c; 13: 199-209.

Radó JP, Szende L, Marosi J. Influence of glyburide on the antidiuretic response induced by 1-deamino-8-d-arginine vasopressin in patients with pituitary diabetes insipidus. *Metabolism* 1974a; 23:1057-63.

Radó JP, Simatupang T, Boer P, Dorhout Mees EJ. Pharmacologic studies in Bartter's syndrome: effect of desmopressin and indomethacin on renal concentrating operation. Part II. *Int J Clin Pharmacol Biopharm* 1978; 16:22-6.

Radó JP, Szende L. Simultaneous familial occurrence of distal renal tubular acidosis, polycystic kidney and nephrogenic diabetes insipidus. *Orvosi Hetilap* 1995; 136:995-1001.

Radó JP, Szende L, Marosi J, Juhos É, Sawinsky I, Takó J. Inhibition of the diuretic action of glibenclamide by clofibrate, carbamazepine and 1-deamino-8-D-arginin vasopressin (desmopressin) in patients with pituitary diabetes insipidus. *Acta Diabetologia Latina* 1974b;11:179-97.

Radó JP, Zdravkova S. Lithium-induced chronic water-metabolism disorder (nephrogenic diabetes insipidus). *Orv Hetil.* 1991;132, 1987-90.

Rybakowski J. Final comment: Half a Century of Inspiring Lithium Controversy. Barry Blackwell: *The Lithium controversy: A historical autopsy*. Collated by Olaf Fjetland. inhn.org. collated. September 30, 2017.

Severus E, Taylor MJ, Sauer C, Pfennig A, Ritter P, Bauer M, Geddes JR. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. *International Journal of Bipolar Disorders* 2014; 2:15.

Stasior DS, Kikeri D, Duel B, Seifter JL. Nephrogenic diabetes insipidus responsive to indomethacine plus desmopressin. *New Eng J Med* 1991; 324: 850-1.

Vierhapper H. Indomethacine in the treatment of lithium-induced nephrogenic diabetes insipidus. *Arch Int Med* 1990; 150: 2419.

Walle JV, Stockner M, Raes A, Nørgaard JP. Desmopressin 30 years in clinical use: A safety review. *Curr Drug Saf.* 2007 2:232-8.

Warnes H. Comment on János Radó's additional final comment: Calcitonin in lithium-induced nephrogenic diabetes insipidus. In: Blackwell B: *The lithium controversy. A historical autopsy*. inhn.org.collated. January 16, 2019.

Weinstock RS, Moses AM. Desmopressin and indomethacine for nephrogenic diabetes insipidus in patients receiving lithium carbonate. *South Med J* 1990; 83: 1475-7.

Zhang Y, Peti-Peterdi J, Brandes A, Riquier-Brison A, Carlson NG, Müller CE, Ecelbarger CM, Kishore BK. Prasugral suppresses development of lithium-induced nephrogenic diabetes insipidus in mice. *Purinergic Signalling* 2017; 13:239-48.

Zhang Y, Peti-Peterdi J, Heiney KM, Riquier-Brison A, Carlson NG, Müller CE, Ecelbarger CM, Kishore BK. Clopidrogel attenuates lithium-induced alterations in renal water and sodium channels/transporters in mice. *Purinergic Signalling* 2015; 11:507-8.

June 27, 2019

Robert H. Belmaker's comments

Thank you for asking me to comment on this learned and mechanistically sophisticated piece by János Radó. I certainly agree that we must find treatments for lithium side effects so that fewer patients feel that they have to stop lithium. However, Radó does not give a biochemical explanation of lithium-induced nephrogenic diabetes insipidus and whether it is so clear that it is related to genetic forms. His data is basically one case of desmopressin-treated lithium-induced diabetes insipidus. Radó points out that the older literature assumed a lower maximum dose for desmopressin; now desmopressin is given in much, much higher doses for its effect on clotting. However, therein exactly lies the rub: the molecule has effects on physiology other than on the kidney, especially at high doses. That is justified for a severe clotting disorder. But we really do not know whether these clotting effects and others not yet known of high dose desmopressin are justified if the high doses were to be given widely for lithium-induced nocturia.

November 21, 2019

János Radó's reply to Robert H. Belmaker's comments

I am grateful for Robert H. Belmaker's essay discussing the divergent physiologic effects of desmopressin on the kidney and blood.

Lithium polyuria covers a broad spectrum of renal concentrating defect. From a small increase of the daily urine volume (perhaps not perceived even by the patient taking lithium) to high polyuria, 10-12 liter a day, or much more. Such magnitude of water intake leaves practically no rest during the night; the patient awakes every half an hour throughout the night to void. We know the natural history of the development of lithium-induced nephrogenic diabetes insipidus, it requires at least 10 years of drug consumption, so generally not the youngest patients suffer from this condition (Radó 2018).

Young patients with lithium polyuria can adapt to the high water intake relative easily with increasing urinary bladder capacity. One of our young female patients voided in 800 ml portions; older patients are mostly not so "fortunate." Decrease in urinary bladder capacity occurring frequently in older patients to 200 ml or 100 ml or less


combined with heavy polyuria induced by lithium is a severe curse, begging relief. I feel that in such a dramatic clinical situation administration of very high doses of desmopressin in combination with indomethacine is justified despite the potential influence on blood clotting mechanism.

It should be noted that although certain hematological disorders caused by a lack of individual blood coagulation factors may improve dramatically in response to desmopressin normal blood coagulation is apparently less influenced by the peptide.

Our experience with the administration of excessive doses of desmopressin began in years 1975-1977, before we began treating patients with lithium (1989-1996). We participated in the elaboration of the clinical pharmacology of desmopressin using extremely small and (at that time) “extremely high” doses of the peptide in patients with central diabetes insipidus, otherwise healthy persons.


As shown in Figure 1 the relationship between time and free water clearance, expressed in the percentage of glomerular filtration (left part of the panel), and urine osmolality (right part of the panel), respectively, after intravenous (upper panel) and intranasal (lower panel) administration of desmopressin (DDAVP) in patients with central diabetes insipidus. Maximal intravenous dose was 24 ug desmopressin, while maximal intranasal dose was 320 ug (Radó, Marosi, Szende et al. 1976). A very special dose-response relationship is obvious: increasing the dose of desmopressin results in a progressive increase in the magnitude of the antidiuretic response (in free water clearance and urine osmolality) but only to a maximal limit; after that, only the duration of the antidiuretic response increases. These data stress the significance of the increase of the dose not only in the magnitude but also in the duration of the antidiuretic response.

Figure 1



The dose-response relationship of desmopressin is striking in Figure 2 using only changes in urine osmolality (Radó, Marosi and Fischer 1977). By the equations presented in Figure 2 (below) one can estimate the expected urine osmolality value (antidiuretic response) after using a given intravenous or intranasal dose of desmopressin (DDAVP) within the first 24 hours after dosing.


Figure 2



These basic clinicopharmacological observations were obtained in the mid-70s, 15 years earlier than the renal effects of lithium treatment were studied (Radó and Zdravkova 1991).


Using our above data including our dosage protocol obtained on the patients with central diabetes insipidus (practically “healthy subjects”) Moses and his coworkers (1984) were able to calculate the degree of “vasopressin resistance” in their two patients with congenital nephrogenic diabetes insipidus (NDI). In Moses, Scheinman and Oppenheim’s (1984) Figure 3, data of their two congenital NDI cases (in left side and center) were compared with that of Radó’s 20 patients with central diabetes insipidus (in five columns on the right side DI). In the Moses group cases, desmopressin was given intranasally (“DDAVP orrspray”) 6x20 ug and 6x40 ug, respectively, per day, while in the Radó cases it was given in 0-320 ug once a day. The antidiuretic effect of desmopressin was followed by urine volume (liter/day, upper panel) and urine osmolality (mOsm/Kg, lower panel). In the two congenital cases of Moses, Scheinman and Oppenheim (1984), NDI responded to large doses of desmopressin. Though 25-50 times as resistant to desmopressin nasal spray as Radó’s patients with central diabetes insipidus (Radó, Marosi, Fischer et al. 1975), these patients could be treated effectively with large doses of the nasal spray. Our dosage protocol is in total agreement with the calculation of Moses, Scheinman and Oppenheim. We gave 250-300 /ug DDAVP nasal spray to our lithium induced NDI patient, which is about 25 times more than a normal 10 /ug dose.

Figure 3



We can see the dramatic antidiuretic effect of desmopressin administered alone and the potentiation of indomethacine in our case of lithium-induced permanent nephrogenic diabetes insipidus shown in Figure 4 (Radó 2018).

Figure 4



We administered high doses of desmopressin also in patients with congenital nephrogenic diabetes insipidus as well as in other type non lithium-induced acquired nephrogenic insipidus. So, we had ample clinical experiences using high doses of desmopressin in several individuals before treating lithium-induced permanent

nephrogenic diabetes insipidus. We have never had observed any significant side effect of administration of high doses vasopressin in the practically “healthy” patients and in the ones with congenital or acquired (but not lithium-induced) nephrogenic diabetes insipidus.

Further studies are necessary to evaluate the exact significance of the influence of desmopressin on the coagulation system as a risk factor in the treatment of lithium-induced severe concentrating defect.

We learned from Robert H. Belmaker’s comments, however, that we should not use desmopressin, a drug with a potential effect on blood coagulation, widely in lithium-treated patients with slight impairment of renal concentrating operation.

References:

Moses AM, Scheinman SJ, Oppenheim A. Marked hypotonic polyuria resulting from nephrogenic diabetes insipidus with partial sensitivity to vasopressin. *J Clin Endocrinol Meta.*1984; 59:1044–9.

Radó JP, Marosi J, Fischer J, Tako J, Kiss N. Relationship between the dose of 1-deamino-8-d-arginine vasopressin (desmopressin) and the antidiuretic response in man. *Endokrinologie* 1975; 66:184-95.

Radó JP, Marosi J, Fischer J. Comparison of the antidiuretic effects of single intravenous and intranasal doses of desmopressin in diabetes insipidus. *Pharmacology* 1977; 15:40-5.

Radó JP, Marosi J, Szende L, Borbely L, Tako J, Fischer J. The antidiuretic action of 1-deamino-8-D-arginine vasopressin (desmopressin) in man. *Int J Clin Pharmacol Biopharm* 1976; 13:199-209.

Radó JP, Zdravkova S. Lithium-induced chronic water-metabolism disorder (nephrogenic diabetes insipidus). *Orv Hetil.* 1991;132:1987-90.

Radó J. János Radó’s final comment on Barry Blackwell: The lithium controversy. A historical autopsy. Collated by Olaf Fjetland. inhn.org/collated. January 25, 2018.

January 9, 2020

János Radó: Mechanism of Lithium Induced Polyuria in Historical Perspective

Abstract

The present therapy for lithium-induced nephrogenic diabetes insipidus in man is to counter anti-vasopressin action of lithium by administration of thiazide diuretics, antiprostaglandin compounds (indomethacin) combined with large doses of desmopressin. (Amiloride supplements the “present therapy” drug group). The “future” treatment seems to be (on the basis of recent animal experiments) to enhance the sensitivity of the kidney to vasopressin action by administering pharmacologic blockade of renal P2Y₁₂ receptor. On theoretical basis it is conceivable that the present therapy of lithium-induced nephrogenic insipidus perhaps could be combined with the “future” pharmacologic blockade.

Introduction

In 1978 we found that in response to indomethacin administered to polyuric patient with familial Bartter syndrome, urine osmolality and free water reabsorption increased simultaneously with the decrease in the excretion of prostaglandin E₂ (PGE₂) (Radó, Simatupang, Boer and Mees 1978). In 2012 Zhang and his coworkers found that lithium-induced polyuria is due to resistance of the medullary collecting duct to the action of arginine vasopressin, apparently mediated by increased production of PGE₂ (Zhang, Pop, Carlson and Kishore 2012). Therefore, PGE₂ must be a key factor in the understanding and treatment of lithium polyuria. My early studies on indomethacin and desmopressin in Bartter polyuria, later studies on indomethacin and desmopressin in lithium-induced permanent nephrogenic diabetes insipidus and the results of the new studies of many investigators working in groups with Zhang and with Zhang and Peti-Peterdi (“Zhang and Peti-Peterdi group”) are discussed together.

The purpose of this paper is to review the newer literature concerning the relationship between lithium polyuria and chemical (PGE₂ and other), as well as genetic (P2Y₁₂ receptor) factors.

Early Studies

In 1978 we investigated the effect of indomethacin and desmopressin on water excretion in a 32-year-old patient with familial Bartter's syndrome in whom urinary concentration was impaired during ad libitum fluid intake without any decrease in maximal concentrating ability (Radó, Simatupang, Boer, Dorhout Mees 1978).

As shown in Figure 1 and Table 1, in response to indomethacin, urine osmolality and free water reabsorption increased simultaneously with the decrease in the excretion of prostaglandin E₂. The indomethacin-induced improvement was, however, less than that obtained after desmopressin with or without indomethacin.

Desmopressin (Minirin) was administered in doses of 40 micrograms three times a day intranasally. After a control period (17 days) the effects of daily 200mcg indomethacin were studied during the last 12 days of a month treatment period. One week after discontinuation of indomethacin treatment desmopressin was given again in the same dose as previously.

We compared the urine osmolality findings obtained in healthy subjects and in a polyuric patient with Bartter syndrome without treatment (“no drug”) and after administration of desmopressin (DDAVP) or indomethacine, as well as after combined administration of desmopressin and indomethacine during ad libitum fluid intake (Figure 1). Two determinations were done during administration of desmopressin after prolonged water




Figure 1. Urine osmolality (U_{osm}) was lower in the untreated patient than in the healthy subjects. After DDAVP this difference disappeared. Indomethacin induced a marked increase in U_{osm} in the patient.

restriction (quadrants).

As shown in Figure 1, in the patient with Bartter syndrome indomethacine potentiated the effect of desmopressin (DDAVP). During prolonged water restriction and desmopressin administration, urine osmolality was 924 mOsm/Kg, increasing to 1169 mOsm/Kg in response to indomethacine (quadrant).

Table 1 shows the effects of indomethacine, desmopressin (DDAVP) and indomethacine plus desmopressin on specific renal function. Results of statistical analysis

	Control	Indomethacin	Indomethacin + DDAVP	Off-treatment Control	DDAVP
n (days)	17	10	2	4	2
Urine osmolality (mOsm/Kg)	594 ^x ± 28	713 ^x ± 52	990 ^x ± 22	504 ± 55	927 ^x ± 28
Osmolal clearance (ml/min)	3.17 ± 0.16	2.94 ± 0.23	2.71 ± 0.45	2.91 ± 0.26	2.86 ± 0.22
Free water reabsorption (ml/min)	1.62 ± 0.14	1.70 ± 0.21	1.91 ± 0.25	1.16 ± 0.20	1.98 ± 0.17
Glomerular filtration rate (ml/min/1.73 M ²)	94.1 ± 3.5	92.6 ± 5.3	110.8 ± 12	96.2 ± 9.4	112.6 ± 8.5

x = p < 0.05. z = contracted: 958 ± 30 (p < 0.001 as compared to control; p < 0.005 as compared to indomethacin)
Osmolal clearance and free-water reabsorption is expressed in the percentage of glomerular filtration rate.

Table 1. Effect of Indomethacin and DDAVP on renal concentrating operation during ad libitum fluid intake.

Int. J. clin. Pharmacol. 16 (1978), 22–26 (No. 1)

23

are indicated.

Effect of indomethacine on prostaglandins

During indomethacin treatment, excretion of PGE₂ was decreased from 138.3 ng/24 hrs to 55 ng/24 hrs (normal range: 9-12 ng/24 hrs). PGA decreased from 205 ng/24 hrs to 97 ng/24 hrs (normal range: 71-144 ng/24 hrs), PGB decreased from 95 ng/24 hrs to 49 ng/24 hrs (normal range: 36-74 ng/24 hrs) and PGF decreased from 146 ng/24 hrs to 64 ng/24 hrs (normal range: 40-83 ng/24 hrs).

The blood level of PGE₁ also decreased from 38.9 pg/ml to 23.2 pg/ml (normal: 5.5 ± 0.8 pg/ml). PGA changed from 241 pg/ml to 269 pg/ml (normal: 94 ± 5 pg/ml), PGB from 129 pg/ml to 107 pg/ml (normal: 119 ± 14 pg/ml) and PGF from 22 pg/ml to 9.4 pg/ml (normal: 17.2 ± 3.3 pg/ml).

(We are greatly indebted to Prof. Dr. A. Horny, Hopital Broussais, Paris, who kindly performed the prostaglandin determinations).

Later Studies on Indomethacine and Desmopressin

In “use of modern antidiuretic agents in the treatment of permanent lithium-induced nephrogenic diabetes insipidus” (Radó 2018a) we found that administration of excessive doses of desmopressin resulted in clinically relevant antidiuresis, enhanced by indomethacine and abolished by calcitonin. A theory was proposed why the presumed

antidiuretic drug calcitonin exerted a “diuretic” action by abolishing the effect of desmopressin (Radó, Zdravkova 1991, 1993; Radó 2018b). These results and thoughts were discussed by Gordon Johnson (2018) and Hector Warnes (2019). Renal toxicity of lithium was reviewed in a balanced manner, considering both the renal insufficiency and end-stage renal disease, as well as the prominent tubular abnormality of nephrogenic diabetes insipidus (Radó 2019b). In this review the role of the large doses of desmopressin was analyzed in counteracting polyuria in congenital as well as in lithium-induced nephrogenic diabetes insipidus during combined administration of many different drugs (thiazide diuretics, indomethacine, piroxicam, calcitonin, etc.). Other drugs also having antidiuretic properties but without coadministration with desmopressin were also mentioned (metformin, statins, sildenafil, clopidrogel, prasugral etc.). Finally, antidiuretic drugs which could have been combined with desmopressin, but not promising in the treatment in lithium-induced nephrogenic insipidus, i.e., chlorpropamide, clofibrate and carbamazepine, were also included. From these compounds carbamazepine is an exception: its weak antidiuretic effect, combined with desmopressin, may be advantageous when it is otherwise indicated from psychiatric point of view (Radó 2019a)

New Investigations of the Zhang and Peti-Peterdi Group

Zhang and his coworkers found that lithium-induced polyuria is due to resistance of the medullary collecting duct to the action of arginine vasopressin (AVP), apparently mediated by increased production of PGE₂. Genetic deletion of the P2Y₂ receptor offered significant resistance to development of lithium polyuria. This change was accompanied by alterations in PGE₂ signaling mediated by a marked decrease in the prostanoid EP₃ receptor protein abundance thus attenuating the decrease in cAMP, modulator of arginine vasopressin, in the renal medulla (Zhang, Pop, Carlson and Kishore 2012; Zhang, Hansson, Liu, Kishore 2019).

P2Y₁₂ Receptor Localizes in the Renal Collecting Duct

P2Y₁₂ receptor signaling reduces cellular cAMP levels, the central modulator of arginine vasopressin. It was hypothesized that if expressed in the renal collecting duct P2Y₁₂ receptor may play a role in renal handling of water in health and in nephrogenic diabetes insipidus. P2Y₁₂ receptor mRNA expression in rat kidney, and immunolocalized its protein and aquaporin-2 in collecting duct principal cells was found (Zhang, Peti-Peterdi, Müller et al. 2015).

Short-Term Studies in the P2Y12 Receptor Knockout Mice

In the P2Y12 receptor knockout mice, enhanced vasopressin activity and increased renal sodium conservation was found. These animals were less sensitive not only to the diuresis enhancement induced by lithium, but also to the lithium-induced natriuresis and kaliuresis due to the attenuation of down regulation of the major sodium or potassium transporter/channel proteins in the collecting duct (Zhang, Li, Kohan et al. 2013).

Long-Term Studies in the P2Y12 Receptor Knockout Mice

Age matched wild type and P2Y12 receptor knockout mice were fed regular or lithium-added diet for five months. There was a steady increase in lithium-induced polyuria, natriuresis and kaliuresis in wild type mice, but increases in these parameters were very low in the knockout mice. Lithium-induced collecting duct proliferation was significantly lower in the knockout vs wild type mice. The results demonstrate that genetic deletion of P2Y12 receptor protects against the key structural and functional alterations in lithium-induced nephrogenic diabetes insipidus. Genetic deletion of P2Y12 receptor offers long-term (five months) protection against lithium-induced polyuria, natriuresis, kaliuresis and collecting duct remodeling and cell proliferation (Zhang, Riquier-Brison, Liu et al. 2018)

The most widely studied purinergic receptor in the kidney is ATP-activated P2Y12 receptor which is expressed in the collecting duct. Signaling mediated through P2Y12 receptor antagonizes the vasopressin action by enhancing the production of PGE2 (Kishore, Carlson, Ecelbarger et al. 2015).

The present therapy for lithium-induced nephrogenic diabetes insipidus in man is to counter anti-vasopressin action of lithium. The future treatment is to enhance the sensitivity of the kidney to vasopressin action (Kishore, Carlson, Ecelbarger et al. 2015).

Administration an Irreversible Inhibitor of the P2Y12 Receptor (clopidogrel)

Clopidogrel bisulfate significantly increased urine concentration and aquaporine protein in the kidneys of Sprague–Dawley rats but did not alter urine concentration in Brattleboro rats that lack arginine-vasopressin. Clopidogrel administration also significantly ameliorated lithium-induced polyuria, improved urine concentrating ability and aquaporine protein abundance and reversed the lithium-induced increase in freewater

excretion. Selective blockade of P2Y₁₂ receptor by the reversible antagonist PSB-0739 in primary cultures of rat inner medullary collecting duct principal cells potentiated the expression of aquaporin and cAMP production induced by desmopressin (Zhang, Peti-Peterdi, Müller et al. 2015).

Clopidrogel alone increased renal aquaporin 2, Na-K-2Cl cotransporter, Na-Cl cotransporter and the subunits of the epithelial Na channel (ENaC) in renal medulla. When combined with lithium, clopidrogel prevented downregulation of aquaporin, Na-K-ATPase and Na-K-2Cl cotransporter but was less effective against downregulation of cortical sodium channel (α - or γ -ENaC). Thus, clopidrogel primarily attenuated lithium-induced downregulation of proteins involved in AVP-sensitive water conservation (Zhang, Peti-Peterdi, Heiney et al. 2015)

Clopidrogel is an antiplatelet drug of the thienopyridine group extensively used in cardiological clinical medicine. Another such drug is prasugral and both are ADP antagonists acting on the P2Y₁₂ receptor. Administration of prasugral completely suppressed lithium-induced polyuria and polydipsia in rats (Zhang, Peti-Peterdi, Brandes et al. 2017)

Pharmacologic Blockade of Renal P2Y₁₂ Receptor

Pharmacologic blockade of renal P2Y₁₂ receptor in rodents increases urinary concentrating ability by augmenting the effect of vasopressin on the kidney and ameliorates lithium-induced nephrogenic diabetes insipidus by potentiating the action of vasopressin on the renal collecting duct (Zhang Peti-Peterdi, Müller et al. 2015). This strategy may offer a novel and effective therapy for lithium-induced nephrogenic diabetes insipidus in man.

Conclusion

Pharmacologic blockade of renal P2Y₁₂ receptor may be combined - at least theoretically - with anti-prostaglandin agents (non-steroidal anti-inflammatory compounds) and supplemented with large doses of desmopressin in the treatment of lithium-induced nephrogenic diabetes insipidus. Lithium-induced excessive prostaglandinuria (increased excretion of PGE₂) can be prevented by pharmacologic blockade of the renal P2Y₁₂ receptor and antagonized by the administration of indomethacine.

We are all definitely convinced by the enormous work of Ban (2017), Blackwell (2014), Rybakowski (2017), Severus, Taylor, Sauer et al. (2014) and others that millions suffering from bipolar disorder need lithium treatment and making it safer by eliminating (at least partly) its most frequent side effect lithium polyuria, is a decent goal for both the investigators and physicians.

References:

- Ban TA. Neuropsychopharmacology in Historical Perspective. Education in the Field in the Post-Neuropsychopharmacology Era. Prologue. inhn.org/education. September 18, 2017.
- Blackwell B. Lithium Controversy. A historical autopsy. inhn.org/controversies. June 19, 2014.
- Johnson G. Comment on János Radó's (January 25, 2018) final comment (Barry Blackwell: The Lithium Controversy. A Historical Autopsy). inhn.org/collated. July 5, 2018.
- Kishore BK, Carlson NG, Ecelbarger CM, Kohan DE, Müller CE, Nelson RD, Peti-Peterdi J, Zhang Y. Targeting Renal Purinergic Signalling for the Treatment of Lithium-induced Nephrogenic Diabetes Insipidus. *Acta Physiol (Oxf)*. 2015 Jun;214(2):176-88.
- Radó JP, Simatupang T, Boer P, Dorhout Mees EJ. Pharmacologic studies in Bartter's syndrome: effect of DDAVP and indomethacin on renal concentrating operation. Part II. *Int J Clin Pharmacol Biopharm*. 1978 Jan;16(1):22-6.
- Radó JP, Zdravkova S. Lithium-induced chronic water-metabolism disorder (nephrogenic diabetes insipidus)]. *Orv Hetil*. 1991;132, 1987-90.
- Radó JP, Zdravkova S. Effect of Indomethacine and Calcitonin During Administration of 1-Deamino-8-D-Arginin-Vasopressin (desmopressin) on Free Water Clearance in Nephrogenic Diabetes Insipidus (NDI). XIIth International Congress of Nephrology. June 13–18, 1993 Jerusalem, Israel.
- Radó J. Final comment (Use of modern antidiuretic agents in the treatment of permanent lithium-induced nephrogenic diabetes insipidus [Barry Blackwell: The lithium controversy. A historical autopsy]). inhn.org/collated. January 25, 2018a.
- Radó J. Addition to final comment: Calcitonin in lithium-induced nephrogenic diabetes insipidus (Barry Blackwell: The lithium controversy. A historical autopsy) inhn.org/collated. September 13, 2018b.
- Radó J. Desmopressin may counteract polyuria in lithium-induced nephrogenic diabetes insipidus (Review of the literature) inhn.org/controversies. June 27, 2019a.
- Radó J. Renal Toxicity of Lithium in Historical Perspective with Special Reference To Nephrogenic Diabetes Insipidus and its Treatment. inhn.org/controversies. May 2, 2019b.
- Rybakowski J. Final comment: Half a Century of Inspiring Lithium Controversy (Barry Blackwell: The Lithium controversy: A historical autopsy. Collated by Olaf Fjetland). inhn.org/collated. September 30, 2017.

Severus E, Taylor MJ, Sauer C, Pfennig A, Ritter P, Bauer M, Geddes JR. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. *Int J Bipolar Disord.* 2014 Dec 20;2:15.

Warnes H. Comment on János Radó's additional final comment: Calcitonin in lithium-induced nephrogenic diabetes insipidus (Barry Blackwell: The lithium controversy. A historical autopsy) *inhn.org.collated.* January 17, 2019.

Zhang Y, Pop I, Carlson NG, Kishore BK. Genetic deletion of the P2Y₁₂ receptor offers significant resistance to development of lithium-induced polyuria accompanied by alterations in PGE₂ signaling. *Am J Physiol Renal Physiol* 2012; 302: F70–F77.

Zhang Y, Li L, Kohan DE, Ecelbarger CM, Kishore BK. Attenuation of lithium-induced natriuresis and kaliuresis in P2Y₁₂ receptor knockout mice. *Am J Physiol Renal Physiol.* 2013;305(3):F407-16.

Zhang Y, Peti-Peterdi J, Müller CE, Carlson NG, Baqi Y, Strasburg DL, Heiney KM, Villanueva K, Kohan DE, Kishore BK. P2Y₁₂ Receptor Localizes in the Renal Collecting Duct and Its Blockade Augments Arginine Vasopressin Action and Alleviates Nephrogenic Diabetes Insipidus. *J Am Soc Nephrol.* 2015; 26(12):2978-87.

Zhang Y, Peti-Peterdi J, Heiney KM, Riquier-Brison A, Carlson NG, Müller CE, Ecelbarger CM, Kishore BK. Clopidrogel attenuates lithium-induced alterations in renal water and sodium channels/transporters in mice. *Purinergic Signal.* 2015;11(4):507-18.

Zhang Y, Peti-Peterdi J, Brandes A, Riquier-Brison A, Carlson NG, Müller CE, Ecelbarger CM, Kishore BK. Prasugral suppresses development of lithium-induced nephrogenic diabetes insipidus in mice. *Purinergic Signal.* 2017;13(2):239-248.

Zhang Y, Riquier-Brison A, Liu T, Huang Y, Carlson, NG, Peti-Peterdi J, Kishore BK. Genetic Deletion of P2Y₁₂ Receptor Offers Long-Term (5 Months) Protection Against Lithium-Induced Polyuria, Natriuresis, Kaliuresis, and Collecting Duct Remodeling and Cell Proliferation. *Front Physiol.* 2018; 9:1765.

Zhang Y, Hansson K M, Liu T, Kishore B. Genetic Deletion of ADP-activated P2Y₁₂ Receptor Ameliorates Lithium-induced Nephrogenic Diabetes Insipidus in Mice. *Acta Physiol (Oxf).* 2019;225(2):e13191.

July 4, 2019

Samuel Gershon's comments

Dr. Radó's report is a detailed outline of his studies on the lithium-induced side effect which had been a serious concern in these cases but also developed it. A number of treatments have been proposed over the years and some have had some beneficial effects (Coats, Trautner and Gershon 1957).

Lithium is a specific for manic-depressive disorder. Initially, it produces a clear effect on water and electrolyte balance, manifest by an increase in urine volume and thirst.

These effects are also seen by its special effect in the manic phase of this disorder. It has been shown that on initial administration there is a retention of lithium in the body, until the mania abates, increased excretion occurs and then homeostasis is restored (Trautner, Morris, Noack and Gershon 1955). In overdose lithium can cause toxicity (Coats, Trautner and Gershon 1957).

One of the rarer effects is the manifestation of a diabetes insipidus-like syndrome. Dr. Radó's paper presents his studies on this particular side effect. It is a very good and thorough presentation, not only of the history of this issue, but a presentation of what now should be the best treatment method available.

References:

Coats DA, Trautner EM, Gershon S. Treatment of Lithium poisoning. Aust. Ann. Med. 1957;1:11-15.

Trautner EM, Morris R, Noack CH, Gershon S. The excretion and retention of ingested lithium and its effect on the ionic balance of man. Med. J. Aust. 1955;2:280-91.

November 14, 2019

János Radó's reply to Samuel Gershon's comment

Thank you, Samuel Gershon, for your comments. In my opinion, you are one of the greatest experts on lithium. Your classic studies on the fate of lithium in the human body and its relationship with the different phases of manic-depressive disorder is worth remembering and learning.

I am delighted by the honor presented to me by your reading and evaluating my work on lithium nephrotoxicity and available treatment methods.

January 23, 2020

Edward Shorter: The Q-T interval and the Mellaril story: a cautionary tale

Is a lengthening of the Q-T interval in the ECG benign or pathological in drug action? This produced a small controversy in the 1960s that had a major impact on patient care. In 2000, the Novartis Company cautioned physicians about further use of the

antipsychotic drug Mellaril (thioridazine). The company announced that the drug can entail dangerous cardiac complications. This information was already known in the mid-1960s, and not only did Sandoz (one of the predecessor companies of Novartis) ignore it, they attempted to discount it at scientific meetings and disregarded the warnings of several clinical scientists. Moreover, in various ad campaigns Sandoz showed elderly “patients” in the artwork, emphasizing that the drug was suitable for geriatric cases, precisely the population most at risk of such complications. The story is a textbook case of ignoring scientific warnings in favor of corporate interests.

It was known early on that Sandoz’s new antipsychotic agent thioridazine (Mellaril), launched in the United States in 1959, lengthened the Q–T interval. But was this good or bad?

There was the benign repolarization school. In 1964, M.H. Wendkos, a cardiologist at the Veterans Administration Hospital in Coatsville, Pennsylvania, published a paper on pharmacologic studies in a hitherto unreported “benign repolarization disturbance among schizophrenics” (Wendkos 1964). Wendkos re-stated this position in his presentation at a psychopharmacology meeting in Quebec (see below), arguing that the recorded ECG changes “represent a benign repolarization disturbance rather than an adverse cardiac effect” (Wendkos 1965).

But events were in the saddle and galloped in a very different direction. Some background: It happens quite frequently that drugs are withdrawn or new warnings of their side-effects are circulated. Yet the story of Sandoz’s antipsychotic medication Mellaril (thioridazine) represents an almost textbook case of a company marching into trouble by ignoring warnings.

On July 31, 2000, Novartis Pharmaceuticals sent a letter to all physicians and pharmacists in Canada, warning that the use of the drug Mellaril should be significantly curtailed. The preparation should henceforth be restricted only to those schizophrenic patients “who fail to show an acceptable response . . . to other antipsychotic drugs.” The reason? “Mellaril has been shown to prolong the QTc interval in a dose related manner, and drugs with this potential, including Mellaril, have been associated with torsade de pointes-type arrhythmias and sudden death” (Novartis Pharmaceuticals Canada 2000).

Simultaneously, the August 18 issue of the *Psychiatric News* cautioned its readers that thioridazine “will include a new boxed warning regarding potentially fatal

cardiovascular effects and will be restricted to second-line use.” The reason again was that “TdP (torsades de pointes) develops spontaneously, usually without warning, and requires immediate emergency intervention.” The note stated that the risk of sudden death was “high” (Psychiatric News 2000).

These warnings came more than thirty years too late. Here is how the controversy unfolded:

In 1963, H.G. Kelly and coworkers in the Faculty of Medicine of Queen’s University in Kingston, Ontario, reported 28 electrocardiograms that depicted a quinidine-like effect of thioridazine on ventricular repolarization (prolongation of the QT interval) in doses as low as 200 mg. a day. T-waves were flattened out and sometimes inverted, occasionally S–T segments became convex and new waves appeared. In that study, two fatal cases of arrhythmia occurred (Kelly, Fay and Laverty 1963).

By this time the Sandoz company, of course, knew of the Queen’s University deaths, and their medical advisor, Roy Stewart, a Montreal cardiologist, brought this to the attention of Thomas Ban, chief of the clinical research service at Verdun Protestant Hospital, a psychiatric inpatient facility in the outskirts of Montreal. It was at Stewart’s request that Ban designed a clinical study, conducted in collaboration with André St. Jean, Scientific Director at Hôpital des Laurentides in L’Annonciation, Quebec, comparing the effects of thioridazine, chlorpromazine, and trifluoperazine on the ECG. In 1964 the investigators reported that thioridazine “modifies the terminal portion (S–T segment, T and U waves) of the human ECG.” They found that, whereas similar changes took place in only 1 of the 6 subjects taking trifluoperazine, and in 3 of 6 taking chlorpromazine, such changes were noted in all 6 of the 6 patients on thioridazine by the 8th day of drug administration, i.e., with 200 to 400 mg of thioridazine per day (Ban and St. Jean 1964).

The study had been completed in 1963, but before it was published, the following incident occurred at Hôpital des Laurentides: A patient who had been receiving high (1500 mg per day) doses of thioridazine over a period of ten weeks, suddenly became unconscious and passed into a state of shock. It happened that there were two physicians in the room, one of them a cardiologist. An ECG demonstrated ventricular tachycardia. It was noted that a prior ECG of the patient, six weeks after the initiation of thioridazine therapy, had shown bradycardia and prolongation of the QT (Desautels, Filteau and St. Jean 1964).

These findings led Ban and co-workers to conduct a survey to determine the incidence of cardiac conductance changes with thioridazine. It was clear that such complications existed, but what was the size of the problem? Ban presented the results later in 1964 at the fourth congress of the Collegium Internationale Neuro-Psychopharmacologicum (CINP) in Birmingham, England. Of the 92 patients receiving drugs other than thioridazine, 12, or 13 percent, displayed an abnormal ECG. Seventeen, or 77.3 percent of all patients receiving thioridazine, manifested abnormal ECG's (Ban, St. Jean and Desautels 1965).

In 1964 or 1965 Ban travelled to Basel to report these findings to Sandoz and met with the president and head of pharmacology of the firm (Ban TA, personal communication to E Shorter, 11 Mar 2013).

On June 4, 1965, the Quebec Psychopharmacological Research Association organized a special symposium at the Hôpital des Laurentides on ECG changes with psychoactive drugs. Ban and coworkers reviewed the aforementioned studies as well as some findings based on a further series of four studies which indicated that “the lowest dose (of thioridazine) which brought about changes was 150 mg per day” (St Jean, Desautels S, Ballon and Ban 1965). At the same meeting Edward Kingstone, in his review of the literature on “neuroleptic drugs and the ECG,” pointed out that in 1964 Graupner and Murphree also described ECG changes associated with the use of thioridazine (Kingstone 1965). Of the 55 patients they studied, 44% developed abnormal electrocardiograms. Most of the changes were concerned with the T-wave. They appeared at all dose levels from 150 to 900 mg per day (Graupner and Murphree 1964).

In organizing the symposium, Ban wanted to ensure that a fair picture of Mellaril was offered. He had mentioned the meeting to Sandoz, and the company paid the travel cost for Wendkos to attend (Ban 2011).

Here is where events took over. Other investigators began learning of the cardiac dangers of thioridazine. In the mid-1960s, Louis Gottschalk, then at the Cincinnati General Hospital, warned Sandoz privately that Mellaril was dangerously increasing the QT interval. Gottschalk later said in an interview, “We got the idea to find out whether there are any differences in the psychoactive drug metabolites in people that get these cardiac irregularities. And lo and behold, we did discover that a metabolite that is not psychoactive, sulforidazine, does have an adverse cardiovascular effect . . . and [we] tried

to get the drug companies to provide further financial support so we could study the biochemical basis. . . . But they were doing so well marketing their drugs, that they would not fund it” (Gottschalk 2011a). Gottschalk, who in the meantime had moved to the Irvine campus of the University of California, reported with co-workers the existence of this previously unknown metabolite of mesoridazine and thioridazine in 1974 (Dinovo, Gottschalk, Noble and Biener 1974); details of a GLC analysis followed in 1976 (Dinovo, Gottschalk, Nandi and Geddes 1976).

Did Sandoz then become interested? Not really. Gottschalk later said, “Everybody told me that the metabolite was not pharmacologically active. I asked the head of the organic chemistry department at UCI whether she could manufacture it for me because I wanted to test the effects of the metabolite on cardiovascular function in dog experiments. She could do it for a certain amount of money, but I never was able to obtain the necessary funds. In general, pharmaceutical companies are not very interested in trying to discover what triggers the adverse side effects of drugs” (Gottschalk 2011b).

Gottschalk was not the only researcher to be brushed off by Sandoz. In 1974 Donald Gallant and co-workers at Tulane University reported a double-blind ECG comparison of thioridazine and thiothixene (Dillenkoffer, George, Bishop and Gallant 1974). “Only one of the 13 thiothixene patients had prolongation of the Q–T,” said Gallant later in an interview, “but 13 out of 13 patients on 800 milligrams a day of thioridazine, and 7 of 13 on 400 milligrams a day had prolongation of the Q–T interval. We published that. In fact, my cardiology fellow that read the EKGs could identify thioridazine, blind... After we published, somebody from Sandoz called and started yelling on the phone at me, criticizing me, saying I was unethical for publishing the data. This was 1972 [1974], and I was shocked that someone from a pharmaceutical firm would start telling me I’m unethical for publishing these findings... It was solid, solid data and Sandoz Company never made any mention about it” (Gallant 2011).

These early warnings did not prevent Sandoz from further marketing the preparation. Indeed, to go by the visual content of the company’s advertisements for Mellaril, the drug was pitched to physicians as especially suitable for geriatric use, a population at risk of cardiac complications. And in 1978 George Simpson and co-workers at Rockland State Hospital found that it was precisely in the elderly that thioridazine prolonged QT intervals (Branchey, Lee, Amin and Simpson 1978). “I stopped using thioridazine at that time,” Simpson later said in an interview (Simpson 2011).

An analysis of images depicted in Mellaril advertisements in *Diseases of the Nervous System* (after 1989 the *Journal of Clinical Psychiatry*) showed that Sandoz launched four major ad campaigns featuring elderly “patients.” For example, in three ads which appeared between May and July 1983, a clearly elderly woman was shown and the text stated that Mellaril “helps keep the disturbed geriatric at home” (*Dis Nerv Syst* 1983). An ad featuring an older male golfer (“effective control of psychotic symptoms”) ran 14 times (*Dis Nerv Syst* 1979–80). Ban in his *Psychopharmacology for the Aged*, published in 1980, noted that “thioridazine has become one of the most extensively employed psychotropic drugs in the aged” (Ban 1980).

While the Ban studies showed that cardiac conductance changes appeared at daily dosages above 150 mg., the above-mentioned ads indicated that dosages below 300 mg were relatively safe. (“Daily doses in excess of 300 mg should be used only in severe neuro- psychiatric conditions.”) (*Dis Nerv Syst* 1979–80).

For Sandoz – and its successor organization Novartis – it was irresponsible not to say reckless to have ignored such warnings for more than thirty years, putting the lives of many patients at risk. The entire story of shortsightedly placing corporate interests ahead of science could be found in an MBA curriculum on how not to market a pharmaceutical preparation.

References:

- Ban TA. *Psychopharmacology for the Aged*. Basel: Karger; 1980. p 66–7.
- Ban TA interviewed by Bunney WE, Jr, in *An Oral History of Neuropsychopharmacology – The First Fifty Years: Peer Interviews* (Thomas A Ban, editor), Volume 9 – “Update” (Barry Blackwell, volume editor). Nashville: American College of Neuropsychopharmacology; 2011. p. 19–35, 26–27.
- Ban TA, St. Jean A, Desautels S. The effects of phenothiazines on the human electrocardiogram, in *Neuropsychopharmacology* (D Bente, PB Bradley, editors), Volume 4. Amsterdam: Elsevier; 1965, p.467–70.
- Ban TA, St. Jean A. The effect of phenothiazines on the electrocardiogram. *J Can Med Assoc* 1964; 91:537–40.
- Branchey MH, Lee JH, Amin R, Simpson GM. High- and low-potency neuroleptics in elderly psychiatric patients. *J Am Med Assoc* 1978; 239: 1860–2.
- Desautels S, Filteau C, St. Jean A. Ventricular tachycardia associated with administration of thioridazine hydrochloride (Mellaril). *J Can Med Assoc* 1964; 90: 1030–1.

Dillenkoffer RL, George RB, Bishop MP, Gallant DM. Electrocardiographic evaluation of thiothixene: a double-blind comparison with thioridazine. *Adv Biochem Psychopharmacol* 1974; 9: 487–95.

Dinovo EC, Gottschalk LA, Noble EP, Biener R. Isolation of a possible new metabolite of thioridazine and mesoridazine from human plasma. *Res Commun Chem Pathol Pharmacol* 1974; 7: 489–96.

Dinovo EC, Gottschalk LA, Nandi BR, Geddes PG. GLC analysis of thioridazine, mesoridazine, and their metabolites. *J Pharma Sci* 1976; 65: 667–9.

Dis Nerv Syst 1979;40 (8) through 1980; 41 (11), Mellaril advertisement (14 instances).

Dis Nerv Syst 1983; 44 (5–7), Mellaril advertisement (3 instances).

Gallant DM interviewed by Ban TA, in *An Oral History of Neuropsychopharmacology – The First Fifty Years: Peer Interviews* (Thomas A. Ban, editor), Volume 4 – “Psychopharmacology” (Jerome Levine, volume editor). Nashville: American College of Neuropsychopharmacology; 2011. p. 75–124, 88.

Gottschalk LA interviewed by Bunney WE. Jr, in *An Oral History of Neuropsychopharmacology – The First Fifty Years: Peer Interviews* (Thomas A. Ban, editor), Volume 1 – “Starting Up” (Edward Shorter, volume editor). Nashville: American College of Neuropsychopharmacology; 2011. p. 265–75, 270.

Gottschalk LA interviewed by Ban TA, in *An Oral History of Neuropsychopharmacology – The First Fifty Years: Peer Interviews* (Thomas A. Ban, editor), Volume 9 – “Update” (Barry Blackwell, volume editor). Nashville: American College of Neuropsychopharmacology; 2011. p. 105–34, 119–20.

Graupner KL, Murphree OD. Electrocardiographic changes associated with the use of thioridazine. *J Can Med Assoc* 1964; 91: 537–40.

Kelly HG, Fay JE, Laverty SG. Thioridazine hydrochloride (Mellaril): its effect on the electrocardiogram and a report of two fatalities with electrocardiographic abnormalities. *J Can Med Assoc* 1963; 89:546–54.

Kingstone E. Review of the literature – neuroleptic drugs and the ECG, in *Toxicity and Adverse Reaction Studies with Neuroleptics and Antidepressants* (HE Lehmann, TA Ban, editors). Montreal: Quebec Psychopharmacological Research Association; 1965, p. 121–8.

Novartis Pharmaceuticals Canada. Important Drug Warning, Sumegi B, Rousseau G to all physicians and pharmacists, July 31, 2000 (“Dear Doctor or Pharmacist”).

Psychiatric News, August 18, 2000, p. 28 (“FDA Approves New Warnings for Thioridazine, Valproate”).

Simpson GM interviewed by Ban TA, in *An Oral History of Neuropsychopharmacology – The First Fifty Years: Peer Interviews* (Thomas A. Ban, editor), Volume 9 – “Update” (Barry Blackwell, volume editor). Nashville: American College of Neuropsychopharmacology; 285–312, 298.

St. Jean A, Desautels S, Ballon J, Ban TA. Studies with thioridazine, in *Toxicity and Adverse Reaction Studies with Neuroleptics and Antidepressants* (HE Lehmann, TA Ban, editors). Montreal: Quebec Psychopharmacological Research Association; 1965 137–42.

Wendkos MH. Experiments with thioridazine, in Toxicity and Adverse Reaction Studies with Neuroleptics and Antidepressants (HE Lehmann, TA Ban, editors). Montreal: Quebec Psychopharmacological Research Association; 1965, p. 143–55.

Wendkos MH. The significance of electrocardiographic changes produced by thioridazine. *J New Drugs* 1964; 4:322–32.

July 18, 2013

János Radó's Comment

I read with interest the Mellaril (thioridazine) Story. It is shocking (even now) how the pharmaceutical industry disregarded the thioridazine induced abnormal ECG changes. The dose-related lengthening of the Q-T interval occurring in a very high percentage of the thioridazine-treated patients "in a drug treated population which will be in the multiple tens of million patient" (Beasley 2015).

The insensitiveness of Sandoz in the thioridazine case resembles to me another phenomenon which had occurred in the case of another Swiss firm, CIBA.

In 1973, we reported in the *British Medical Journal* the first well-documented case of water intoxication induced by another psychotropic drug carbamazepine (Tegretol). After this first report of water-intoxication, a series of such carbamazepine-induced complication was published in the *British Medical Journal* and in other journals (Radó 1973). Large patient populations were studied and the hyponatremia associated with the use of carbamazepine was well documented. I, personally, published 19 articles on the use of carbamazepine (alone or in combination with chlorpropamide) in diabetes insipidus. In these articles, we described the changes observed in serum sodium levels. Despite this evidence, hyponatremia and water intoxication was not listed among the side effects in the advertisements of carbamazepine (Tegretol) for several years. CIBA was as insensitive in the case of hyponatremia and water intoxication induced by carbamazepine as was Sandoz in the case of thioridazine-induced ECG alterations.

References:

Beasley Ch. Comment on Edward Shorter's Q-T interval and the Mellaril story. inhn.org/controversies. August 27, 2015.

Radó JP. Water-intoxication during carbamazepine treatment. *British Medical Journal* 1973; 3 (5878):4.

September 24, 2015

**Milestones and the lifetime achievements of a scientist and clinician –
Happy Birthday Professor János Radó!**

By Ágnes Haris



One of the prominent events of 2020 is our celebration of Professor János Radó's 90th birthday and the 66th anniversary of his medical practice. János Radó's outstandingly successful career's specialty is that in his professional work patient care has been closely associated with his experimental interest, mutually facilitating each other. This polyhistor-type approach is exemplary for the young generation working in medicine.

After completing medical university (1948-1954), Professor Radó commenced clinical practice in the János Hospital in Budapest as a junior internal medicine resident. Thanks to his diligence, widespread interests and outstanding intellectual quality, his professional career rose very quickly; he was quickly assigned as a senior resident and still at a young age became an assistant professor. Although he devoted his work to patient care since beginning, he was also engaged in clinical science as early as his medical university years. As he stated later in one of his publications* – he became “attracted by science.”

His first scientific experiences originated from daily clinical practice. Soon after receiving his diploma he published some of his observations about the clinical manifestations of infectious mononucleosis in 1954 and Waterhouse-Friedrichsen syndrome in 1955. His career has been substantially influenced by his excellent teachers, including István Rusznyák, Pál Gömöri, Imre Magyar, Gyula Petrányi, Imre Haynal, Imre Shill and Imre Fodor. Together with Professor Fodor he published a number of articles in 1956 about the effect of mercurial diuretics and the treatment of refractory edema. By 1958, which was the year of his first medical specialty exam, he had already written several articles in prestigious English and German language journals. At that time his interest was attracted by the mechanisms of edema generation and the effects of diuretic drugs. In addition, he documented numerous significant observations about characteristics of internal medicine diseases not or hardly known at that time, such as the course of polycythemia or dissemination of herpes zoster infection in patients under corticosteroid treatment.

Since the 1960s his investigations were oriented toward fluid and electrolyte homeostasis and the influence diuretic drugs had on it. He made one of his most important discoveries at that time, a new isotope diagnostic tool, the “furosemide renography,” the methodology of which he first published in the *Lancet* in 1967.

His never ending curiosity and search for relationships between causes and consequences led him to discover several adverse drug effects. He was the first who described how carbamazepine caused water intoxication, published in 1973 in the *British Medical Journal*; hallucinosis provoked by Halidor; and paradoxically increased diuresis by glibenclamide. The discovery of hyponatremia as an adverse event of clofibrate administration and the hyperkalemic paralysis caused by spironolactone have also been attributed to him.

Since the 1970s his studies have been primarily focused on the clinical manifestations of nephrogenic and central diabetes insipidus; the diuretic effects of desmopressin and other drugs with diuretic effects; and the clinical characteristics and treatment options of renal tubular acidosis.

Between 1976 and 1978 he worked for Utrecht University as an invited researcher. His task was to introduce in Netherlands the renal clearance studies, glomerular filtration and plasma flow measurements he had previously worked out in Hungary. He also studied the disorders of potassium homeostasis; described the “upright-” or “outpatient-hyperkalemia”; and published about the consequences of aldosterone secretion abnormalities, the effect of osmolality on potassium homeostasis and the glucose induced paradox hyperkalemia.

In 1980 he completed his master’s thesis about diuretic and antidiuretic drugs. In 1995 he finished his dissertation on the form of a habilitation process with the topic of renal and nephrogenic tubular acidosis, and, in 1999, he was awarded the title of Doctor of the Hungarian Academy of Sciences, with his thesis describing interactions between disease and drugs regarding potassium metabolism.

Professor Radó was the head of the 3rd Department of Internal Medicine in Uzsoki Hospital, Budapest between 1980 and 1996. These years were characterized by his activities in establishing a school for his younger colleagues. Among his coworkers from that time - with his stimulation and help - many of us also became “attracted by science.” During the 1990s each physician working in his department wrote papers, either presenting interesting cases or researching, reviewing topics of fluid and electrolyte disorders. But we learned more than just “doing research.” Professor Radó taught us the right approach to highlight the relationships and interactions of diseases that covered the wide profiles of medications including their effects and adverse effects, which all have to

be considered during the practice of a medical profession. Daily medical rounds provided lifetime professional experiences and also reinforced the idea that an excellent physician can only be a person who is cultivated and has a wide range of vision and humanity. Our workdays were characterized as passing in a friendly atmosphere flavored by humor, in which he ensured not only professional progress but personal development for each of us. For all who were interested in research he taught the technic of systematic data collection and the precise, high quality work necessary for scientific investigations and, not least, he highlighted the beauty of providing presentations and publications.

Radó's professional career in the 2000s was engaged in writing books and book chapters. Moreover, he edited the Hungarian periodical, *Hypertension and Nephrology*, with great success and, as fruits of his pensioner-years, he established and presently augments the rich material of the Nephrological Historical Committee of the Hungarian Society of Nephrology.

His prominent activity as a researcher is highlighted by his outstanding publications. Between 1954 and 2019 he published almost 400 articles and he is continuously writing articles today. The number of his citations exceeds 1,000 which indicate that his scientific results provide basis for several other scientists' research. Importantly however, Professor Radó has always prioritized his love for and commitment to his patients. This is nicely shown (in his own opinion) as he considered one of his most important achievements the establishment of the Dialysis Unit in Budapest's Uzsoki Hospital, which provided the opportunity for saving uremic patients' lives. He did not abandon caring for them even after finishing his assignment as head of department; he continued clinical activity as a consultant physician for patients suffering nephrological or endocrinological diseases.

Several medical societies have acknowledged Prof. Radó by awarding him precious prizes: the Semmelweis Award in 1972; the Markusovszky Award in 1989; the Batthyány Strattmann László Award in 1996; and the Korányi Sándor Award in 2004. In 2005 he was honored with the Lifetime Achievement Award for the Hungarian Nephrology by the University of Debrecen and in the same year with the Gömöri Pál Award. In 2007 he received the Lifetime Award of the Hungarian Foundation of Nephrology and in 2012 he was given the Eszter Török Medallion. Among the highlights of his success, in 2012 he was elected as a "Pioneer of the European Archives of Nephrology."

Reviewing his professional activity it is unquestionable that clinical research represents extraordinary importance for him, yet, according to the 2012 interview he gave for the Archives he felt that emphatic patient-physician relationship and winning patients' confidence have outstanding significance. He pointed out the importance of treating the patient as an individual, even in the era of evidence-based medicine, and that in our everyday clinical work it is critically important to afford sufficient time and energy for the patients.

A summary of Professor Radó's achievements would not be complete without mentioning his wife, Maria Löffler, who has provided him a stable, loving background and continuous support. We congratulate her as well for these achievements and wish her good health!

This short summary has been prepared as an appreciation for our teacher and ideal, wishing by this article a very happy birthday for him!

* A complete list of János Radó publications can be found at inhn.org/profiles.

December 10, 2020

János Radó: 90th Year Birthday

I compiled my festive presentation in early February 2020 when there was no immediate domestic epidemic threat. Now I am trying to convert it to an article in an edited form. I originally planned a reflection on the “beauties of old age” wrapped in personal success and professionalism, but my acquaintanceship vehemently protested against it, saying who cares about the “beauty” of old age. In addition, the olden *bon mot* of the famous compere Dezső Kellér came to my mind on the beauties of old age: "tell me just one." What actually originally motivated me was the lecture by Canadian psychiatrist Professor Lehmann (2020), “What is wrong with getting old?” Thus, although I abandoned my original plan, it affected me in that I do not present my entire oeuvre in a linear way (since I had already done so at the Festive Scientific Meeting held in honor of my 80th birthday at Uzsoki Hospital), but after a few highlights I will deal with my scientific work done at my old age, namely over the last five years (even more two years), which were partly published on the website of the American International Network for the History of Neuropsychopharmacology (INHN) (Ban 2017) and on the website of the Hungarian Commission for the History of Nephrology.


I was born on May 25, 1930 but the Festive Scientific Meeting scheduled for my 90th birthday was announced for June 3 by the Uzsoki Hospital and the Hungarian Nephrological Society. My wife paid for a Mediterranean round trip as a birthday present, so the Festive Scientific Meeting had to be postponed. Covid 19 left it all behind. (If this Festive Session will ever be reorganized lies in the future)

Some summary statistics for my oeuvre (Radó 2018) are shown in Table 1.

Table 1				
No. of Papers	Per Year	Where	When	Total
127	4.8	János Hospital	1954-1980	
99	6.0	Uzsoki Hospital	1980-1996	
180	7.8	after retirement	1997-2020	
				406

The time distribution of the publications can be seen in Figure 1 on the website of the Hungarian Academy of Sciences.

The figure shows the situation before the date of this publication. Today's situation: 407 instead of 405; all citations, 1938 instead of 1910; 10 papers instead of four in 2020.



To present my oeuvre (Radó 2018), I selected six items from the 78 significant new results I have published so far; these are included in Table 2. Of these, I would like to discuss only the last two items listed in more detail (i.e., Herpes Zoster Virus Epidemic Study and Desmopressin Pharmacology).

Table 2		
Paper	Import	Reference
Diuretic Renography	World's first description	Radó, Banos and Tako 1967
Hyperkalemic Paralysis Due to Spironolactone	first case	Herman and Radó 1966
Water Intoxication Caused by Carbamazepine	first case	Radó 1973
Increase in Diuresis Due to Glibenclamide in Diabetes Insipidus	first description	Radó and Borbely 1971
Herpes Zoster Virus Epidemic Study	U.S. NASA publication	Radó, Tako, Geder and Jeney 1965; Mehta, Cohrs, Forghani et al. 2003
Desmopressin Pharmacology	U.S. Navy publication	Radó JP, Marosi J, Fischer et al. 1975; Doubt and Thorp 1992

Herpes zoster virus epidemic study

Pediatrician von Bókay was the first to find that varicella in children and herpes zoster, which mostly occurs in the elderly, are essentially the same disease (VZ). The VZ virus lurks in the human nervous system (ganglia) after the disease (mostly varicella) has taken place. However, it can reactivate in a variety of conditions when cell-mediated immunity declines, causing mostly herpes zoster, in elderly individuals, cancer patients, in those with autoimmune diseases and AIDS (Radó, Marosi, Fischer et al. 1975). We noticed in the early 1960s that a “home” epidemic of herpes zoster had developed in our hospital ward, but only patients *treated with steroids* became infected. *It was impossible not to think that zoster and varicella diseases developed in steroid-treated patients as a consequence of the reactivation of the latently present VZ virus.* László Géder, viral researcher trained in the laboratory of Professor Sabin, confirmed the origin of VZ virus in steroid-treated zoster varicella patients by means of virus cultures and serological tests (Radó, Marosi, Fischer et al. 1975).

The VZ “domestic epidemic” we observed was praised in an editorial in 1967 in the *Schweizerische Medizinische Wochenschrift* (Schwarz 1967); in 1969 in the *Quarterly*

Journal of Medicine (Ashton 1969); in 1972 in the British Medical Journal (Editorial 1972); and in 1985 in the Lancet (Steele 1985).

The VZ home epidemic has been included in the literature citations of a manuscript from the National Aeronautics and Space Administration (NASA), Lyndon B. Johnson Space Center, Houston, Texas, labelled as “Source of Acquisition NASA Johnson Space Center” handled as NASA internal material).

This manuscript was later published in the *Journal of Medical Virology* on Nov. 17, 2004, “*Stress-induced subclinical reactivation of varicella zoster virus in astronauts*” (Mehta, Cohrs, Forghani et al. 2004). A main author of the manuscript is Duane L. Pierson from the group of the NASA Johnson Space Center (JSC). Pierson is the director of NASA’s Microbiology Laboratory and a professor at Baylor College of Medicine and the University of Texas Medical Branch. Another outstanding author in terms of scientific merit is Donald H. Gilden, a professor in the Department of Neurology and Microbiology at the University of Colorado. In his four papers (Gilden, Dueland, Cohrs et al. 1991; Gilden, Mahalingam, Dueland and Cohrs 1992; Gilden, Kleinschmidt-DeMasters, LaGuardia et al. 2000; Nagel and Gilden 2016) he also referred to one of our patients with generalized herpes zoster (varicella) treated with a steroid (not belonging to the epidemic group), who also had zoster meningoencephalitis (Takó and Radó 1965).

During spaceflight, huge gravitational changes occur abruptly during launch and landing. The NASA team was particularly inspired by their finding that in a 47-year-old astronaut, out of 81 physically fit healthy individuals, chest herpes zoster developed two days before the launch. Therefore, eight astronauts were tested for VZ virus in saliva. Thirty per cent of the saliva samples became VZ virus positive during and after spaceflight. The anti-VZ virus IgG levels were found to increase 2-3-fold after spaceflight.

Subclinical reactivation of the VZ virus was observed in astronauts during space flight stress. Later, the effect of spaceflight on ACTH and cortisol levels was also investigated and, based on the observed increase, it was hypothesized that subclinical reactivation of the VZ virus was due to this. Previous clinical experience has also suggested that steroid activity may lead to VZ virus reactivation, as described by Radó et al. in their publication in the Archives of Internal Medicine in 1965 (Radó, Tako, Geder and Jeney 1965). So perhaps it can be stated that our work could even be considered an intellectual forerunner by this NASA task force.

Desmopressin pharmacology

I have been dealing with the pharmacology of Desmopressin (DDAVP) almost continuously for nearly 50 years. One of our communications (Radó, Marosi, Fischer et al. 1975) caught the attention of researchers at the U.S. Navy (NAVY) Research Institute and they used our data to evaluate the results of their own experiments (Doubt and Thorp 1992). *In this paper, they described our DDAVP dose-response relationship.*

The cover page of the American article (Doubt and Thorp 1992) (Figure 2).

The title of the American article was written in Navy jargon. SDV = seal dive vehicle = submarine carrying commandos on the high seas. AM and PM refers to a day and night dive respectively.

Practical (free) translation of the title of their paper (more precisely, their 45-page monograph): *Weight loss of commandos during day and night SDV dives and the application of DDAVP.*

The problem for the Navy was the weight loss of the commandos due to the loss of water in their naval (submarine) vehicles due to high temperatures. Therefore, they resorted to using DDAVP during their day and night dives in the hope that it would prevent weight loss. However, their hypothesis did not work because DDAVP did not prevent weight loss. *Analyzing the cause of their failure, they checked our dose-response relationship study and concluded that they did not use a sufficient dose of DDAVP.* They wrote, “It is possible that the DDAVP dose (20 mcg) was too low to have a pronounced effect on hydration during water dives. Radó, Marosi, Fischer et al. (1975) found that 10 and 20 mcg intranasal doses of DDAV were nearly equivalent in inhibiting water-loaded diuresis. However, a distinct antidiuretic effect was observed at higher doses (40–320 mcg) (Doubt and Thorp 1992).

Figure 2

NAVAL MEDICAL RESEARCH INSTITUTE

Bethesda, Maryland 20889-5055

NMRI 92-75

September 1992

**AD-A257 527**

②

WEIGHT LOSS AFTER AM AND PM SDV DIVES AND USE OF DDAVP

T. J. Doubt
J. W. Thorp

S **DTIC**
ELECTE
NOV 19 1992
A **D**

Naval Medical Research
and Development Command
Bethesda, Maryland 20889-5044

Department of the Navy
Naval Medical Command
Washington, DC 20372-5210

Approved for public release:
distribution is unlimited

9

115
92-29810





I should mention here that at New York University, Moses et al. made a similar comparison between the data from our dose-response relationship study and the dose-response of DDAVP when applied to their own patients (Moses, Scheinman and Oppenheim 1984).

In their Figure, (Figure 3) of our dose-response study is labelled as “DI Radó, 1975” (Translation of the Hungarian title: Comparison of the effectiveness of dDAVP in nephrogenic diabetes insipidus (NDI) and central diabetes insipidus (DI).

Figure 3


dDAVP hatékonyságának összehasonlítása nephrogen (NDI) és „valódi” (DI) diabetes insipidusban



Our DDAVP dose-response relationship studies were conducted in the 1970s. Perhaps it is remarkable that Oiso, Robertson, Nørgaard and Juul in 2013, Garrahy and Thompson in 2020; Gasthuys, Dossche, Michelet et al. in 2020; and da Silva Jr., Barros, Daher and Veronese in 2020 referred to these papers.

After so much experience with DDAVP, we developed a new treatment method, a combination of indomethacin and an excessive dose of DDAVP, for a patient with permanent lithium-induced nephrogenic diabetes insipidus who was enrolled in 1989 at the 3rd Department of Nephrology and Hypertension of Uzsoki Hospital. He was also treated with calcitonin due to joint and bone pain (Radó and Zdravkova 1991). **Our results are shown in Figure 5.** We selected free water clearance expressed as a percentage of glomerular filtration as the most sensitive parameter to study the antidiuretic effect. *It can be seen that although DDAVP is effective, indomethacin significantly increases its effect.* Indomethacin alone is hardly effective. Our surprising discovery was that calcitonin suspended the effect of DDAVP, which was presented by Radó and Zdravkova at the 1993 International Congress of Nephrology in Jerusalem.

Figure 5



During the period of these studies, between 1989 and 1993, further publication of our detailed data was cancelled. Treatment with lithium was in the descending period when our professional research concept took shape. The elaborate treatment, the need to regularly determine plasma lithium concentrations, the side effects, the frequent urine concentration defect and sometimes the unavoidable end-stage renal disease, as well as the appearance of new molecules replacing lithium have diverted physicians from lithium-treatment. However, when treatment with lithium became popular again in 2017, it seemed worth rethinking the issue and I wrote a paper that INHN published on January 25, 2018 (Radó 2018). In a later post, Barry Blackwell noted that lithium “this simple ion remains the best, safest, and least expensive treatment to prevent recurrent episodes of bipolar disorder” (Blackwell 2018). Blackwell also wrote that if Cade (1912-1980 - the discoverer of lithium treatment) and Mogens Schou (1918-2005 - the greatest clinical pharmacologist of the treatment) could have seen our paper, they “would have been happy.” *I could not have received more laudation.*

Thereafter I wrote an additional paper on the possible background of DDAVP and calcitonin antagonism, which was published on September 13, 2018 on the INHN website (Radó 2018). The website editors then asked me to write about the renal toxicity of lithium, which was published on May 2, 2019 (Radó 2019a). In these three publications I dealt so much with the effects of DDAVP that it seemed worthwhile to provide a literature review on the issue that *DDAVP can counteract lithium polyuria*. This paper

was published on June 27, 2019 (Radó 2019b). While working on this last manuscript I realized that a genetic discovery potentially points to the use of new drugs against lithium polyuria, as detailed in my fifth work, published on July 4, 2019 (Radó 2019c). Finally these five papers (Radó 2018a,b; Radó 2019a,b,c) were published together in an E-Book in Canada and partly in the columns of this Journal (Radó in press).

Figure 6

Thomas A. Ban: Neuropsychopharmacology in Historical Perspective (Collated 38)

Lithium E-BOOK Chapter 6. Safety

Janos Radó

Mechanism of Lithium Induced Polyuria

Use of Modern Antidiuretic Agents in the Treatment of Lithium Induced Permanent
Nephrogenic Diabetes Insipidus

Calcitonin in Lithium-Induced Nephrogenic Diabetes Insipidus

Desmopressin May Counteract Polyuria in Lithium Induced Nephrogenic Diabetes Insipidus

Renal Toxicity of Lithium in Historical Perspective with Special Reference to Lithium Induced
Nephrogenic Diabetes Insipidus

It made my old age beautiful that I could contribute to the topic of treating “bipolar disorder” depression, a disease that affects millions - and thereby approach the theme “beauties of old age” from a positive perspective. It was also a great pleasure for me to be able to participate in the editing of this Journal from 1999 to 2012, so I thank the harmonious collaboration to my fellow editors, Sándor Alföldi and György Reusz. I thank the encouraging help of Thomas Ban, Emeritus Professor of Psychiatry at Vanderbilt University in Nashville and Editor-in-Chief of INHN.

I take this opportunity to pay tribute to my former colleagues at János Hospital (Csaba Bános, late Lajos Borbély, Éva Juhos, Slava Kalceva, Judit Marosi, László Szende and József Takó) and in the Uzsoki Street Hospital (József Arányi, Mária Csabuda, late György Gercsák, Ágnes Haris, Anna Hartai, Éva Karácsony, Andrea Kovács, Géza Megyeri, Éva Pató, Andor Tóth and Szdreska Zdravkova). It is a pity that although many more colleagues deserve it, they were not added to the lists above. I also

think of them with a grateful heart. Last but not least, I would like to thank my wife, Mária Löffler, for not only tolerating my scientific work, but rather for supporting and sometimes participating in it.

References:

Ashton H, et al. Management of Herpes Zoster: Quarterly Review-Therapeutics VIII. Quarterly Journal of Medicine. 1969; 1:874-76.

Ban TA. Neuropsychopharmacology in Historical Perspective. Education in the Field in the Post-Neuropsychopharmacology Era. Prologue. inhn.org/education. September 18, 2017.

Blackwell B. Final reply to Janos Radó's final comment. (Blackwell B. Lithium Controversy. A historical autopsy.) inhn.org/controversies. May 10, 2018.

da Silva B Jr, Barros E, Daher EDF, Veronese FV. Renal Function Evaluation in Tropical Diseases. In: da Silva B Jr, De Francesco DE, Barros E, editors. Tropical Nephrology. Springer, Cham. 2020.

Doubt TJ, Thorp JW. Weight loss after AM and PM SDV dives and use of DDAVP. Naval Medical Research Institute. Bethesda Maryland. NMRI 1992.

Editorial. Zoster and Hodgkin's Disease. *Br Med J*. 1972; 3:130.

Garrahy A, Thompson CJ. Management of central diabetes insipidus. *Best Practice & Research Clinical Endocrinology & Metabolism*. 2020.

Gasthuys E, Dossche L, Michelet R, Nørgaard JP, Devreese M, Croubels S, Vermeulen A, Van Bocxlaer J, Walle JV. Pediatric Pharmacology of Desmopressin in Children with Enuresis: A Comprehensive Review - *Pediatric Drugs*. *Paediatr Drugs*. 2020;22(4):369-83.

Gilden DH, Dueland AN, Cohrs R, Martin JR, Kleinschmidt-DeMasters BK, Mahalingam R. Preherpetic neuralgia. *Neurology* 1991; 41(8):1215.

Gilden DH, Mahalingam R, Dueland AN, Cohrs R. Herpes zoster: pathogenesis and latency. *Progress in Medical Virology*. 1992; 39:19-75.

Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam R, Cohrs RJ. Neurologic complications of reactivation of varicella zoster virus. *N Engl J Med*. 2000;342(14):1063.

Herman E, Radó J. Fatal hyperkalemic paralysis associated with spironalactone. Observation on a patient with severe renal disease and refractory edema. *Arch Neurol*. 1966;15(1):74-7.

Lehmann HE. What is wrong with getting old. Manuscript. Lehmann Collection. inhn.org/archives. December 17, 2020.

Mehta SK, Cohrs RJ, Forghani B, Zerbe G, Gilden DH, Pierson DL. Stress-induced subclinical reactivation of varicella zoster virus in astronauts. *J Med Virol.* 2004; 72(1):174-9.

Moses AM, Scheinman SJ, Oppenheim A. Marked hypotonic polyuria resulting from nephrogenic diabetes insipidus with partial sensitivity to vasopressin. *J Clin Endocrinol Metab.* 1984; 59(6):1044–9.

Nagel MA Gilden, D. Developments in varicella zoster vasculopathy. *Curr Neurol Neurosci Rep.* 2016;16(2):12.

Osio Y, Robertson GL, Nørgaard JP, Juul KV. Treatment of neurohypophyseal diabetes insipidus. *J Clin Endocrinol Metab.* 2013; 98(10):3958-67.

Radó J. My 64 year (1954-2018) life product. (Supplementation to My Biographic Sketch) (Radó Collection). inhn.org/archives. July 26, 2018.

Radó JP, Banos C, Tako J. Frusemide renography. *Lancet.* 1967;2(7531):1419-20.

Radó JP. Water intoxication during carbamazepine treatment. *Br Med J.* 1973;3(5878):479.

Radó JP, Borbely L. Enhancement of polyuria by glibenclamide in diabetes insipidus. *Lancet.* 1971;2(7717):216.

Radó JP, Tako J, Geder L, Jeney E. Herpes Zoster House Epidemic in Steroid-Treated Patients. A Clinical and Viral Study. *Arch Intern Med.* 1965;116:329.

Radó JP, Marosi J, Fischer J, Tako J, Kiss N. Relationship between the dose of 1-deamino-8-d-arginine vasopressin (DDAVP) and the antidiuretic response in man. *Endokrinologie.* 1975;66(2):184-95.

Radó JP, Zdravkova S. Lithium-induced chronic water-metabolism disorder (nephrogenic diabetes insipidus). *Orv Hetil.* 1991;132(36):1987-90.

Radó JP, Zdravkova S. Effect of Indomethacine and Calcitonin During Administration of 1-Deamino-8-D-Arginin-Vasopressin (dDAVP) on Free Water Clearance in Nephrogenic Diabetes Insipidus (NDI). XIIth International Congress of Nephrology. June 13–18, 1993 Jerusalem.

Radó J. Final Comment. Use of modern antidiuretic agents in the treatment of permanent lithium induced nephrogenic diabetes insipidus. (Barry Blackwell: The lithium controversy. A historical autopsy. Collated by Olaf Fjetland.) inhn.org/controversies. January 25, 2018a.

Radó J. Addition to final comment. Calcitonin in lithium-induced nephrogenic diabetes insipidus (Barry Blackwell: The lithium controversy. A historical autopsy.) inhn.org/collated. September 13, 2018b.

Radó J. Renal Toxicity of Lithium in Historical Perspective with Special Reference To Nephrogenic Diabetes Insipidus and its Treatment. inhn.org/controversies. May 2, 2019a.

Radó J. Desmopressin may counteract polyuria in lithium-induced nephrogenic diabetes insipidus (Review of the literature). inhn.org/controversies. June 27, 2019b.

Radó J. Mechanism of Lithium Induced Polyuria in Historical Perspective. inhn.org/perspective. July 4, 2019c.

Radó J: Prevention of polyuria during lithium treatment. (New researches and history.) Hungarian Hypertonology and Nephrology. (in press)

Schwarz K. Herpes zoster epidemie. Schweizerische Medizinische Wochenschrift. 1967; 97:60.

Steele RW. Outbreaks of Shingles. Lancet. 1985; 326(8464): 1105-6.

Takó J, Radó JP. Zoster meningoencephalitis in a steroid-treated patient. Arch Neurol. 1965; 12:610-2.

Zhang Y, Pop I, Carlson NG, Kishore BK. Genetic deletion of the P2Y12 receptor offers significant resistance to development of lithium-induced polyuria accompanied by alterations in PGE2 signaling. Am J Physiol Renal Physiol 2012; 302: F70–7.

Zhang Y, Riquier-Brison A, Liu T, Huang Y, Carlson, NG, Peti-Peterdi J, Kishore BK. Genetic Deletion of P2Y12 Receptor Offers Long-Term (5 Months) Protection Against Lithium-Induced Polyuria, Natriuresis, Kaliuresis, and Collecting Duct Remodeling and Cell Proliferation. Front Physiol. 2018; 9: 1765.

Zhang Y, Peti-Peterdi J, Brandes A, Riquier-Brison A, Carlson NG, Müller CE, Ecelbarger CM, Kishore BK. Prasugral suppresses development of lithium-induced nephrogenic diabetes insipidus in mice. Purinergic Signal. 2017;13(2):239-48.

January 21, 2021

Janos Radó's comment on the 2017 research article of Lin, Zhang, Feng, et al., "Aliskiren increases aquaporin-2 expression and attenuates lithium-induced nephrogenic diabetes insipidus"

Purpose of the study

The purpose of their 2017 study was to investigate whether Aliskiren regulates AQP2 expression in the collecting duct principal cells and whether Aliskiren treatment attenuates lithium-induced nephrogenic diabetes insipidus (NDI).

Physiological background

In the collecting ducts increased intracellular levels of cAMP activate protein kinase A, which phosphorylates aquaporin 2 (AQP2) with translocation of the water channel from intracellular vesicles to the apical plasma membrane. This results in increased osmotic water permeability and urinary concentration. Angiotensin II stimulates upregulation of renal AQP2 abundance in vivo and in vitro, as well as an increased intracellular trafficking of AQP2 to the plasma membrane. Dysregulation of AQP2 plays a fundamental role in acquired forms of nephrogenic diabetes insipidus, e.g., sustained lithium intake, which are associated with depletion of AQP2 protein from the collecting ducts and a defect in urinary concentration. However, whether the synthesized nonpeptide renin inhibitor Aliskiren regulates AQP2 expression independent of RAS activation is unknown.

The direct renin inhibitor

The direct renin inhibitor Aliskiren has a high affinity and specificity for human renin and inhibits the enzyme renin by binding to its catalytic site and thus reducing angiotensin II levels in the plasma. In contrast to ACE inhibitors and angiotensin II receptor blockers, Aliskiren decreases plasma renin activity and reduces plasma angiotensin I and angiotensin II levels, but strongly increases renin and prorenin concentrations. Increasing evidence shows that Aliskiren has a renal protective effect in animals and in patients with hypertension or diabetes. Interestingly, the antihypertensive and antiproteinuric effects of Aliskiren persist for a long time, even after treatment is discontinued.

Effect of Aliskiren on the kidney

Renin may act on the nephrons and collecting ducts via activating the (pro)renin receptor. Nephron and collecting duct-specific deletion of the prorenin receptor is associated with polyuria and impaired countercurrent multiplication, accompanied by reduced levels of medullary aquaporin-2 (AQP2) and Na- K-2Cl cotransporter.

Studies showed that Aliskiren may accumulate in the kidney, where it localizes in glomeruli, afferent arterioles and in the thick ascending limb of Henle and the medullary collecting ducts, which are important for sodium and water reabsorption as well as urinary concentration, indicating a new mechanism of action for this drug.

Aliskiren treatment

Aliskiren treatment improved urinary concentrating defect in lithium-treated mice and partially prevented the decrease of AQP2 and pS256-AQP2 protein abundance in the inner medulla of the kidney.

In conclusion, the direct renin inhibitor Aliskiren upregulates AQP2 protein expression in inner medullary collecting duct principal cells and prevents lithium-induced nephrogenic diabetes insipidus likely via cAMP-PROTEIN KINASE A pathways.

Effect mechanism of Aliskiren

Aliskiren decrease the expression of prorenin receptor in rat kidney. Aliskiren treatment was associated with ~20% reduction of prorenin receptor in inner medulla compared with the lithium group, accompanied by increased AQP2 expression and improved polyuria. This suggests that prorenin receptor is unlikely to play a role in lithium-induced urinary concentration defect. The observed improvement of urinary concentration in lithium-induced NDI likely indicates a direct effect of Aliskiren in the collecting ducts, in particular in the principal cells. The direct reininhibitor Aliskiren increased the collecting duct AQP2 expression and partially improved the urine concentration defect in lithium-treated mice, likely by directly activating the cAMP-PROTEIN KINASE A pathway in the principal cells.

In conclusion, the direct renin inhibitor Aliskiren upregulates AQP2 protein expression in inner medullary collecting duct principal cells and prevents lithium-induced nephrogenic diabetes insipidus likely via cAMP-PROTEIN KINASE A pathways.

My comments

Lin et al.'s work shows that Aliskiren is a new drug on the palette which is able to counteract (at least in part) the polyuria induced by lithium treatment. However, from the discovery that a new drug is able to abolish lithium-induced nephrogenic diabetes insipidus to the administration in clinical practice is a long way. According to MEDSCAPE Concomitant use of Aliskiren with other agents acting on the RAAS (e.g., ACEIs or ARBs) is associated with an increased risk of hypotension, hyperkalemia and changes in renal function (including acute renal failure). Furthermore, in the "Interaction checker" there are 19 medicines with which coadministration of Aliskiren is strictly contraindicated, 63 medicines with which coadministration requires closely monitoring. Although Aliskiren upregulates AQP2 protein expression in inner medullary collecting duct principal cells and prevents lithium-induced

nephrogenic diabetes insipidus in mice, there are difficulties in the administration of this drug to humans.

We wrote that in such an important form of psychiatric treatment as lithium is, a serious side effect, the disturbance of water metabolism, can be alleviated by clever use of modern antidiuretic interventions (Radó 2018) combination of excessive doses of desmopressin with indomethacine. It was emphasized by us that it is important to save lithium treatment for millions of people suffering from bipolar disorder and other psychiatric abnormalities in an age when its use has gradually declined and many less-established drugs are preferred. This can be done (at least partly) by demonstrating that treatment of lithium-induced permanent nephrogenic diabetes insipidus is not so hopeless as it appears from some recent articles dealing with lithium induced nephrotoxicity. Our therapeutic armamentarium include several drugs, thiazide diuretics, nonsteroid anti-inflammatory drugs, amiloride and desmopressin. On the basis of the available literature desmopressin alone and in combination with other antidiuretic drugs seemed to be an effective means in counteracting lithium-induced polyuria (Radó 2019a). Whether Aliskiren can belong in this group of antidiuretic medicines remains to be established.

Zhang and his coworkers found that lithium-induced polyuria is due to resistance of the medullary collecting duct to the action of arginine vasopressin (AVP), apparently mediated by increased production of PGE₂. Genetic deletion of the P₂Y₂ receptor offered significant resistance to development of lithium polyuria. This change was accompanied by alterations in PGE₂ signaling mediated by a marked decrease in the prostanoid EP₃ receptor protein abundance thus attenuating the decrease in cAMP, modulator of arginine vasopressin, in the renal medulla (Zhang, Pop, Carlson and Kishore 2012; Zhang, Hansson, Liu, Kishore 2019).

Clopidrogel is an antiplatelet drug of the thienopyridine group extensively used in cardiological clinical medicine. Another such drug is prasugral and both are ADP antagonists acting on the P₂Y₁₂ receptor. Administration of prasugral as well as clopidrogel completely suppressed lithium-induced polyuria and polydipsia in rats (Zhang, Peti-Peterdi, Brandes et al. 2017)

Pharmacologic blockade of renal P₂Y₁₂ receptor in rodents increases urinary concentrating ability by augmenting the effect of vasopressin on the kidney and ameliorates lithium-induced nephrogenic diabetes insipidus by potentiating the action of vasopressin on the renal collecting duct (Zhang Peti-Peterdi, Müller et al. 2015). This strategy may offer a novel and effective therapy for lithium-induced nephrogenic diabetes insipidus in man.

Pharmacologic blockade of renal P₂Y₁₂ receptor may be combined - at least theoretically - with anti-prostaglandin agents (non-steroidal anti-inflammatory compounds) and supplemented with large doses of desmopressin in the treatment of lithium-induced nephrogenic diabetes

insipidus (Radó 2019b). Lithium-induced excessive prostaglandinuria (increased excretion of PGE₂) can be prevented by pharmacologic blockade of the renal P2Y₁₂ receptor and antagonized by the administration of indomethacine.

The present therapy for lithium-induced nephrogenic diabetes insipidus in man is to counter anti-vasopressin action of lithium by administration of thiazide diuretics, antiprostaglandin compounds (indomethacine) combined with large doses of desmopressin. (Amiloride supplements the “present therapy” drug group). The “future” treatment seems to be (on the basis of recent animal experiments) to enhance the sensitivity of the kidney to vasopressin action by administering pharmacologic blockade of renal P2Y₁₂ receptor. (Zhang, Riquier-Brison, Liu, et al. 2018.) On theoretical basis it is conceivable that the present therapy of lithium-induced nephrogenic insipidus perhaps could be combined with the “future” pharmacologic blockade. Whether Aliskiren can belong in this group of antidiuretic medicines remains to be established.

We are all definitely convinced by the enormous work of Ban (2017), Blackwell (2014), Rybakowski (2017), Severus, Taylor, Sauer et al. (2014) and others that millions suffering from bipolar disorder need lithium treatment and making it safer by eliminating (at least partly) its most frequent side effect lithium polyuria, is a decent goal for both the investigators and physicians.

References:

- Ban TA. Neuropsychopharmacology in Historical Perspective. Education in the Field in the Post-Neuropsychopharmacology Era. Prologue. inhn.org/education. September 18, 2017.
- Blackwell B. Lithium Controversy. A historical autopsy. inhn.org/controversies. June 19, 2014.
- Kishore BK, Carlson NG, Ecelbarger CM, Kohan DE, Müller CE, Nelson RD, Peti-Peterdi J, Zhang Y. Targeting renal purinergic signalling for the treatment of lithium-induced nephrogenic diabetes insipidus. *Acta Physiol (Oxf)*, 2015;214(2):176-88.
- Lin Y, Zhang T, Feng P, Qiu M, Liu Q, Li S, Zheng P, Kong Y, Levi M, Li C, Wang W. Aliskiren increases aquaporin-2 expression and attenuates lithium-induced nephrogenic diabetes insipidus. *Am J Physiol Renal Physiol*, 2017;313:F914-25.
- Radó J. Use of modern antidiuretic agents in the treatment of permanent lithium induced nephrogenic diabetes insipidus. (Administration of excessive doses of desmopressin resulted in clinically relevant antidiuresis, enhanced by indomethacine and abolished by calcitonin). (Janos Radó's final comment on Barry Blackwell: The lithium controversy. A historical autopsy. Collated by Olaf Fjetland). Thomas A. Ban: Neuropsychopharmacology in historical perspective. Education in the field in the post-psychopharmacology era. Collated 14. inhn.org/controversies. January 25, 2018.
- Radó J. Desmopressin may counteract polyuria in lithium-induced nephrogenic diabetes insipidus (Review of the literature) inhn.org/controversies. June 27, 2019a.

Radó J. Renal Toxicity of Lithium in Historical Perspective with Special Reference To Nephrogenic Diabetes Insipidus and its Treatment. *inhn.org.controversies*. May 2, 2019b.

Rybakowski J. Final comment: Half a Century of Inspiring Lithium Controversy (Barry Blackwell: The Lithium controversy: A historical autopsy. Collated by Olaf Fjetland). *inhn.org.collated*. September 30, 2017.

Severus E, Taylor MJ, Sauer C, Pfennig A, Ritter P, Bauer M, Geddes JR. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. *Int J Bipolar Disord*, 2014;2:15.

Zhang Y, Pop I, Carlson NG, Kishore BK. Genetic deletion of the P2Y₁₂ receptor offers significant resistance to development of lithium-induced polyuria accompanied by alterations in PGE₂ signaling. *Am J Physiol Renal Physiol*, 2012;302:F70–7.

Zhang Y, Peti-Peterdi J, Müller CE, Carlson NG, Baqi Y, Strasburg DL, Heiney KM, Villanueva K, Kohan DE, Kishore BK. P2Y₁₂ Receptor Localizes in the Renal Collecting Duct and Its Blockade Augments Arginine Vasopressin Action and Alleviates Nephrogenic Diabetes Insipidus. *J Am Soc Nephrol*, 2015;26(12):2978-87.

Zhang Y, Peti-Peterdi J, Brandes A, Riquier-Brison A, Carlson NG, Müller CE, Ecelbarger CM, Kishore BK. Prasugral suppresses development of lithium-induced nephrogenic diabetes insipidus in mice. *Purinergic Signal*, 2017;13(2):239-48.

Zhang Y, Riquier-Brison A, Liu T, Huang Y, Carlson, NG, Peti-Peterdi J, Kishore BK. Genetic Deletion of P2Y₁₂ Receptor Offers Long-Term (5 Months) Protection Against Lithium-Induced Polyuria, Natriuresis, Kaliuresis, and Collecting Duct Remodeling and Cell Proliferation. *Front Physiol*, 2018;9:1765.

Zhang Y, Hansson K M, Liu T, Kishore B. Genetic Deletion of ADP-activated P2Y₁₂ Receptor Ameliorates Lithium-induced Nephrogenic Diabetes Insipidus in Mice. *Acta Physiol (Oxf)*, 2019;225(2):e13191.

March 4, 2021

János Radó: My teacher, Pál Gömöri (1905-1973)



Pál Gömöri

Introduction

Great Hungarian physicians have contributed significantly to the development of international medical science. *Pál Gömöri* was one of them. It is now the 70th anniversary of me being a third-year medical student and him my internal propedeutics professor in 1951, at Budapest University of Medicine's Clinic for Internal Medicine no. 1. It would be impossible to list the versatility of his scientific interests, but one of his ambitions was the introduction of the investigational methods of renal nuclear medicine to Hungary. I feel that my own activity in renal nuclear medicine concerning "diuretic renography" was inspired partly by what I had learned from Gömöri. His conduct in life, his professional and social achievements, his commitment to renal physiology and renal diseases appeared to be a path to be followed by many a talented medical student.

Pál Gömöri was the first truly modern Hungarian internist: he turned from the issues of the hospital bed *to the animal testing model* and returned to the patient having solved the issue. He reproduced nearly every mechanism leading to the clinical picture of

extrarenal azotaemia using animal testing (Gomori, Romhanyi, Foldi and Szabo 1954; Gomori, Munkacsi, Nagy et al. 1962; Gomori, Glaz, Suhanyeczky and Csapo 1960). In fact, it was perhaps at a lecture of Gömöri's that I heard that according to the famed American-Hungarian internist, *Henrik Lax*, the Semmelweis' tragic fate – the inability to convince his contemporaries of his truth – could be traced back to him *not carrying out animal testing* (the fact that he “was his own worst enemy,” according to a 2004 *New England Journal of Medicine* review of a biographical book published in the United States could also have been at play [Nuland 2004])). There were other internists in Hungary who conducted animal tests, including *Rusznyák*, *Földi*, and *Szabó*; however, most results of their experiential pathophysiological research could only be utilized in clinical medicine in a more removed and indirect manner. The immortal *Sándor Korányi*, being the genius life scientist that he was, was a more conservative internist than the three mentioned above (Radó 2005). In this he resembled other Greats, such as *Ernő Jendrassik*, *Imre Fodor* (Radó 2011a), and *Imre Magyar*, who only conducted animal experiments by way of exception, on select issues. Pál Gömöri did not have a hard time convincing his contemporaries of his truth: he carried out the animal testing-based elaboration of the ideas he had acquired beside the hospital bed within the framework of an exceptionally broad scientific team (Gomori, Romhanyi, Foldi and Szabo 1954; Gomori, Munkacsi, Nagy et al. 1962; Gomori, Glaz, Suhanyeczky and Csapo 1960; Endes, Takacs-Nagy, Rubanyi and Gomori 1955; Gomori, Kovach, Takacs, et al. 1960; Gomori, Harsing, Kallay et al. 1969; Gomori, Takacs and Kallay 1960; Gomori and Takacs 1960).

It is therefore hardly surprising that Pál Gömöri achieved everything there was to achieve for an internist in Hungary. To name but a few of his positions and distinctions: Department Head of the Clinic for Internal Medicine no. 2 of the Semmelweis University of Medicine; Director of the National Institute of Internal Medicine; Chairman of the Hungarian Medical Societies and Associations; Full Member of the Hungarian Academy of Sciences and Chairman of its Medical Sciences Section; Member of the Academy of Sciences of the Soviet Union; Kossuth Prize laureate. Quite unlike Sándor Korányi, who had also achieved everything but was sent to retirement dishonorably in a bad era, with his clinic dissolved and his school disbanded (Radó 2005). As for Pál Gömöri, he stayed at the top in different bad eras. Perhaps he was born under a lucky star; his personal charisma and popularity might have also made a difference – as likely did his self-sacrifice. The latter is confirmed by my research of online sources.

Relative to Hungarian medical scientists of a similar stature, of the 255 (248, according to others) works of Pál Gömöri relatively few appeared in foreign publications. Of the 70 works available online, published between 1950 and 1973, most appeared in foreign languages (chiefly in English in journals produced by the [communist] Hungarian State). Of the 24 publications between 1950 and 1956 only nine were published in a foreign language but all of these saw the light of day in *Hungarian (or GDR-based) journals*. In the so-called Rákosi era, even a scientist as renowned as Pál Gömöri could not risk publishing, as he had been wont, his scientific results in a Western journal (as well). After 1956, we again see his works appear in reputable journals, including in *The Lancet* (Gomori, Glaz, Suhanyeczky and Csapo 1960; Gomori, Takacs and Kallay 1962; Gomori and Takacs 1960).

Pál Gömöri was not only my teacher but also chaired my final examination. In the wee hours of the examination day, I wanted to go through the acid-base balance once again. Alas, I fell asleep reading and entered the classroom 45 minutes late; two of my classmates had already finished the examination. Professor Gömöri posed quite challenging questions (typhus exanthematicus, rheumatoid arthritis and lead poisoning) but gave me the top mark.

I was a fan of his classroom lectures. He was a captivating, brilliant, logical lecturer. He presented his subject with such confidence that his knowledge seeped into us. He barely had a voice, however; we could hardly hear him even when he was speaking into a microphone, hoarsely but enthusiastically.

In 1953-54, my classmate and friend, *Pál Dévényi* (he resides in Canada, was formerly a family doctor and thereafter an alcoholologist), spent a whole year at Gömöri's clinic as a medical student, just as I did at the Rókus Hospital (Radó 2011b). He invited me to the clinic a number of times; I partook in the Professor's grand rounds and scientific report sessions. I was impressed by Gömöri's style of doing rounds. He barely spent time on patients with known diseases, who were unproblematic and in a stable condition. He did, however, sit down at the "problem cases"; his doctors, such as Assistant Professor (later, Professor) Sándor Gerő, Teaching Assistant Szigeti and others, huddled around him and at times a fiery scientific debate erupted. Later, while serving as a Chief Medic and Department Head, I made great use of the style of doing rounds with which I had familiarized myself at Gömöri's clinic. Gömöri's superiority was conspicuous during the report sessions. Whenever a question was undecided, he instructed one of his subordinates

during the session: “Go and make a phone call – but right now!” He was not one to tolerate procrastination.

One could run into Gömöri at downtown nightlife spots as well. His scientific productivity, career path, as well as the professional, public and social success – and his *lifestyle* – had become an example to be followed for the late *László Riesz* (also a friend and a classmate of mine) and for myself. In contemporary terms, one could perhaps say that this was a “model career trajectory.” We were intent on mimicking Gömöri. (In the end, László Riesz became a family doctor and I have held positions of Chief Medic Department Head and University Lecturer; neither of us has become a head of department at a university).

Gömöri’s favorite fields of interests were salt and water balance, kidney function, and hypertension. In his books published in 1953 and 1966, too, he dealt with kidney conditions and hypertension. His scientific results were on a par with international standards. Even *Homer Smith*, the eternal “Kidney Pope” made references to his works. Homer Smith’s “Kidney Bible” – titled *The Kidney* – was published in 1951, and in the “Renal function in Addison’s disease” chapter the author noted that it was Gömöri (along with his colleague, *Margitay Becht*) who had first described GFR decrease in Addison’s disease (Margitai-Becht and Gömöri 1938).

Homer Smith chose the spectacular *juxtaglomerular apparatus*, colored using histological methods, as the cover of his book. This, too, underlines the brilliance of the author: already in his time, Smith held up the significance of this apparatus – also of dominant importance in our current view of hypertension research – vis-à-vis any other histological field (formula) characteristic of the kidney. Gömöri had advocated for the introduction of isotope renography to advance the diagnostics of renovascular hypertension (Gráf 1973; Nagy 1983) but later became disillusioned with the method. It was not specific and sensitive enough, there were all too many false positives and negatives. Initially, the present author had also applied this method to hypertension research but later, as a by-product of sorts, described “furosemide (diuretic) renography,” suitable for the diagnosis of ureteral obstruction (Rado, Banos and Tako 1967). Our first such treatise was published in *The Lancet*, in 1967, followed by nine publications on the same topic. Finally, 36 years after the first article, we again provided an overview of the significance of this method (Radó 2001a,b). Gömöri lived to see the birth of diuretic renography in 1967, to see that – upon the obstruction of the ureter, and in response to furosemid – a characteristic, so called “obstruction curve,” emerges. However, he was

not there to witness more recent developments (1984, see also the addendum), namely, that a very similar change in renovascular hypertension is prone to develop also as a response to *captropil* (Oei, Geyskes, Dorhout and Puijlaert 1984). In Hungary, Sallai and Fornet introduced “captropil renography” in 1986 (Sallai, Fornet, Nánay et al 1986). (Mihály Horváth, the pioneering scholar of Hungarian nuclear medicine, has emphasized just how soon after the method’s initial development [Horváth 1995]). *Gömöri would doubtlessly have been most delighted to learn that isotope renography, after all, has become significant in the differential diagnosis of hypertension. (By now, to be sure, the even more efficient methods have relegated to the background the use of this technique as well.)*

Gömöri’s scientific results are preserved in international medical journals, libraries, and on the Internet. The spirit of his medical teachings, however, must be passed on by his students and disciples, so as to postpone the fading his memory to the farthest possible future.

Acknowledgements:

It is with a thankful heart that I remember Professor Pál Gömöri, who supported my work at the János Hospital (Radó 2009). I thank Professor Béla Székács, Chairman of the Board of Trustees at the Pál Gömöri Hypertension and Kidney Foundation, and Professor Csaba Farsang, Lifetime Honorary Chairman of the Hungarian Society of Hypertension and the Board of the Hungarian Society of Hypertension for selecting me to give the 2005 Pál Gömöri Memorial Lecture. Even a cursory glance at the list of former speakers suffices to show how great an honor this was: 1995: Rudolf de Châtel; 1996: Edit Gláz; 1997: Csaba Farsang; 1998: László Rosivall; 1999: Sándor Sonkodi; 2000: István Kiss; 2001: Ede Kékes; 2002: György Ábrahám; 2003: Zoltán Nagy; 2004: György Jermendy; 2006: János Szegedi; 2007: Zoltán Járαι; 2008: Ferenc Paulin; 2009: Ákos Koller; and 2010: Dénes Páll. I thank Professor László Rosivall for his permission to use the portrait of Gömöri and other materials featured in the lecture he held at the 1999 Congress of the Hungarian Society of Hypertension, upon receiving the Pál Gömöri Award.

Addendum

The obstruction curves observable in the course of isotope renography may vary. Significant interindividual differences are possible. As a result, the renogram deformed in response to captopril in renovascular hypertension may show similarities to the differences caused by furosemide, observable in renal curves in ureteral obstruction (O'Reilly 1989). Furosemide renography was developed in 1967 (Radó, Banos and Tako 1967), while captopril renography in 1984 (Oei, Geyskes, Dorhout et al. 1984); that is to say, the "obstruction curves" described and presented by us predated captopril renogram by 17 years in scientific literature. We wish to underscore this since the issue bears a personal pertinence to the history of medicine. For it is my assumption that furosemide curves might have facilitated the development of captopril renography through a personal connection.

I spent 1976 and 1977 in the Netherlands, at the University of Utrecht's Clinic for Internal Medicine, as a Visiting Scientist at the Hypertension and Nephrology Department, supported by the *Nierstichting* (an organization roughly equivalent to the Hungarian Kidney Foundation). During these two years, material for 18 of my publications was developed in cooperation with *dr. Evert J. Dorhout-Mees*, Head of the Hypertension and Nephrology Department. His deputy, *G. G. Geyskes*, and *dr. H. Y. Oei* of the Department of Nuclear Medicine were the first to describe captopril renography in 1984. I developed a close personal connection to *dr. Oei*. *Dr. Oei* and his wife who would invite me and my first wife to their home and would also visit us on occasion. I gifted an offprint of my publications to *dr. Oei*; we have discussed my works at quite some length and they might have facilitated the emergence of captopril renography as an idea.

To be sure, far be it from me to vindicate an unrightful role for myself in the development of captopril renography (which occurred seven years after my departure from the Netherlands!). Nevertheless, it cannot be excluded that the professional discussions during the hours spent together, along with the indeed spectacular curves of furosemide renography, provided a source of inspiration for *dr. Oei*. *That said, the credit of developing captopril renography obviously goes to him and dr. G. G. Geyskes.*

The latter section is pertinent to this piece of commemorative history of medicine since I was fascinated by *Gömöri's* eagerness to research renovascular hypertension and his initial optimism with regard to isotope renography. It is highly likely that *Gömöri's* aura played a role in me developing furosemide renography. I have no way of knowing whether my works had indeed exerted an influence on *dr. Oei* but if so, then *Gömöri's* spirit had a bit to do with that as well.

Another remark

I was already in the process of writing this publication when I had a chance to talk freely with medical interns from a Budapest hospital's department of internal medicine. They had never heard of Gömöri. A teaching assistant from a clinic of internal medicine – incidentally, from the very same one where Gömöri used to lecture as a professor – who happened to be present was unsure whether he had heard of Gömöri.

References:

Book Review. The Doctors' Plague: Germs, Childbed Fever, and the Strange Story of Ignác Semmelweis. *N Engl J Med*, 2004;350(13):1368.

Endes P, Takacs-Nagy L, Rubanyi P, Gomori P. The pathogenesis of malignant hypertension. *Acta Morphol Acad Sci Hung*, 1955;5(1-2):113-31.

Gömöri P. Belgyógyászati vesebajok és a hypertoniabetegség általános diagnosztikája és klinikuma. Budapest: Egészségügyi Kiadó. A gyakorló orvos könyvtára; 1953, p. 15.

Gomori P, Romhányi Gy, Foldi M, Szabo Gy. Functional and morphological changes of the kidney in dehydration. *Acta Morphol Acad Sci Hung*, 1954;4(1):9-23.

Gomori P, Glaz E, Suhanyeczky A, Csapo G. Aldosterone and hydrocortisone secretion in dehydration. *Lancet*, 1960;1:259-60.

Gomori P, Takacs L. Circulatory regulation and shifting in hypoxia. *Am Heart J*, 1960;59:161-5.

Gomori P, Kovach A, Takacs L, Foldi M, Szabo G, Nagy Z, Wiltner W, Kallay K. The regulation of cardiac output in hypoxia. *Acta Med Acad Sci Hung*, 1960;16:93-8.

Gomori P, Munkacs S, Nagy Z, Takacs L, Kallay K. Ischaemia and arteriovenous anastomoses of the kidney in shock, haemorrhage, dehydration and arterial hypoxia in dogs. *Acta Med Acad Sci Hung*, 1962;18:119-25.

Gomori P, Takacs L, Kallay K. The effect of synthetic angiotensin II on the redistribution and shifting of blood. *Arch Int Pharmacodyn Ther*, 1962;138:254-62.

Gömöri P. A hypertoniabetegség és a vesebajok. Budapest: Medicina; 1966.

Gomori P, Harsing L, Kallay K, Bartha J, Debreczeni L. Arterio-venous anastomoses in the kidney. I. Renal blood flow following the infusion of serum albumin. *Acta Physiol Acad Sci Hung*, 1969;35(3):201-10.

Gráf F. Dr. Gömöri Pál 1905–1973. *Orv Hetil*, 1973;46:2760.

Horváth M. A hazai nukleáris medicina története. Ahogy én láttam. Kiadó: Horváth Mihály, Balatonfüred; 1995.

Margitai-Becht A, Gömöri P. Die nierenfunktion bei der addisonischen krankheit. Zeitschr f d ges Exp Med, 1938;104:22.

Nagy Z. Gömöri Pál emlékezete. Orv Hetil, 1983;52:3181.

Nuland SB. The doctors' plague: germs, childbed fever, and the strange story of Ignác Semmelweis (Great Discoveries.). New York: W.W. Norton; 2003.

Oei HY, Geyskes GG, Dorhout Mees EJ, Puijlaert CBAJ. Captopril induced renographic alteration in unilateral renal artery stenosis. J Nucl Med, 1984;25:36.

O'Reilly P. Scintirenography in urinary tract obstruction. In: Blaufox MD, editor. Evaluation of renal function and disease with radionuclides: The upper urinary tract. Basel, London, New York: Karger; 1989, p. 248.

Radó J. A fagyáspontcsökkenéstől az ozmolalitásig (Korányi Sándor Emlékelőadás 2004 alapján). Hypertonia és Nephrologia, 2005;9:4-13.

Radó J. A diuretikus terápia (hazai) fejlődéstörténete I.: Fodor Imre. V. Hámori Artur Belgyógyászati Napok, Pécs. Program ésabsztraktfüzet. Magyar Belorvosi Archívum sajtó alatt. March 26, 2011a.

Radó J. A szerkesztő levele. Scylla és Charybdis – A hypertonia kezelése. Hypertonia és Nephrologia, 2011b;15(1):4.

Rado JP, Banos C, Tako J. Furosemide renography. Lancet, 1967;2(7531):1419-20.

Radó J. A furosemid vese-scintigraphia helye a húgyuti obstrukciók kivizsgálási algoritmusában. Magyar Radiológia, 2001a;75:154-61.

Radó J. A "furosemid-renographia" felfedezése és jelentősége. Hypertonia és Nephrologia 2001b;6(1):16-24.

Radó J. A Hypertonia és Nephrologia folyóirat története. II. Kortörténeti háttér. Hypertonia és Nephrologia, 2009;13(3):134-5.

Sallai, G. Fonet, B, Nánay A, Sylvester I, Toth. Captopril hatásban végzett funkcionális vesescintigráfia renovascularis hypertonia szűrésére. Orv Hetil, 1986;127(16):931-5.

Smith HW. The Kidney. Structure and function in health and disease. New York: Oxford University Press; 1951.

May 13, 2021

On March 15, 2021, Janos Radó was the recipient of “Iron Pen” of the Association of Hungarian Journalists (Magyar Újságírók Országos Szövetsége – MUOSZ) in recognition of his lifetime contributions. The Association awards its members with this recognition after their 90th birthday.



June 24, 2021

Photos of János Radó



(From left): Nadia Kuprina, Giorgina B. Piccoli, János Radó, Stanley Shaldon and Jacques Bernheim. Photo taken in Paris, France on May 24, 2012. Photo received from János Radó.

July 19, 2018

Vignette 1

János Radó Hungarian, nephrologist, endocrinologist and inventor of “diuretic renography,” is pictured with Stanley Shaldon (Great Britain) and Jaques Bernheim (Israel), Pioneers of the Archives of European Nephrology, on the stage during the Opening Ceremony of the ERA-EDTA Congress held in Paris, France, May 24, 2012. Giorgina B. Piccoli, filmmaker, poet, artist, and nephrologist, along with opera-singer Nadia Kuprina are also pictured. Piccoli conducted all of the 27 interviews seen in the film “Portraits of Pioneers” that was shown at the conference. It was based on an initiative of the Société de Néphrologie that was initially limited to French-speaking and Italian Pioneers of Nephrology and then extended to the whole of Europe. Photo taken by Maria Radó.

August 2, 2018

Vignette 2: History of the photo taken on May 24, 2012, in Paris

During the first days of Spring 2011 I was informed by László Rosivall, President of the Hungarian Kidney Foundation, that I had been chosen by Pierre Ronco, Professor of Nephrology, Hôpital Tenon (Hôpitaux Universitaires Est Parisien), Paris, for an in-depth interview. It was known at that time that Pierre Ronco had been selected for President of the Congress of Nephrology to be held in Paris in May 2012 and Laszlo Rosivall was a member of the Scientific Committee of that Congress. Professor Rosivall's decision was endorsed by a voting in the Steering Committee of the Hungarian Society of Nephrology.

The interview was conducted by Dr. G.B. Piccoli on September 13, 2011, in Bruxelles, Belgium, in a cafe on the Grote Markt, and was filmed by Gilberto Richiero and his photographer, in the presence of Professors Ronco and Rosivall and my wife.

The interview was about patients and doctors; clinical medicine and nephrology; and personal history and views, including my life story and achievements.

Seven years later, on April, 2018, Piccoli wrote an article in BMC Nephrology entitled "On the shoulders of giants. The story behind the Pioneers of Nephrology project" (Piccoli, Jaar and Henderson 2018). In the article she declares: "...the interviews are not dealing with their achievements and their success: they try to pass on to future generations the idea of how they were, why they were passionate, what they loved, and, last where they found poetry in our profession."

My interview was one of 27 interviews of the "Pioneers of the Archives of European Nephrology," among them an interview with the "Master of the Masters," Gabriel Richet, at that time 97-years-old (Piccoli, Richiero and Jaar 2018). The interviewers wanted to listen to the stories of the Pioneers and compose from them a film to be presented on the evening of the Opening Ceremony of the XIIth congress of Nephrology held in Paris on May 24, 2012.

The spirit of the interview was very special indeed. I cannot describe it in simple words. It is well characterized, however, with Piccoli's own words in the quotation above. The interview was (also) about poetry, i.e., poetry in medicine. Piccoli has a sui generis gift (among several other talents) of making poetry even from nephrology. Piccoli is a nephrologist in Torino, Italy (nowadays also in Le Mans, France), and an internationally known poet.

Piccoli describes the story of her achievement in the Archives of the European Nephrology. The project began almost 30 years ago when, with her two friends (David and Paolo), they made a film about Shoah (the Holocaust). Her next film was about the Pioneers of Nephrology, with Giorgina's self-selected producer Pierre Ronco. Although David and Paolo did not take part in this film, concerning the interviews David suggested to Giorgina: "take the poetry out of them. It has to deal with poetry in the end" (Piccoli, Jaar and Henderson 2018). So, when I got the question about poetry in the course of the interview, I responded with a short story of my medical life.

I had observed the development of an interventricular septal defect (the first case in Hungary) in one of my cardiac patients when I was a young resident in 1954, in the János Hospital of Budapest. My chief, the great internist Fodor Imre, however, did not believe in this diagnosis. So, I went to the chief pathologist (Professor Antal Kálló) noting my diagnostic opinion. Everyone on the staff from the medical and pathological departments was present at the necropsy when my clinical diagnosis was confirmed. I was sure that I would be fired and there would be no job offer in any hospital in Hungary in the near future. After a sleepless night, next day I participated in the morning conference as usual, Imre Fodor declared that he was proud to publish with me this interesting, rare, extraordinary case (Fodor, Kincsesy and Radó 1955; Radó, Kincsesy and Fodor 1958). Later, in 1956, when he suffered from a deadly disease, Fodor invited me to join his treatment team, even though I was the youngest member in the department. What is this, if not poetry?

In the photograph taken on May 24, 2012, by my wife, G.B. Piccoli stands between Nadia Kuprina, opera singer, and me on the stage of the Big Auditorium of the Conference Center Paris. In the photo you can see two others, Stanley Sheldon, one of the founding fathers of the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) and a famous British-French nephrologist, and Jacques Bernheim, eminent nephrologist from Israel. (Unfortunately, both have since died). The other 24 famous nephrologists on the stage are not seen in this photo, among them Gabriel Richet, Stewart Cameron, Evert Dorhout Mees, Carl Eric Mogensen, Anita Aperia, Eberhard Ritz and Eliahou Ypersele.

The complete interview series of all Nephrology Pioneers can now be seen on videos on the ERA-EDTA website (era-edta.org). In the near future plans are underway for their edited text to be available in a remarkable new series of BMC Nephrology. The editor of this journal is none other than Giorgina Piccoli, shown in the photo between Nadia Kuprina and me.

References:

Fodor I, Kincsesy A, Radó J. Az interventricularis septumperforatio klinikája és pathológiája (Diagnosis and pathology of perforated interventricular septum; intravital observation of two cases). *Orvosi Hetilap* 1955; 96: 1293-300.

Piccoli, GB, Jaar, BG, Henderson H. On the shoulders of giants. The story behind the Pioneers of Nephrology project. *Nephrology* 2018; 1: 58-9.

Piccoli, GB, Richiero G, Jaar, BG The Pioneers of Nephrology-Professor Gabriel Richet: "I will maintain." *BMC Nephrology* 2018; 19:60.

Radó J, Kincsesy A, Fodor I. Die klinischen und pathologischen Probleme der interventrikulären Septumperforation im Lichte der Literatur und unserer eigenen Fälle. (Clinical and pathological problems of the intraventricular septum perforation in the light of the literature and our own cases). *Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete* 1958; 13: 227-35.

December 20, 2018



János Radó (left) and Thomas A. Ban. Photo taken on October 11, 2014, in Budapest, Hungary, on the occasion that they were receiving their diamond diploma, 60 years after graduation from medical school. Photo received from János Radó.

September 3, 2015